

**MFT TRUST FORMULARY**

**Manchester University**  
NHS Foundation Trust

|             | <b>BNF Chapter</b>                                |
|-------------|---------------------------------------------------|
| Section 1:  | Gastro-Intestinal System                          |
| Section 2:  | Cardiovascular System                             |
| Section 3:  | Respiratory System                                |
| Section 4:  | Central Nervous System                            |
| Section 5:  | Infections                                        |
| Section 6:  | Endocrine System                                  |
| Section 7:  | Obstetrics, gynaecology & urinary tract disorders |
| Section 8:  | Malignant disease & immunosuppression             |
| Section 9:  | Nutrition & blood                                 |
| Section 10: | Musculoskeletal & Joint Diseases                  |
| Section 11: | Eye                                               |
| Section 12: | Ear, nose & oropharynx                            |
| Section 13: | Skin                                              |
| Section 14: | Immunological products & vaccines                 |
| Section 15: | Anaesthesia                                       |
| Section 16: | Miscellaneous                                     |

**Version 8.11 (December 2023)**

**NICE** National Institute for  
Health and Care Excellence

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

## Formulary status definitions

**Formulary** (OK to be prescribed - but after any 1<sup>st</sup> or 2<sup>nd</sup> line options)

1<sup>st</sup> line formulary (when there are few formulary options, this is the 1<sup>st</sup> choice)

2<sup>nd</sup> line formulary (when there are few formulary options, this is the 2<sup>nd</sup> choice)

Where there is no preferred 1<sup>st</sup> line agent provided, the drug choice appears in alphabetical order.

1<sup>st</sup> line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



## PCT Red/Amber/Green classifications



### Adult RAG, DNP & Grey list Paediatric RAG, DNP & Grey list

#### Red

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

#### Amber

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP). [See here for a list of GMMMG approved SCPs.](#)

#### Green

Drugs that are suitable for initiation and ongoing prescribing within primary care.

#### Green

specialist initiation

Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

#### Green

following specialist recommendation

Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

#### Do Not Prescribe: DNP

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

#### Grey: Grey

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

#### Unlicensed: U

Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be highlighted in the template as follows: drug name<sup>U</sup>

### MMC Medicines Management Committee decision tables



Summary of Product Characteristics



Blueteq Enabled Forms



British National Formulary (BNF)



Controlled Drug



British National Formulary for Children (BNFC)



High Cost Medicine



NICE guidance



Payment by Results high cost excluded drug

**NOT STOCKED**

Not routinely stocked, can be ordered if existing patient supply is exhausted

## PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY



GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

## Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (**No password required**)

British National Formulary for Children (**No password required**)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

# Section 1: Gastro-Intestinal System

Supported by the  
formulary ([click here](#))



## 1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

## 1.2 Anti-spasmodics & other drugs altering gut motility

- Antimuscarinics
- Other Antispasmodics
- Motility Stimulants

## 1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H<sub>2</sub>-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

## 1.4 Acute diarrhoea

- 1.4.2 Antimotility Drugs

## 1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response
  - Cytokine Modulators

## 1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

## 1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

## 1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

## 1.10 Miscellaneous preparations

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Faecal Incontinence (CG49)  
 Irritable Bowel Syndrome (CG61)  
 Diarrhoea and vomiting in children under 5 (CG84)  
 Constipation in children and young people (CG99)  
 Acute upper GI bleeding (CG141)  
 Dyspepsia and gastro-oesophageal reflux disease (CG184)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Crohn's disease: management (NG129)  
 Ulcerative colitis: management (NG130)  
 Ulcerative colitis (acute exacerbations) - infliximab (TA163)  
 Crohn's disease - infliximab & adalimumab (TA187)  
 Constipation (women) - prucalopride (TA211)  
 Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)  
 Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)  
 Naloxegol for treating opioid induced constipation (TA345)  
 Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)  
 Obeticholic acid for treating primary biliary cholangitis (TA443)  
 Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)  
 Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)  
 Naldemedine for treating opioid-induced constipation (TA651)  
 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)  
 Filgotinib for treating moderately to severely active ulcerative colitis (TA792)  
 Teduglutide for treating short bowel syndrome (TA804)  
 Ozanimod for treating moderately to severely active ulcerative colitis (TA828)  
 Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)  
 Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)  
 Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)  
 Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

## GMMM Formulary

Formulary Homepage  
 Chapter 1: Gastro-Intestinal system (Complete)  
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 1.1 Dyspepsia & gastro-oesophageal reflux disease               |                                                                                                                                                                        | GMMMG                                    |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| 1.1.1 Antacids & Simeticone                                     |                                                                                                                                                                        |                                          |
| Aluminium & Magnesium Containing Antacids                       |                                                                                                                                                                        |                                          |
| Co-magaldrox                                                    |   | 1 <sup>st</sup> line use                 |
| 195/220 suspension <sup>SF</sup>                                |                                                                                                                                                                        |                                          |
| Magnesium Trisilicate                                           |   |                                          |
| suspension                                                      |                                                                                                                                                                        |                                          |
| Simeticone alone (activated dimeticone)                         |                                                                                                                                                                        |                                          |
| Simeticone                                                      |   | <b>RESTRICTED</b><br>Paediatric use only |
| Infacol® 40mg/mL liquid                                         |                                                                                                                                                                        |                                          |
| 1.1.2 Compound Alginates & Proprietary Indigestion Preparations |                                                                                                                                                                        |                                          |
| Alginate raft-forming oral suspensions <sup>SF</sup>            |   |                                          |
| suspension                                                      |                                                                                                                                                                        |                                          |

## 1.2 Anti-spasmodics & other drugs altering gut motility



### Antimuscarinics

#### Hyoscine Butylbromide

tablets; injection



MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease

#### Glycopyrronium Bromide (Glycopyrrolate)

Green

(Robinul®, Sialanar®) tablets; injection; oral solution; cream



### Other Antispasmodics

#### Mebeverine Hydrochloride

135mg tablets



**1<sup>st</sup> line use**

#### Peppermint oil

capsules



### Motility Stimulants

#### Metoclopramide

10mg tablets ([see also section 4.6](#))



**1<sup>st</sup> line use**

MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects

#### Domperidone

Green

10mg tablets ([see also section 4.6](#))



**Use where 1<sup>st</sup> line unsuitable**

MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

| 1.3 Antisecretory drugs & mucosal protectants                                                                                                                                                          |  | GMMMG            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------|
| <b>1.3.1 H<sub>2</sub>-receptor antagonists</b>                                                                                                                                                        |  |                  |
| <b>Famotidine</b><br>Green<br>20mg; 40mg tablets                                                                                                                                                       |  | MMC BNF emc      |
| <b>Ranitidine</b><br>150mg; 300mg tablets                                                                                                                                                              |  | BNF emc          |
| <b>1.3.3 Chelates &amp; Complexes</b>                                                                                                                                                                  |  |                  |
| <b>Sucralfate</b><br>Green<br>1g tablets; oral suspension (restricted Wythenshawe)                                                                                                                     |  | MMC BNF emc      |
| <b>Bismuth Subsalicylate (<i>Pepto-Bismol</i>®)</b><br>262.5mg chewable tablets                                                                                                                        |  | MMC BNF emc      |
| <b>1.3.5 Proton Pump Inhibitors</b>                                                                                                                                                                    |  |                  |
| <b>Omeprazole</b><br>10mg; 20mg; 40mg capsules; 40mg infusion                                                                                                                                          |  | NICE BNF emc     |
| <b>Lansoprazole</b><br>15mg & 30mg capsules; 15mg & 30mg orodispersible tablets                                                                                                                        |  | NICE MMC BNF emc |
| <b>Esomeprazole</b><br>40mg infusion                                                                                                                                                                   |  | MMC BNF emc      |
| MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice<br>MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus |  |                  |
| <b>Other PPIs are not available at this Trust</b>                                                                                                                                                      |  |                  |

## 1.4 Acute diarrhoea



### 1.4.2 Antimotility Drugs

#### Loperamide hydrochloride

2mg capsules; 1mg/5mL syrup<sup>SF</sup>



**1<sup>st</sup> line use**

#### Codeine Phosphate

15mg; 30mg & 60mg tablets



**RESTRICTED**  
Adults - high output stomas

#### Teduglutide



Revestive® injection



**RESTRICTED** Gastro. Consultants  
only in line with NICE TA804

| 1.5 Chronic bowel disorders                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | GMMMG                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| <b>1.5.1 Aminosalicylates</b>                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                       |
| <b>Mesalazine</b><br>Green<br>tablets; M/R tablets; M/R granules; enema; foam enema; suppositories                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                         | <b>PRESCRIBE BY BRAND NAME</b>                                        |
| <b>Balsalazide Sodium</b><br>750mg capsules                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                        |                                                                       |
| <b>1.5.2 Corticosteroids &amp; Enemas</b>                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                       |
| <b>Prednisolone</b><br>5mg tablets                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                         | <b>1<sup>st</sup> line use</b>                                        |
| <b>Budesonide (Budenofalk®)</b><br>3mg capsules; rectal foam                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                        |                                                                       |
| <b>Budesonide (Jorveza®)</b><br>Green<br>1mg orodispersible tablets                                                                                                                                                                                                                               |                                                                                                                                                                                       | <b>RESTRICTED</b><br>Adults - eosinophilic esophagitis                |
| <b>Budesonide</b><br>Green<br>3mg CR capsules                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                        | <b>RESTRICTED</b><br>Adults - Gastro. Consultants only                |
| <b>Hydrocortisone</b><br>foam enema                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                         |                                                                       |
| <b>Short chain fatty acid enema</b><br> Nutricon® enema                                                                                                                                                           |                                                                                                                                                                                                                                                                        | <b>RESTRICTED</b><br>Adults - Gastro. Consultants only                |
| <b>1.5.3 Drugs Affecting the Immune Response</b>                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                       |
| <b>Azathioprine</b><br>Amber<br>tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                     | <b>1<sup>st</sup> line use</b>                                        |
| <b>Ciclosporin</b> (oral and I.V. preparations)<br>Amber<br>capsules; infusion; oral solution (see also section 8.2.2)                                                                                                                                                                            |                                                                                                                                                                                                                                                                  |                                                                       |
| <b>Mercaptopurine</b><br>Amber<br>tablets; oral suspension (see also section 8.1.3)                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                     |                                                                       |
| <b>Methotrexate</b> (s/c and oral preparations)<br>Amber<br>tablets; injection; oral solution (see also section 10.1.3)                                                                                                                                                                           |                                                                                                                                                                                                                                                                  |                                                                       |
| MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions<br>MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                       |
| <b>Mirikizumab</b><br>Red  <br>Omvoh® injection; infusion                                                                    |                                                                                            | <b>RESTRICTED</b> Gastro. Consultants in line with NICE TA925         |
| <b>Ozanimod</b><br>Red  <br>Zeposia® capsules                                                                                |       | <b>RESTRICTED</b> Gastro. Consultants in line with NICE TA828         |
| <b>Vedolizumab</b><br>Red  <br>infusion                                                                                      |       | <b>RESTRICTED</b> Gastro. Consultants in line with NICE TA342 & TA352 |

| <b>Cytokine Modulators</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| <b>Adalimumab</b><br>                                                                                                                                                                                                                                                                                                                                                                                   | <b>RESTRICTED</b> Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE |
| injection (see also sections 10.1.3, 11.4.2 & 13.5.3)<br>      |                                                                                            |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                            |
| <b>Infliximab</b><br>                                                                                                                                                                                                                                                                                                                                                                                   | <b>RESTRICTED</b> Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE |
| infusion (see also sections 10.1.3 & 13.5.3)<br>               |                                                                                            |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                            |
| <b>Filgotinib</b><br>                                                                                                                                                                                                                                                                                                                                                                                   | <b>RESTRICTED</b> Gastro. Consultants for Ulcerative colitis as per NICE                   |
| 100mg; 200mg tablets (see also section 10.1.3)<br>             |                                                                                            |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                            |
| <b>Golimumab</b><br>                                                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b> Gastro. Consultants for Crohn's Disease & Ulcerative colitis as per NICE |
| injection (see also section 10.1.3)<br>                        |                                                                                            |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                            |
| <b>Risankizumab</b><br>                                                                                                                                                                                                                                                                                                                                                                                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA888                              |
| 75mg; 150mg injection<br>                                      |                                                                                            |
| <b>Tofacitinib</b><br>                                                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b> Consultants only in line with NICE                                       |
| tablets (see also section 10.1.3)<br>                          |                                                                                            |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                            |
| MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                            |
| MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                            |
| MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                            |
| <b>Upadacitinib</b><br>                                                                                                                                                                                                                                                                                                                                                                                 | <b>RESTRICTED</b> Consultants only in line with NICE TA856 / TA905                         |
| MR tablet (see also section 10.1.3)<br>                  |                                                                                            |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                            |
| <b>Ustekinumab</b><br>                                                                                                                                                                                                                                                                                                                                                                              | <b>RESTRICTED</b> Gastro. Consultants as per NICE                                          |
| injection (see also sections 10.1.3)<br>           |                                                                                            |
| <b>ICAM-1 Inhibitor</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                            |
| <b>Alicaforsen</b><br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b>RESTRICTED</b> Gastro. Consultants only - pouchitis                                     |
| enema<br>                                                                                                                                                                                                                                                                                                     |                                                                                            |

| 1.6 Laxatives                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                    | GMMMG                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1.6.1 Bulk-forming Laxatives                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Ispaghula husk</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                    | <b>1<sup>st</sup> line use</b>                                                  |
| 3.5g sachets                                                                                                                                                |                                                                                                                                                                               |                                                                                 |
| 1.6.2 Stimulant Laxatives                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Docusate Sodium</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                    | <b>1<sup>st</sup> line use</b>                                                  |
| capsules; oral solution                                                                                                                                     |                                                                                                                                                                               |                                                                                 |
| <b>Senna</b>                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                    | <b>1<sup>st</sup> line use</b>                                                  |
| tablets; oral solution                                                                                                                                      |                                                                                                                                                                               |                                                                                 |
| MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Bisacodyl</b>                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| tablets; suppositories                                                                                                                                      |                                                                                                                                                                               |                                                                                 |
| MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Glycerol</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| suppositories                                                                                                                                               |                                                                                                                                                                               |                                                                                 |
| <b>Sodium Picosulfate</b>                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| oral solution                                                                                                                                               |                                                                                                                                                                               |                                                                                 |
| MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Co-Danthramer</b>                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Adults, Palliative Care only                               |
| oral suspension                                                                                                                                             |                                                                                                                                                                               |                                                                                 |
| <b>Co-Danthrusate</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Adults, Palliative Care only                               |
| oral suspension                                                                                                                                             |                                                                                                                                                                               |                                                                                 |
| 1.6.3 Faecal Softeners                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Arachis oil</b>                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| enema                                                                                                                                                       |                                                                                                                                                                           |                                                                                 |
| 1.6.4 Osmotic Laxatives                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Lactulose</b>                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                    | <b>1<sup>st</sup> line use</b>                                                  |
| oral solution                                                                                                                                               |                                                                                                                                                                           |                                                                                 |
| <b>Macrogols (Polyethylene glycols)</b>                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                    | <b>2<sup>nd</sup> / 3<sup>rd</sup> line use</b> Rehab patients /<br>paediatrics |
| sachets                                                                                                                                                     |                                                                                        |                                                                                 |
| <b>Phosphates (Rectal)</b>                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| 128mL enema                                                                                                                                                 |                                                                                                                                                                           |                                                                                 |
| <b>Sodium Citrate (Rectal)</b>                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| 450mg micro-enema                                                                                                                                           |                                                                                                                                                                           |                                                                                 |
| 1.6.5 Bowel Cleansing Preparations                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions                                                                                |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Sodium Picosulfate with Magnesium Citrate</b>                                                                                                            |                                                                                                                                                                                                                                                                                                                                                    | <b>1<sup>st</sup> line use</b>                                                  |
| Picolax® oral powder                                                                                                                                        |                                                                                                                                                                           |                                                                                 |
| <b>Macrogols (Klean-Prep® &amp; Moviprep®) oral powder</b>                                                                                                  |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| oral powder                                                                                                                                                 |                                                                                                                                                                           |                                                                                 |
| 1.6.6 Peripheral opioid-receptor antagonists                                                                                                                |                                                                                                                                                                                                                                                                                                                                                    |                                                                                 |
| <b>Methylnaltrexone Bromide</b>                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Adults, Palliative Care only                               |
| injection                                                                                                                                                   |                                                                                                                                                                           |                                                                                 |
| <b>Naldemedine</b>                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Adults only in line with TA651                             |
|  200 microgram tablets                                                    |     |                                                                                 |
| <b>Naloxegol</b>                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Adults only in line with TA345                             |
|  12.5mg; 25mg tablets                                                     |     |                                                                                 |

| 1.6.7 Other drugs used in constipation                                                                                                             |                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| <div><div>Prucalopride</div><div>Green</div><div>1mg; 2mg tablets</div></div> <div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div> | <div>RESTRICTED - Adult women, Gastro. Consultants only</div>                   |
| <div><div>Linaclotide</div><div>Green</div><div>290 micrograms capsules</div></div> <div><div>MMC</div><div>BNF</div><div>emc</div></div>          | <div>RESTRICTED - 3<sup>rd</sup> line use Adults Gastro. Consultants only</div> |

| 1.7 Local preparations for anal & rectal disorders                                                                                                                                                                         |                                                                                                                                                                                                                                                          | GMMMG                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids                                                                                                                                                             |                                                                                                                                                                                                                                                          |                                       |
| <b>Anusol®</b><br><br>ointment                                                                                                                                                                                             |                                                                                     |                                       |
| <b>Proctosedyl®</b><br><br>ointment                                                                                                                                                                                        |                                                                                     |                                       |
| <b>Scheriproct®</b><br><br>ointment; suppositories                                                                                                                                                                         |                                                                                     |                                       |
| 1.7.4 Management of anal fissures                                                                                                                                                                                          |                                                                                                                                                                                                                                                          |                                       |
| <b>Glyceryl Trinitrate</b><br><br>Rectogesic® 0.4% ointment                                                                                                                                                                |    | 1 <sup>st</sup> line for anal fissure |
| <b>Diltiazem Hydrochloride</b><br> <br>2% cream; ointment |                                                                                     |                                       |

## 1.9 Drugs affecting intestinal secretions



### 1.9.1 Drugs affecting biliary composition & flow

#### Ursodeoxycholic acid

150mg tablets



**1<sup>st</sup> line use**

#### Obeticholic acid



Ocaliva® 5mg; 10mg tablets



**RESTRICTED** Hepatology  
Consultants only 2<sup>nd</sup> line per TA443

### 1.9.2 Bile acid sequestrants

#### Colestyramine

Green

powder 4g sachet (see also section 2.12)



**1<sup>st</sup> line use**

#### Colesevelam Hydrochloride

Green

625mg tablets (see also section 2.12)



**RESTRICTED** adults. Gastro & Lipid  
Clinic Consultants only

### 1.9.4 Pancreatin

#### Pancreatin

Green

capsules



**NOT  
STOCKED**

## 1.10 Miscellaneous preparations



### Glucarpidase



Voraxaze® 1,000 unit injection ([see also sections 8.4, 10.4 & 13.14](#))

PbR X

MMC



**RESTRICTED**

2<sup>nd</sup> line rescue therapy

## Section 2: Cardiovascular System

Supported by the  
formulary (click here)



### 2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

### 2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

### 2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

### 2.4 Beta-adrenoceptor blocking drugs

### 2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
  - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
  - 2.5.5.2 Angiotensin-II Receptor Antagonists
  - 2.5.5.3 Renin Inhibitors
  - 2.5.5.4 Heart Failure

### 2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

### 2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

### 2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

### 2.9 Antiplatelet drugs

### 2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

### 2.11 Antifibrinolytic drugs & haemostatics

### 2.12 Lipid-regulating drugs

### 2.13 Local sclerosants

### 2.14 Miscellaneous preparations

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Familial hypercholesterolaemia (CG71)  
 Chest pain of recent onset (CG95)  
 Stable angina (CG126)  
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)  
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)  
 Chronic heart failure in adults: diagnosis and management (NG106)  
 Hypertension in pregnancy: diagnosis and management (NG133)  
 Hypertension in adults: diagnosis and management (NG136)  
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)  
 Acute coronary syndromes (NG185)  
 Atrial fibrillation: diagnosis and management (NG196)  
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)  
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)  
 Myocardial infarction - thrombolysis (TA52)  
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)  
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)  
 Hypercholesterolaemia - Ezetimibe (TA132)  
 Coronary artery disease - drug eluting stents (TA152)  
 Venous thromboembolism - dabigatran (TA157)  
 Rivaroxaban for the prevention of VTE (TA170)  
 Atrial Fibrillation - dronedarone (TA197)  
 Vascular disease - clopidogrel and dipyridamole (TA210)  
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)  
 Acute coronary syndromes - ticagrelor (TA236)  
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)  
 Atrial fibrillation - dabigatran etexilate (TA249)  
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)  
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)  
 Stroke (acute, ischaemic) - alteplase (TA264)  
 Chronic heart failure - ivabradine (TA267)  
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)  
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)  
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)  
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)  
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)  
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)  
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)  
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)  
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)  
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)  
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)  
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)  
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)  
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)  
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)  
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)  
 Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)  
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)  
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)  
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)  
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)  
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)  
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)  
 Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

## GMMM Formulary

Formulary Homepage  
 Chapter 2: Cardiovascular system (Complete)  
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 2.1 Positive inotropic drugs



### 2.1.1 Cardiac Glycosides

#### Digoxin

tablets; elixir; injection

**1<sup>st</sup> line use**

#### Digoxin-specific antibody

Red

infusion



### 2.1.2 Phosphodiesterase Inhibitors

#### Enoximone

*Perfan*® 5mg/1mL injection

#### Milrinone

*Primacor*® 10mg/10mL injection**1<sup>st</sup> line use Paediatrics**

#### Levosimendan

*Simdax*® 12.5mg/5mL Injection**RESTRICTED** adults.  
Cardiology ITU Consultant only

## 2.2 Diuretics



### 2.2.1 Thiazides & Related Diuretics

#### Bendroflumethiazide

tablets

**1<sup>st</sup> line use**

#### Chlortalidone

tablets



#### Metolazone

Green

tablets

**2<sup>nd</sup> line use with loop diuretic**

MHRA Drug Safety Update (Jan-23): Xaquia (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations

### 2.2.2 Loop Diuretics

#### Furosemide

tablets; liquid; injection

**1<sup>st</sup> line use**

#### Bumetanide

tablets; oral solution

**2<sup>nd</sup> line use**

### 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists

#### Amiloride hydrochloride

tablets; oral solution

**1<sup>st</sup> line use**

#### Spironolactone

tablets

**1<sup>st</sup> line use**

MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

#### Eplerenone

Green

tablets



**RESTRICTED** adults.  
Cardiology Consultant only

#### Finerenone

Green

Kerendia® tablets



**RESTRICTED** adults.  
Diabetes / Renal Consultant only

### 2.2.4 Potassium-sparing Diuretics with other Diuretics

#### Co-amilofruse

tablets

**1<sup>st</sup> line use**

### 2.2.5 Osmotic Diuretics

#### Mannitol

infusion



## 2.3 Anti-arrhythmic drugs



### 2.3.2 Drugs for Arrhythmias

#### Adenosine

injection



#### Amiodarone Hydrochloride

Amber Red

tablets; injection



MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision

#### Disopyramide

capsules; tablets



#### Flecainide Acetate

Red Paeds - until stabilised then Green

tablets; injection



#### Lidocaine (Lignocaine) Hydrochloride

injection



#### Mexiletine

Red

NaMuscla® 167mg capsules

**RESTRICTED**  
Neurology only

#### Mexiletine Hydrochloride

U

Mexitil® 50mg; 100mg; 200mg capsules

**RESTRICTED**  
Cardiology / Neurology only

#### Propafenone Hydrochloride

tablets



#### Dronedarone

Green

tablets

**RESTRICTED** adults. Cardiology  
Consultant only, in line with TA197

MHRA Drug Safety Update (Oct-11): Dronedarone (Multaq ▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements

| 2.4 Beta-adrenoceptor blocking drugs                                                        |                                                                                                                                                                           | GMMMG                                                                                              |
|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                                                             |                                                                                                                                                                           | NICE NG106                                                                                         |
|                                                                                             |                                                                                                                                                                           | NICE NG136                                                                                         |
|                                                                                             |                                                                                                                                                                           | NICE NG196                                                                                         |
| <b>2.4 Beta-Adrenoceptor Blocking Drugs</b>                                                 |                                                                                                                                                                           |                                                                                                    |
| <b>Atenolol</b>                                                                             |                                                                                                                                                                           |                                                                                                    |
| tablets; liquid; injection                                                                  |       |                                                                                                    |
| <b>Bisoprolol Fumarate</b>                                                                  |                                                                                                                                                                           | <b>RESTRICTED</b> adults.<br>Cardiology Consultant only                                            |
| tablets                                                                                     | MMC   |                                                                                                    |
| <b>Carvedilol</b>                                                                           |                                                                                                                                                                           | <b>RESTRICTED</b> adults.<br>Cardiology Consultant only<br><b>ALSO 2ND LINE FOR VARICEAL BLEED</b> |
| tablets                                                                                     | MMC   |                                                                                                    |
| <b>Esmolol Hydrochloride</b>                                                                |                                                                                                                                                                           | <b>RESTRICTED</b><br>I.V. only                                                                     |
| injection                                                                                   |       |                                                                                                    |
| <b>Etilefrine Hydrochloride</b>                                                             |                                                                                                                                                                           | <b>RESTRICTED</b> Haematology<br>Consultants - SCD                                                 |
| <br>tablets | MMC   |                                                                                                    |
| <b>Labetalol Hydrochloride</b>                                                              |                                                                                                                                                                           | <b>RESTRICTED</b><br>oral preps in pregnancy                                                       |
| tablets; injection                                                                          |       |                                                                                                    |
| <b>Metoprolol Tartrate</b>                                                                  |                                                                                                                                                                           |                                                                                                    |
| tablets; injection                                                                          |       |                                                                                                    |
| <b>Nadolol</b>                                                                              |                                                                                                                                                                           | <b>RESTRICTED</b> paed. ventricular<br>arrhythmias in long QT syndrome                             |
| tablets                                                                                     | MMC   |                                                                                                    |
| <b>Nebivolol</b>                                                                            |                                                                                                                                                                           |                                                                                                    |
| tablets                                                                                     |    |                                                                                                    |
| <b>Propranolol Hydrochloride</b>                                                            |                                                                                                                                                                           | <b>RESTRICTED</b><br>not in Cardiology                                                             |
| tablets; capsules; oral solution; injection                                                 |   |                                                                                                    |
| <b>Sotalol Hydrochloride</b>                                                                |                                                                                                                                                                           |                                                                                                    |
| tablets                                                                                     |   |                                                                                                    |

| 2.5 Hypertension & heart failure                                                                                                                                      |                   | GMMMG                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------|
|                                                                                                                                                                       |                   | NICE NG106                                                         |
|                                                                                                                                                                       |                   | NICE NG136                                                         |
|                                                                                                                                                                       |                   | NICE NG196                                                         |
| <b>2.5.1 Vasodilator Antihypertensive Drugs</b>                                                                                                                       |                   | NHSE PAH                                                           |
| <b>Hydralazine Hydrochloride</b>                                                                                                                                      |                   | 1 <sup>st</sup> line use                                           |
| tablets; injection                                                                                                                                                    | BNF emc           |                                                                    |
| <b>Minoxidil</b>                                                                                                                                                      |                   |                                                                    |
| tablets                                                                                                                                                               | BNF emc           |                                                                    |
| <b>Ambrisentan</b>                                                                                                                                                    |                   | RESTRICTED<br>PAH in line with NHSE                                |
| Red ££                                                                                                                                                                | PbR X MMC BNF emc | NHS England                                                        |
| tablets                                                                                                                                                               |                   |                                                                    |
| <b>Bosentan</b>                                                                                                                                                       |                   | RESTRICTED<br>PAH in line with NHSE                                |
| Red ££                                                                                                                                                                | PbR X MMC BNF emc | NHS England                                                        |
| tablets                                                                                                                                                               |                   |                                                                    |
| <b>Sildenafil</b>                                                                                                                                                     |                   | RESTRICTED<br>PAH in line with NHSE                                |
| Red ££                                                                                                                                                                | MMC BNF emc       | NHS England                                                        |
| Revatio® tablets; injection (see also section 7.4.5)                                                                                                                  |                   |                                                                    |
| MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction |                   |                                                                    |
| <b>Macitentan</b>                                                                                                                                                     |                   | RESTRICTED<br>PAH in line with NHSE                                |
| Red ££                                                                                                                                                                | PbR X MMC BNF emc | NHS England                                                        |
| Opsumit® tablets                                                                                                                                                      |                   |                                                                    |
| <b>Tadalafil</b>                                                                                                                                                      |                   | RESTRICTED<br>PAH in line with NHSE                                |
| Red ££                                                                                                                                                                | PbR X MMC BNF emc | NHS England                                                        |
| Adcirca® tablets (see also section 7.4.5)                                                                                                                             |                   |                                                                    |
| <b>2.5.2 Centrally Acting Antihypertensive Drugs</b>                                                                                                                  |                   |                                                                    |
| <b>Clonidine Hydrochloride</b>                                                                                                                                        |                   |                                                                    |
| tablets; oral solution; injection; patches                                                                                                                            | BNF emc           |                                                                    |
| <b>Methyldopa</b>                                                                                                                                                     |                   |                                                                    |
| tablets                                                                                                                                                               | BNF emc           |                                                                    |
| <b>Moxonidine</b>                                                                                                                                                     |                   | RESTRICTED 3 <sup>rd</sup> line use<br>after other treatments fail |
| Green                                                                                                                                                                 | MMC BNF emc       |                                                                    |
| tablets                                                                                                                                                               |                   |                                                                    |
| <b>2.5.4 Alpha-Adrenoceptor Blocking Drugs</b>                                                                                                                        |                   |                                                                    |
| <b>Doxazosin</b>                                                                                                                                                      |                   | 1 <sup>st</sup> line use                                           |
| DNP                                                                                                                                                                   | BNF emc           |                                                                    |
| 1mg; 2mg & 4mg tablets                                                                                                                                                |                   |                                                                    |
| <b>Phenoxybenzamine Hydrochloride</b>                                                                                                                                 |                   | RESTRICTED adults.<br>Specialist initiation only                   |
| 10mg capsules                                                                                                                                                         | BNF emc           |                                                                    |
| <b>Phentolamine Mesilate</b>                                                                                                                                          |                   | RESTRICTED adults.<br>Specialist use, theatres only                |
| injection                                                                                                                                                             | BNF emc           |                                                                    |
| <b>2.5.5 Drugs Affecting the Renin-Angiotensin System</b>                                                                                                             |                   |                                                                    |
| <b>2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors</b>                                                                                                         |                   |                                                                    |
| MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia                         |                   |                                                                    |
| <b>Ramipril</b>                                                                                                                                                       |                   |                                                                    |
| 1.25mg; 2.5mg; 5mg & 10mg capsules                                                                                                                                    | BNF emc           |                                                                    |
| <b>Captopril</b>                                                                                                                                                      |                   | RESTRICTED<br>Paediatrics only                                     |
| 12.5mg; 25mg & 50mg tablets                                                                                                                                           | BNF emc           |                                                                    |
| <b>Lisinopril</b>                                                                                                                                                     |                   | 1 <sup>st</sup> line use                                           |
| 2.5mg; 5mg; 10mg & 20mg tablets                                                                                                                                       | MMC BNF emc       | GMMMG                                                              |
| <b>Perindopril</b>                                                                                                                                                    |                   |                                                                    |
| DNP                                                                                                                                                                   | BNF emc           |                                                                    |
| 2mg; 4mg & 8mg tablets                                                                                                                                                |                   |                                                                    |

| 2.5.5.2 Angiotensin-II Receptor Antagonists                                                                                                   |                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia |                                                                |
| <b>Candesartan Cilexetil</b><br>Green<br>2mg; 4mg; 8mg; 16mg & 32mg tablets<br>MMC BNF emc                                                    | 1 <sup>st</sup> line use hypertension<br>GMMMG                 |
| <b>Losartan Potassium</b><br>12.5mg; 25mg; 50mg & 100mg tablets<br>BNF emc                                                                    | 2 <sup>nd</sup> line use hypertension                          |
| <b>Irbesartan</b><br>75mg; 150mg & 300mg tablets<br>MMC BNF emc                                                                               | 2 <sup>nd</sup> line use hypertension                          |
| <b>Valsartan</b><br>40mg; 80mg & 160mg capsules<br>MMC BNF emc                                                                                | 2 <sup>nd</sup> line use hypertension                          |
| <b>Sacubitril / Valsartan</b><br>Green<br>24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets<br>NICE MMC BNF emc                                 | RESTRICTED<br>use in line with NICE TA388                      |
| 2.5.5.3 Renin inhibitors                                                                                                                      |                                                                |
| <b>Aliskiren</b><br>DNP<br>150mg; 300mg tablets<br>MMC BNF emc                                                                                | RESTRICTED adults.<br>Specialist initiation only               |
| MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions                                   |                                                                |
| 2.5.5.4 Heart Failure                                                                                                                         |                                                                |
| <b>Dapagliflozin</b><br>Green<br>Forxiga ® tablets<br>NICE MMC BNF emc                                                                        | RESTRICTED adults.<br>Specialist initiation in line with TA679 |
| <b>Empagliflozin</b><br>Green<br>Jardiance ® tablets<br>NICE MMC BNF emc                                                                      | RESTRICTED adults.<br>Specialist initiation in line with TA773 |

## 2.6 Nitrates, calcium-channel blockers & other antianginals



### 2.6.1 Nitrates

#### Glyceryl Trinitrate

S/L tablets; S/L spray; patches; Injection; ointment



#### Isosorbide Mononitrate

tablets; capsules



### 2.6.2 Calcium-channel Blockers

#### Amlodipine

tablets; oral solution



**1<sup>st</sup> choice dihydropyridine**



#### Diltiazem

tablets; capsules; ointment



**1<sup>st</sup> choice**

**non-dihydropyridine**

**PRESCRIBE BY BRAND NAME**

#### Nifedipine

tablets; capsules; oral drops



**2<sup>nd</sup> choice**

**dihydropyridine**

**PRESCRIBE BY BRAND NAME**

#### Verapamil Hydrochloride

tablets; injection; oral solution



**2<sup>nd</sup> choice**

**non-dihydropyridine**

#### Nimodipine

tablets; infusion



**RESTRICTED** subarachnoid  
haemorrhage / *I.V.* then oral

### 2.6.3 Other Antianginal Drugs

#### Nicorandil

tablets



**1<sup>st</sup> line use**

MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications

#### Ivabradine

Green

tablets



**RESTRICTED** adults 2<sup>nd</sup> line.  
Cardiology Consultant only

MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects

#### Ranolazine

Green

M/R tablets



**RESTRICTED** adults 3<sup>rd</sup> line angina  
patients not suitable for surgery

### 2.6.4 Peripheral Vasodilators & Related Drugs

#### Naftidrofuryl Oxalate

capsules



#### Defibrotide

Red

££

infusion

PbR X



**RESTRICTED** Specialist use only in  
line with NHSE

NHS  
England

## 2.7 Sympathomimetics



### 2.7.1 Inotropic Sympathomimetics

#### Dobutamine

infusion



**RESTRICTED / I. V.**  
Specialist use only

#### Dopamine Hydrochloride

infusion



**RESTRICTED / I. V.**  
Specialist use only

#### Dopexamine

infusion



**RESTRICTED / I. V.**  
Specialist use only

#### Isoprenaline

injection



**RESTRICTED / I. V.**  
Specialist use only

### 2.7.2 Vasoconstrictor Sympathomimetics

#### Ephedrine Hydrochloride

injection



**RESTRICTED / I. V.**  
Specialist use only

#### Metaraminol



injection



#### Midodrine

Green

tablets



**Specialist use** Cardiology /  
Healthcare of the elderly

#### Noradrenaline acid tartrate

infusion



**RESTRICTED / I. V.**  
Specialist use only

#### Phenylephrine Hydrochloride

injection



**RESTRICTED / I. V.**  
Specialist use only

### 2.7.3 Cardiopulmonary Resuscitation

#### Adrenaline / Epinephrine

injection



## 2.8 Anticoagulants & protamine



### 2.8.1 Parenteral Anticoagulants

**NICE NG89**

#### ACD-A Anticoagulant Citrate Dextrose

**RESTRICTED**  
Specialist use only CRRT

solution

**MMC** **BNF** **emc**

#### Dalteparin Sodium

**1<sup>st</sup> line LMWH**

injection

**MMC** **BNF** **emc**

#### Epoprostenol

**RESTRICTED / V.**  
Specialist use only

 Red **££**

infusion

PbR X

**BNF** **emc**

MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices

#### Heparin

injection; infusion

**BNF** **emc**

#### Bivalirudin

**RESTRICTED** adults.  
Cardiac Catheter Lab only.

Red

infusion

**NICE** **MMC** **BNF** **emc**

#### Fondaparinux Sodium

**RESTRICTED** adults.  
Haematology Consultants only.

Green Red

injection

**MMC** **BNF** **emc**

#### Tinzaparin Sodium

**RESTRICTED** Obs & Gynae;  
ACS & VTE in Renal impairment only.  
Paeds: haemodialysis

Green Red

injection

**MMC** **BNF** **emc**

#### Enoxaparin Sodium

**RESTRICTED** ACS & VTE in Renal  
impairment only.

Green Red

injection

**MMC** **BNF** **emc**

#### Argatroban monohydrate

**RESTRICTED** adults.  
Treatment of HIT

infusion

**MMC** **BNF** **emc**

| <b>2.8.2 Oral Anticoagulants</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| <b>Acenocoumarol</b><br><br>tablets <div>BNF  </div>                                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>warfarin intolerant patients only.          |
| <b>Phenindione</b><br><br>tablets <div>BNF  </div>                                                                                                                                                                                                                                                                           |                                                                  |
| <b>Warfarin Sodium</b><br><br>tablets <div>BNF  </div>                                                                                                                                                                                                                                                                       |                                                                  |
| MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic<br>MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR<br>MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis                                                                                                                                   |                                                                  |
| <b>Apixaban</b><br>Green <div>PbR X    </div> tablets                                                                                                      | <b>RESTRICTED</b> in line with NICE                              |
| MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment                                                                                                                                                                                                                                                                                                                             |                                                                  |
| <b>Dabigatran Etexilate</b><br>Green <div>PbR X    </div> capsules                                                                                         | <b>RESTRICTED</b> in line with NICE                              |
| MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment<br>MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage                                                                                                                                                                                                                                    |                                                                  |
| <b>Edoxaban</b><br>Green <div>PbR X    </div> tablets                                                                                                      | <b>RESTRICTED</b> in line with NICE                              |
| MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment                                                                                                                                                                                                                                                                                                                             |                                                                  |
| <b>Rivaroxaban</b><br>Green <div>PbR X    </div> tablets                                                                                                   | <b>RESTRICTED</b> in line with NICE                              |
| MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment<br>MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food<br>MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial                              |                                                                  |
| <b>Antidotes</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                  |
| <b>Andexanet Alfa</b><br>Red  <div>   </div> Ondexxya® infusion | <b>RESTRICTED</b> in line with NICE                              |
| <b>Idarucizumab</b><br>Red  <div>  </div> Praxbind® infusion                                                                                       | <b>RESTRICTED</b> reversal of dabigatran<br>in emergency surgery |
| <b>2.8.3 Protamine Sulfate</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                  |
| <b>Protamine Sulfate</b><br><br>injection <div>BNF  </div>                                                                                                                                                                                                                                                               |                                                                  |

## 2.9 Antiplatelet drugs


**NICE NG185**

### Aspirin

tablets (dispersible &amp; E/C); suppositories



### Clopidogrel

tablets



For ACS patients; stroke patients intolerant of aspirin; high-risk patients who've stroked on aspirin

MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia

MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice

### Ticagrelor

Green

tablets; orodispersible tablets



In combination with aspirin for primary PCI in ACS patients & in line with NICE TA420

### Prasugrel

Green

tablets



**RESTRICTED** adults. Cardiac Catheter Lab as per NICE

MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding

MHRA Drug Safety Update (May-11): Prasugrel (Efient▼): rare but serious hypersensitivity reactions

### Dipyridamole

M/R capsules; oral suspension; tablets; injection



2<sup>RY</sup> prevention of stroke in patients already on aspirin

### Tirofiban

infusion



**RESTRICTED** adults. Cardiac Catheter Lab only (1<sup>st</sup> line)

### Eptifibatide

injection; infusion



**RESTRICTED** adult patients admitted on this or tirofiban

## 2.10 Stable angina, ACS & fibrinolysis



- Stable angina (BNF treatment summary)
- Acute coronary syndromes (BNF treatment summary)
- Fibrinolytic Drugs (BNF treatment summary)

NICE CG126

NICE NG128

### 2.10.2 Fibrinolytic Drugs

#### Tenecteplase

Red

injection

NICE MMC BNF emc

#### Streptokinase

Red

infusion

NICE BNF emc

#### Urokinase

Red

injection

BNF emc

#### Alteplase

Red

injection; infusion

NICE MMC BNF emc

RESTRICTED

| 2.11 Antifibrinolytic drugs & haemostatics                                                              |                                                                                                                                                                                                                                                                                                                                          | GMMMG                                                                               |                                                                                     |
|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 2.11 Antifibrinolytic Drugs & Haemostatics                                                              |                                                                                                                                                                                                                                                                                                                                          |                                                                                     |                                                                                     |
| <b>Etamsylate</b>                                                                                       |                                                                                                                                                                                                                                                                                                                                          |                                                                                     |                                                                                     |
| tablets                                                                                                 |                                                                                                                                                                       |                                                                                     |                                                                                     |
| <b>Tranexamic acid</b>                                                                                  |                                                                                                                                                                                                                                                                                                                                          |                                                                                     |                                                                                     |
| injection; tablets                                                                                      |                                                                                                                                                                       |                                                                                     |                                                                                     |
| <b>Aprotinin</b>                                                                                        |                                                                                                                                                                                                                                                                                                                                          |                                                                                     | <b>RESTRICTED</b>                                                                   |
| infusion                                                                                                |                                                                                                                                                                       |                                                                                     |                                                                                     |
| <b>Aminocaproic acid</b>                                                                                |                                                                                                                                                                                                                                                                                                                                          |                                                                                     | <b>RESTRICTED</b>                                                                   |
| sachets                                                                                                 |                                                                                      |                                                                                     |                                                                                     |
| <b>Emicizumab</b>                                                                                       |                                                                                                                                                                                                                                                                                                                                          |                                                                                     | <b>RESTRICTED</b>                                                                   |
| <br>Hemlibra® injection |     |  |  |
| <b>Vonicog alfa</b>                                                                                     |                                                                                                                                                                                                                                                                                                                                          |                                                                                     | <b>RESTRICTED</b>                                                                   |
| Veyvondi® injection                                                                                     |                                                                                      |  |                                                                                     |

## 2.12 Lipid-regulating drugs



| <b>Statins</b>                                                                          |                                                                                          |
|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| <b>Simvastatin</b>                                                                      |                                                                                          |
| tablets                                                                                 | PbR X NICE BNF emc                                                                       |
| MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis |                                                                                          |
| <b>Atorvastatin</b>                                                                     | 1 <sup>st</sup> line use                                                                 |
| DNP                                                                                     |                                                                                          |
| tablets                                                                                 | PbR X NICE BNF emc                                                                       |
| MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis |                                                                                          |
| <b>Rosuvastatin</b>                                                                     | RESTRICTED<br>Not stocked                                                                |
| tablets                                                                                 | PbR X NICE MMC BNF emc                                                                   |
| MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis |                                                                                          |
| <b>Pravastatin Sodium</b>                                                               | RESTRICTED MCSH for cases with potential drug interactions                               |
| tablets                                                                                 | PbR X NICE BNF emc                                                                       |
| MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis |                                                                                          |
| <b>Bile Acid Sequestrants</b>                                                           |                                                                                          |
| <b>Colestyramine</b>                                                                    |                                                                                          |
| Green                                                                                   |                                                                                          |
| sachets (see also section 1.9.2)                                                        | BNF emc                                                                                  |
| <b>Colesevelam Hydrochloride</b>                                                        | RESTRICTED adults. Gastro & Lipid Clinic Consultants only                                |
| DNP                                                                                     |                                                                                          |
| tablets (see also section 1.9.2)                                                        | MMC BNF emc                                                                              |
| <b>Fibrates</b>                                                                         |                                                                                          |
| <b>Bezafibrate</b>                                                                      |                                                                                          |
| 1 <sup>st</sup> line use                                                                |                                                                                          |
| M/R tablets; tablets                                                                    | BNF emc                                                                                  |
| <b>Fenofibrate</b>                                                                      | 2 <sup>nd</sup> line use                                                                 |
| 67mg / 200mg / 267mg capsules; 160mg tablets                                            | MMC BNF emc                                                                              |
| <b>Omega-3 fatty acid compounds</b>                                                     |                                                                                          |
| <b>Omega-3-acid ethyl esters</b>                                                        |                                                                                          |
| Green                                                                                   |                                                                                          |
| capsules                                                                                | MMC BNF emc                                                                              |
| <b>Ezetimibe</b>                                                                        |                                                                                          |
| <b>Ezetimibe</b>                                                                        |                                                                                          |
| 10mg tablets                                                                            | NICE MMC BNF emc                                                                         |
| <b>Lipid-regulating drugs</b>                                                           |                                                                                          |
| <b>Alirocumab</b>                                                                       |                                                                                          |
| Red                                                                                     |                                                                                          |
| Praluent® injection                                                                     | PbR X NICE MMC BNF emc                                                                   |
| <b>Bempedoic acid (see also Nustendi®)</b>                                              | RESTRICTED adults. Consultants in line with TA694                                        |
| Green                                                                                   |                                                                                          |
| Nilemdo® tablets                                                                        | PbR X NICE MMC BNF emc                                                                   |
| <b>Bempedoic acid (see also Nilemdo®)</b>                                               | RESTRICTED adults. Consultants in line with TA694                                        |
| Green                                                                                   |                                                                                          |
| Nustendi® tablets                                                                       | PbR X NICE MMC BNF emc                                                                   |
| <b>Evolocumab</b>                                                                       | RESTRICTED. Lipid Clinic Consultants for HoFH / & NICE TA394                             |
| Red                                                                                     |                                                                                          |
| Repatha® injection                                                                      | PbR X NICE MMC BNF blueeq emc                                                            |
| <b>Icosapent Ethyl</b>                                                                  | RESTRICTED adults in line with NICE TA805                                                |
| Green                                                                                   |                                                                                          |
| Vazkepa® capsules                                                                       | PbR X NICE MMC BNF emc                                                                   |
| <b>Inclisiran</b>                                                                       | RESTRICTED adults. Lipid Clinic Consultants in line with TA733 for Primary Care Referral |
| Green                                                                                   |                                                                                          |
| Leqvio® injection                                                                       | PbR X MMC BNF emc                                                                        |
| <b>Lomitapide</b>                                                                       | RESTRICTED adults. Lipid Clinic Consultants in line with NHSE 170059P                    |
| Red                                                                                     |                                                                                          |
| Lojuxta® capsules                                                                       | PbR X MMC BNF blueeq emc                                                                 |
| <b>Volanesorsen</b>                                                                     | RESTRICTED adults. Lipid Clinic Consultants in line with HST13                           |
| Red                                                                                     |                                                                                          |
| Waylivra® injection                                                                     | PbR X NICE MMC BNF blueeq emc                                                            |

| 2.13 Local sclerosants    |                                                                                                                                                                                                                                                            |  |
|---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Local Sclerosants         |                                                                                                                                                                                                                                                            |                                                                                    |
| Ethanolamine Oleate       | <br>  |                                                                                    |
| injection                 |                                                                                                                                                                                                                                                            |                                                                                    |
| Sodium Tetradecyl Sulfate | <br>  |                                                                                    |
| injection                 |                                                                                                                                                                                                                                                            |                                                                                    |

## 2.14 Miscellaneous preparations



### Ajmaline



*Gilurytma*® 50mg/10mL injection



**RESTRICTED** adults.  
Cardiology Consultant only

### Dapagliflozin

Green

tablets



**RESTRICTED**  
in line with NICE TA679 / TA902

MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus

### Empagliflozin

Green

tablets



**RESTRICTED**  
in line with NICE TA929

### Regadenoson



*Rapiscan*® 400micrograms/5mL injection



**RESTRICTED** adults.  
Myocardial perfusion scans

## Section 3: Respiratory System

Supported by the  
formulary (click here)



### 3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
  - Inhaler Devices
  - Nebuliser Diluent

### 3.2 Corticosteroids

- Compound preparations

### 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

### 3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

### 3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

### 3.6 Oxygen (refer to oxygen guidelines)

### 3.7 Mucolytics

### 3.8 Aromatic inhalations

### 3.9 Cough preparations

- 3.9.1 Cough Suppressants
  - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

### 3.10 Systemic Nasal Decongestants

### 3.11 Antifibrotics

## Trust Guidelines

Adult medicines and prescribing guidelines  
Paediatric medicines and prescribing guidelines  
Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Idiopathic pulmonary fibrosis (CG163)  
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)  
Inhaler devices for children under 5 (TA10)  
Asthma (older children) - inhaler devices (TA38)  
Asthma (in children) - corticosteroids (TA131)  
Asthma (in adults) - corticosteroids (TA138)  
Venom anaphylaxis - immunotherapy pharmlagen (TA246)  
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)  
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)  
Omalizumab for previously treated chronic spontaneous urticaria (TA339)  
Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)  
Reslizumab for treating severe eosinophilic asthma (TA479)  
Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)  
Benralizumab for treating severe eosinophilic asthma (TA565)  
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)  
Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)  
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)  
Dupilumab for treating severe asthma with type 2 inflammation (TA751)  
Palforzia for treating peanut allergy in children and young people (TA769)  
Tezepelumab for treating severe asthma (TA880)

## GMMMG Formulary

Formulary Homepage  
Chapter 3: Respiratory system (Complete)  
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 3.1 Bronchodilators                                                                       |  | GMMMG                                                                 |  |
|-------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------|--|
| <b>Asthma</b>                                                                             |  |                                                                       |  |
| <b>Methacholine Chloride</b><br><div>Red U</div> <i>Provocholine</i> ® nebuliser solution |  | <b>RESTRICTED</b> detection test for bronchial airway hyperreactivity |  |
| <b>3.1.1 Adrenoceptor agonists</b><br><b>3.1.1.1 Selective beta<sub>2</sub> agonists</b>  |  | GMMMG GMMMG GMMMG                                                     |  |
| <b>Salbutamol</b><br><div>Red</div> injection                                             |  |                                                                       |  |
| <b>Terbutaline Sulfate</b><br><div>Red</div> injection                                    |  |                                                                       |  |
| <b>Salmeterol</b>                                                                         |  |                                                                       |  |
| <b>Formoterol Fumarate</b>                                                                |  | <b>Asthma BTS step 3 add-on therapy</b>                               |  |
| <b>3.1.1.2 Other Adrenoceptor Agonists</b><br><b>Ephedrine Hydrochloride</b>              |  |                                                                       |  |
| <b>3.1.2 Antimuscarinic Bronchodilators</b><br><b>Ipratropium Bromide</b>                 |  | GMMMG GMMMG GMMMG                                                     |  |
| <b>Tiotropium</b>                                                                         |  | <b>1<sup>st</sup> line use</b>                                        |  |
| <b>Acclidinium Bromide</b><br><i>Eklira Genuair</i> ®                                     |  | <b>2<sup>nd</sup> line use</b><br>COPD maintenance                    |  |
| <b>Glycopyrronium Bromide</b><br><i>Seebri Breezhaler</i> ®                               |  | <b>2<sup>nd</sup> line use</b><br>COPD maintenance                    |  |
| <b>Umeclidinium Bromide</b><br><i>Incruse Ellipta</i> ®                                   |  | <b>2<sup>nd</sup> line use</b><br>COPD maintenance                    |  |
| <b>Compound Preparations</b>                                                              |  |                                                                       |  |
| <b>Acclidinium Bromide / Formoterol Fumarate Dihydrate</b><br><i>Duaklir Genuair</i> ®    |  | <b>3<sup>rd</sup> line use</b><br>COPD maintenance                    |  |
| <b>3.1.3 Theophylline</b>                                                                 |  |                                                                       |  |
| <b>Theophylline</b><br>M/R tablets; M/R capsules                                          |  | <b>1<sup>st</sup> line use</b><br><b>PRESCRIBE BY BRAND NAME</b>      |  |
| <b>Aminophylline</b><br><div>Red</div> injection<br>M/R tablets; injection                |  | <b>PRESCRIBE BY BRAND NAME</b>                                        |  |

| 3.1.4 Compound Bronchodilator Preparations                       |              | GMMMG             |                                                    |
|------------------------------------------------------------------|--------------|-------------------|----------------------------------------------------|
| <b>Ipratropium Bromide / Salbutamol</b>                          |              |                   |                                                    |
| Combivent®                                                       | BNF emc      |                   |                                                    |
| <b>Glycopyrronium Bromide / Formoterol Fumarate</b>              |              |                   | <b>3<sup>rd</sup> line use</b><br>COPD maintenance |
| Bevespi Aerosphere®                                              | MMC BNF emc  |                   |                                                    |
| <b>Glycopyrronium Bromide / Indacaterol Maleate</b>              |              |                   | <b>3<sup>rd</sup> line use</b><br>COPD maintenance |
| Ultibro®                                                         | MMC BNF emc  |                   |                                                    |
| <b>Tiotropium Bromide Monohydrate / Olodaterol Hydrochloride</b> |              |                   | <b>3<sup>rd</sup> line use</b><br>COPD maintenance |
| Spolto Respimat®                                                 | MMC BNF emc  |                   |                                                    |
| <b>Umeclidinium Bromide / Vilanterol Trifenatate</b>             |              |                   | <b>3<sup>rd</sup> line use</b><br>COPD maintenance |
| Anoro Ellipta®                                                   | MMC BNF emc  |                   |                                                    |
| 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers             |              | GMMMG GMMMG GMMMG |                                                    |
| <b>Inhaler Devices</b>                                           |              |                   |                                                    |
| <b>Volumatic® (spacer inhaler)</b>                               |              |                   |                                                    |
|                                                                  | NICE BNF     |                   |                                                    |
| <b>Aerochamber® Plus (spacer device)</b>                         |              |                   |                                                    |
|                                                                  | NICE BNF     |                   |                                                    |
| <b>Able Spacer® (spacer device)</b>                              |              |                   |                                                    |
|                                                                  | NICE MMC BNF |                   |                                                    |
| <b>Nebuliser Diluent</b>                                         |              |                   |                                                    |
| <b>Sodium Chloride</b>                                           |              |                   |                                                    |
| 0.9% nebuliser diluent                                           | BNF emc      |                   |                                                    |

## 3.2 Corticosteroids



### Corticosteroids



MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

#### Beclometasone Dipropionate

MDI (Clenil Modulite® 50, 100, 200, 250)



#### Beclometasone Dipropionate CFC-free

MDI (Qvar Easi-Breathe® or Qvar Autohaler® 50, 100)



**PRESCRIBE BY BRAND NAME**

#### Budesonide

DPI (Easyhaler®; Pulmicort® Turbuhaler® 100, 200, 400)  
500micrograms/2mL & 1mg/2mL nebuliser liquid



#### Fluticasone Propionate

MDI (FlixotideEvohaler®) 50, 125, 250;  
DPI (FlixotideAccuhaler® 50, 100, 250, 500)



### Compound preparations

#### Budesonide / Formoterol fumarate

DPI (Fobumix Easyhaler® 80/4.5, 160/4.5, 320/9);  
DPI (Symbicort Turbuhaler® 100/6, 200/6, 400/12);  
DPI (Duoresp Spiromax® 160/4.5, 320/9)



Asthma BTS step 3 management



#### Beclometasone Dipropionate / Formoterol fumarate

MDI (Fostair®100/6, 200/6); DPI (Fostair NEXThaler® 100/6, 200/6)



Asthma BTS step 3 management

#### Fluticasone Furoate / Vilanterol Trifenatate

DPI (Relvar Ellipta® 92/22 asthma or COPD; 184/22 asthma)



Asthma BTS step 3 management

#### Fluticasone Propionate / Salmeterol

MDI (Sirdupla® 125, 250)



Asthma BTS step 3 management

#### Fluticasone Propionate / Salmeterol

MDI (SeretideEvohaler® 50, 125, 250)



Asthma BTS step 3 management

#### Fluticasone Propionate / Formoterol Fumarate

MDI (Flutiform® 50/5, 125/5, 250/10)



Asthma BTS step 3 management

#### Beclometasone dipropionate / Formoterol fumarate / Glycopyrronium bromide

MDI (Trimbow 87/5/9® & 172/5/9®) DPI (Trimbow NEXThaler 88/5/9®)



**RESTRICTED - COPD patients who require triple therapy**

GMMMG  
COPD

GMMMG  
Asthma

#### Fluticasone Furoate / Vilanterol Trifenatate / Umeclidinium Bromide

DPI (Trelegy Ellipta® 92/55/22 micrograms)



**RESTRICTED - COPD patients who require triple therapy**

#### Formoterol fumarate / Glycopyrronium Bromide / Budesonide

DPI (Trixeo Aerosphere® 5/7.2/160 micrograms)



**RESTRICTED - COPD patients who require triple therapy**

#### Indacaterol / Mometasone Furoate

DPI (Atecura® Breezhaler®)



GMMMG Asthma Guideline 2022

#### Mometasone Furoate / Glycopyrronium Bromide / Indacaterol

DPI (Enerzair® Breezhaler®)



GMMMG Asthma Guideline 2022

MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

### 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists



#### 3.3.1 Cromoglicate & Related Therapy

##### Sodium Cromoglicate



#### 3.3.2 Leukotriene Receptor Antagonists

##### Montelukast

tablets; chewable tablets; sachets



BTS step 2 or 3 in paediatrics

MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

#### 3.3.3 Phosphodiesterase type-4 inhibitors

##### Roflumilast

Green

tablets



**RESTRICTED**  
as per NICE TA461

## 3.4 Antihistamines, hyposensitisation & allergic emergencies



### 3.4.1 Antihistamines

#### Non-sedating antihistamines

##### Cetirizine Hydrochloride

tablets; oral solution



##### Loratadine

tablets; oral solution



##### Desloratadine

tablets; oral solution



**RESTRICTED**  
children 1-2 years old

##### Fexofenadine Hydrochloride

tablets



#### Sedating antihistamines

##### Chlorphenamine Maleate

tablets; oral solution; injection



##### Hydroxyzine Hydrochloride

tablets; oral solution



MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes

##### Promethazine Hydrochloride

tablets; oral solution



##### Alimemazine Tartrate

DNP

tablets; oral solution



### 3.4.2 Allergen Immunotherapy

#### Allergoid immunotherapy tablets



Lofarma Lais®



**RESTRICTED**  
Immunology Consultants only

#### Bee venom extract

Red

injection



**RESTRICTED**  
Immunology Consultants only

#### Wasp venom extract

Red

injection



**RESTRICTED**  
Immunology Consultants only

#### Grass & Rye or tree pollen extract

Red

Pollinex®



**RESTRICTED**  
Immunology Consultants only

#### Grass Pollen extract

DNP

Grazax® oral lyophilisates



**RESTRICTED**  
Immunology Consultants only

#### House Dust Mite extract

Red

Acarizax 12-SQ HDM oral lyophilisates®



**RESTRICTED**  
Immunology Consultants only

#### Peanut Protein powder

Red

££

Palforza® oral powder in capsules; sachet



**RESTRICTED**  
Immunology Consultants only

#### Wasp venom extract

Red

injection



**RESTRICTED**  
Immunology Consultants only

#### White birch (*Betula verrucosa*) Pollen extract

Red

Itulazax 12-SQ Bet oral lyophilisates®



**RESTRICTED**  
Immunology Consultants only

#### Omalizumab

##### Omalizumab

Red

DNP

££

injection



**RESTRICTED**  
as per NICE

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| <b>Anti-interleukin-5 (IL-5) antibody</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                               |
| <b>Benralizumab</b><br> <br><i>Fasenra</i> ® injection<br>                                                                                                                | <b>RESTRICTED</b><br>as per NICE TA565                                                                                        |
| <b>Dupilumab</b><br>  <br><i>Dupixent</i> ® injection (see also section 13.5.3)<br>      | <b>RESTRICTED</b><br>as per NICE TA751                                                                                        |
| MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                               |
| <b>Mepolizumab</b><br> <br><i>Nucala</i> ® injection<br>                                                                                                                  | <b>RESTRICTED</b><br>as per NICE                                                                                              |
| <b>Reslizumab</b><br> <br><i>Cinqaero</i> ® infusion<br>                                                                                                                  | <b>RESTRICTED</b><br>as per NICE TA479<br><b>NOT STOCKED</b>                                                                  |
| <b>Tezepelumab</b><br> <br><i>Tezspire</i> ® injection<br>                                                                                                                | <b>RESTRICTED</b><br>as per NICE TA880                                                                                        |
| <b>3.4.3 Allergic Emergencies</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                               |
| <b>Adrenaline / Epinephrine</b><br><br>injection<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>PRESCRIBE BY BRAND NAME</b>                                                                                                |
| MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                               |
| MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                               |
| MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                               |
| <b>Berotrastat</b><br> <br><i>Orladeyo</i> ® capsules<br>                                                                                                                                                                                                    | <b>RESTRICTED</b><br><b>specialist use only</b><br>as per NICE TA738                                                          |
| <b>C1 esterase inhibitor</b><br> <br><i>Beriner</i> ®; <i>Cinryze</i> ® injection<br>                                                                                   | <b>RESTRICTED</b><br>acute attacks of HAE  |
| <b>Conestat Alfa</b><br> <br><i>Ruconest</i> ® injection<br>                                                                                                                                                                                 | <b>RESTRICTED</b> adults<br>acute attacks of HAE                                                                              |
| <b>Icatibant</b><br> <br><i>Firazyr</i> ® injection<br>                                                                                                 | <b>RESTRICTED</b> adults<br>acute attacks of HAE                                                                              |
| <b>Lanadelumab</b><br> <br><i>Takhzyro</i> ® injection<br>                                                                                                | <b>RESTRICTED</b><br>in line with NICE TA606                                                                                  |
| <b>Oxandrolone</b><br><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | <b>RESTRICTED</b> adults<br>acute attacks of HAE                                                                              |

| 3.5 Respiratory stimulants & pulmonary surfactants                                                   |                                                                                                                                                                                                                                                                         | GMMMG                                           |
|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| 3.5.1 Respiratory Stimulants                                                                         |                                                                                                                                                                                                                                                                         |                                                 |
| Doxapram Hydrochloride                                                                               |                                                                                                                                                                                                                                                                         |                                                 |
| injection                                                                                            | <br>BNF                                                                                             |                                                 |
| Caffeine Citrate                                                                                     |                                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>apnoea in premature babies |
| injection                                                                                            | <br>MMC <br>BNF    |                                                 |
| 3.5.2 Pulmonary Surfactants                                                                          |                                                                                                                                                                                                                                                                         |                                                 |
| Poractant Alfa                                                                                       |                                                                                                                                                                                                                                                                         |                                                 |
| <br>Curosurf® liquid | <br>PbR X <br>BNF  |                                                 |

## 3.6 Oxygen ([refer to oxygen guidelines](#))



## 3.7 Mucolytics



### Mucolytics

#### Sodium Chloride (hypertonic)

Nebusal® 7% nebulules



#### Mannitol inhalation powder

Red

Bronchitol® capsules



#### Mannitol diagnostic kit

Red

Osmohale® capsules



#### Carbocysteine

capsules; oral solution; sachets



#### Dornase Alfa

Red

££

Pulmozyme® nebulules



#### Elexacaftor with Tezacaftor and Ivacaftor

Red

££

Kaftrio® tablets



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

#### Ivacaftor

Red

££

Kalydeco® tablets; granules



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

#### Lumacaftor with Ivacaftor

Red

££

Orkambi® tablets; granules



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

#### Tezacaftor with Ivacaftor

Red

££

Symkevi® tablets



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

**RESTRICTED**  
Respiratory only in line with NICE

**RESTRICTED**  
Respiratory only

**RESTRICTED**  
COPD Consultant / referral only

**RESTRICTED**  
Respiratory only

**RESTRICTED**  
Specialist use only

NHS  
England

**RESTRICTED**  
Paediatric Consultants only

NHS  
England

**RESTRICTED**  
Specialist use only

NHS  
England

**RESTRICTED**  
Specialist use only

NHS  
England

| 3.8 Aromatic inhalations                   |                                                                                                                                                                       | GMMMG |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Aromatic Inhalations                       |                                                                                                                                                                       |       |
| Benzoin Tincture, Compound, BP             |   |       |
| <i>Friars' Balsam liquid</i>               |                                                                                                                                                                       |       |
| Menthol and Eucalyptus Inhalation, BP 1980 |   |       |
| inhalation vapour                          |                                                                                                                                                                       |       |

## 3.9 Cough preparations



### 3.9.1 Cough Suppressants

#### Codeine Phosphate

oral solution



MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine

#### Pholcodine

oral solution



**Withdrawn from UK market as per  
MHRA alert March 2023**

MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure

#### Dextromethorphan hydrobromide

oral solution



**RESTRICTED**  
non-ketotic hyperglycinaemia

#### Cough Suppressants *(Palliative Care ONLY)*

#### Methadone Hydrochloride

liquid



#### Morphine Hydrochloride

oral solution



### 3.9.2 Demulcent & expectorant cough preparations

#### Simple Linctus

liquid



3.10 Systemic nasal decongestants



Systemic Nasal Decongestants

NO DRUGS ARE RECOMMENDED FROM THIS GROUP



NHSE: OTC prescribing reduction

|                                                                                                                                                                                                                                                                                                            |  |                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------|
| 3.11 Antifibrotics                                                                                                                                                                                                                                                                                         |  |             |
| Antifibrotics                                                                                                                                                                                                                                                                                              |  |                                                                                               |
| <div><div>Pirfenidone</div><div><div>Red</div><div>££</div></div><div>capsules; tablets</div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div><div></div><div>bluebird bio</div></div></div> |  | <div><div>RESTRICTED</div><div>Respiratory Consultants only</div><div>NOT STOCKED</div></div> |
| MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing                                                                                                                                                                            |  |                                                                                               |

## Chapter 4: Central Nervous System

Supported by the  
formulary ([click here](#))



### 4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.1.4 Other hypnotics and anxiolytics

### 4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

### 4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

### 4.4 CNS stimulants & drugs used for ADHD

### 4.5 Drugs used in the treatment of obesity

### 4.6 Drugs used in nausea & vertigo

### 4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

### 4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

### 4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

### 4.10 Drugs used in substance dependence

### 4.11 Drugs for dementia

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)  
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)  
 Drug misuse: opioid detoxification (CG52)  
 Depression with a chronic physical health problem (CG91)  
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)  
 Anxiety (CG113) (replaces CG22)  
 Neuropathic pain - pharmacological management (CG173)  
 Psychosis and schizophrenia in adults (CG178)  
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)  
 Eating Disorders: recognition and treatment (NG69)  
 Parkinson's disease in adults (NG71)  
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)  
 Stop smoking interventions and services (NG92)  
 Dementia: supporting people with dementia and their carers in health and social care (NG97)  
 Post-traumatic stress disorder (NG116)  
 Depression in children and young people: identification and management (NG134)  
 Epilepsies in children, young people and adults (NG217)  
 Depression in adults: treatment and management (NG222)  
 Motor Neurone Disease: Riluzole (TA20)  
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)  
 Drug Misuse: Methadone & Buprenorphine (TA114)  
 Drug Misuse: Naltrexone (TA115)  
 Smoking Cessation: Varenicline (TA123)  
 Schizophrenia - aripiprazole (TA213)  
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)  
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)  
 Bipolar disorder (children) - aripiprazole (TA292)  
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)  
 Vortioxetine for treating major depressive episodes (TA367)  
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)  
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)  
 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)  
 Galcanezumab for preventing migraine (TA659)  
 Cenobamate for treating focal onset seizures in epilepsy (TA753)  
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)  
 Fremanezumab for preventing migraine (replacing TA631) (TA764)  
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)  
 Eptinezumab for preventing migraine (TA871)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Rimegepant for preventing migraine (TA906)  
 Rimegepant for treating migraine (TA919)  
 Daridorexant for treating long-term insomnia (TA922)

## GMMMG Formulary

Formulary Homepage  
 Chapter 4: Central Nervous system (Complete)  
 GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 4.1 Hypnotics & anxiolytics                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                       | GMMMG                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 4.1.1 Hypnotics                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                       | NICE CG112                                                                                               |
| Benzodiazepines                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Temazepam</b><br>                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets; oral solution                                                                                                                                                                                                                                                        | BNF                                                                                                                                                                               |                                                                                                          |
| <b>Nitrazepam</b><br>                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets; oral suspension                                                                                                                                                                                                                                                      | BNF                                                                                                                                                                               |                                                                                                          |
| Zaleplon, Zolpidem & Zopiclone                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Zopiclone</b><br>                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets                                                                                                                                                                                                                                                                       | NICE  BNF                                                                                        |                                                                                                          |
| Chloral & Derivatives                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Chloral Hydrate</b><br>                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| oral solution; suppositories                                                                                                                                                                                                                                                  | BNF                                                                                                                                                                               |                                                                                                          |
| MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Clomethiazole</b><br>                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| 192mg capsules                                                                                                                                                                                                                                                                | BNF                                                                                                                                                                               |                                                                                                          |
| Sodium Oxybate                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Sodium Oxybate</b><br>   |                                                                                                                                                                                                                                                                                                                                                       | <b>RESTRICTED</b><br>2 <sup>nd</sup> line narcolepsy with cataplexy                                      |
| oral solution                                                                                                                                                                                                                                                                 | PbR X  BNF    |                                                                                                          |
| Melatonin                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Melatonin</b><br>                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                       | <b>RESTRICTED</b><br> |
| capsules; tablets; oral solution                                                                                                                                                                                                                                              | MMC                                                                                                                                                                               |                                                                                                          |
| Melatonin (licensed product 1 <sup>st</sup> line) - Paediatric patients, e.g. sleep disorders, ADHD                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                       |                      |
| Melatonin (licensed product only) - Adult patients over 55yrs of age                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                       |                     |
| Melatonin - management of jet lag                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                       |                     |
| 4.1.2 Anxiolytics                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                       | NICE CG113                                                                                               |
| Benzodiazepines                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Chlordiazepoxide hydrochloride</b><br>                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                       | <b>Symptomatic relief of acute alcohol withdrawal</b>                                                    |
| capsules                                                                                                                                                                                                                                                                      | BNF                                                                                                                                                                           |                                                                                                          |
| <b>Diazepam</b><br>                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets; liquid; injection; rectal tube                                                                                                                                                                                                                                       | BNF                                                                                                                                                                           |                                                                                                          |
| <b>Lorazepam</b><br>                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets; injection                                                                                                                                                                                                                                                            | BNF                                                                                                                                                                           |                                                                                                          |
| <b>Oxazepam</b><br>                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets                                                                                                                                                                                                                                                                       | BNF                                                                                                                                                                           |                                                                                                          |
| Busiprone                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Busiprone Hydrochloride</b><br>                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| tablets                                                                                                                                                                                                                                                                       | BNF                                                                                                                                                                           |                                                                                                          |
| Others                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Pregabalin</b><br>                                                                                    |                                                                                                                                                                                                                                                                                                                                                       | <b>RESTRICTED</b> generalised anxiety disorder after standard treatment following NICE has failed.       |
| capsules; oral solution                                                                                                                                                                                                                                                       | MMC  BNF                                                                                   |                                                                                                          |
| 4.1.3 Barbiturates                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>NO DRUGS ARE RECOMMENDED FROM THIS GROUP</b>                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| 4.1.4 Other hypnotics and anxiolytics                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                       |                                                                                                          |
| <b>Daridorexant</b><br>                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                       | <b>RESTRICTED</b><br>in line with NICE TA922<br><b>NOT STOCKED</b>                                       |
| Quviviq® tablets                                                                                                                                                                                                                                                              | NICE  BNF                                                                                  |                                                                                                          |

| 4.2 Drugs used in psychoses & related disorders                                                                                                  |                                                                                                                                                                                                                                                                                                                                                          | GMMMG                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| 4.2.1 Antipsychotic Drugs                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                          | NICE CG178                                                            |
| MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia                                 |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Chlorpromazine Hydrochloride</b><br>Green<br>tablets; oral solution; injection                                                                | <br><br>                                                                                           |                                                                       |
| <b>Haloperidol</b><br>Green<br>tablets; capsules; oral solution                                                                                  | <br><br>                                                                                          |                                                                       |
| MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium      |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Levomepromazine</b><br>Green<br>tablets                                                                                                       | <br><br>                                                                                          |                                                                       |
| <b>Promazine Hydrochloride</b><br>tablets; oral solution                                                                                         | <br><br>                                                                                          |                                                                       |
| <b>Sulpiride</b><br>tablets; oral solution                                                                                                       | <br><br>                                                                                          |                                                                       |
| <b>Trifluoperazine</b><br>tablets; oral solution                                                                                                 | <br><br>                                                                                          |                                                                       |
| <b>Zuclopenthixol</b><br>tablets                                                                                                                 | <br><br>                                                                                          |                                                                       |
| <b>Atypical Antipsychotic Drugs</b>                                                                                                              |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Amisulpride</b><br>Amber Red<br>tablets; oral solution                                                                                        | <br><br>                                                                                           | <b>RESTRICTED</b> adults.<br>Consultant Psychiatrist only             |
| <b>Aripiprazole</b><br>Amber Red<br>tablets; oral solution                                                                                       | <br><br>  | <b>RESTRICTED</b> paediatrics.<br>Consultant Psychiatrist only        |
| MHRA Drug Safety Update (Dec-23): Aripiprazole (Ablify and generic brands): risk of pathological gambling                                        |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Clozapine</b><br>Red<br>tablets                                                                                                               | <br><br>                                                                                    |                                                                       |
| MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity                               |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Olanzapine</b><br>Amber Red<br>tablets; orodispersible tablets; oral solution                                                                 | <br><br>                                                                                    |                                                                       |
| <b>Quetiapine</b><br>Amber Red<br>tablets; M/R tablets                                                                                           | <br><br>                                                                                     | <b>RESTRICTED</b> - Consultant initiation -<br>schizophrenia patients |
| <b>Risperidone</b><br>Amber Red<br>tablets; orodispersible tablets; oral solution                                                                | <br><br>                                                                                    |                                                                       |
| <b>4.2.2 Antipsychotic Depot Injections</b>                                                                                                      |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Flupentixol Decanoate</b><br>Amber<br>injection                                                                                               | <br><br>                                                                                    | <b>RESTRICTED</b><br>Consultant Psychiatrist only                     |
| <b>Fluphenazine Decanoate</b><br>Amber<br>injection                                                                                              | <br><br>                                                                                    | <b>RESTRICTED</b><br>Consultant Psychiatrist only                     |
| <b>Haloperidol Decanoate</b><br>Amber<br>injection                                                                                               | <br><br>                                                                                    | <b>RESTRICTED</b><br>Consultant Psychiatrist only                     |
| MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium      |                                                                                                                                                                                                                                                                                                                                                          |                                                                       |
| <b>Risperidone</b><br>Amber<br>injection                                                                                                         | <br><br>                                                                                    | <b>RESTRICTED</b><br>Consultant Psychiatrist only                     |
| <b>Zuclopenthixol Decanoate</b><br>Amber<br>injection                                                                                            | <br><br>                                                                                    | <b>RESTRICTED</b><br>Consultant Psychiatrist only                     |

|                                                                                                                                                  |                                                                                                                                                                       |                                |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--|
| 4.2.3 Drugs used for mania and hypomania                                                                                                         |                                                                                                                                                                       |                                |  |
| <b>Lithium Carbonate</b><br><div>Amber</div><br>tablets; M/R tablets                                                                             |   | <b>PRESCRIBE BY BRAND NAME</b> |  |
| <b>Lithium Citrate</b><br><div>Amber</div><br>oral solution                                                                                      |   | <b>PRESCRIBE BY BRAND NAME</b> |  |
| <b>Valproic Acid</b><br><div>Green</div><br>Gastro-resistant tablets                                                                             |   |                                |  |
| MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance |                                                                                                                                                                       |                                |  |
| MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended                                                |                                                                                                                                                                       |                                |  |

| 4.3 Antidepressant drugs                                                                                                                                    |                                                                                                                                                                            | GMMMG                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
|                                                                                                                                                             |                                                                                                                                                                            | NICE CG31                                                     |
|                                                                                                                                                             |                                                                                                                                                                            | NICE CG91                                                     |
| 4.3.1 Tricyclic & Related Antidepressant Drugs                                                                                                              |                                                                                                                                                                            | NICE NG134                                                    |
| Tricyclic antidepressants                                                                                                                                   |                                                                                                                                                                            | NICE NG222                                                    |
| <b>Amitriptyline Hydrochloride</b> (standard release preparations only)                                                                                     |                                                                                                                                                                            |                                                               |
| tablets; oral solution                                                                                                                                      |       |                                                               |
| <b>Clomipramine Hydrochloride</b> (standard release preparations only)                                                                                      |                                                                                                                                                                            |                                                               |
| capsules                                                                                                                                                    |       |                                                               |
| <b>Doxepin Hydrochloride</b>                                                                                                                                |                                                                                                                                                                            |                                                               |
| capsules                                                                                                                                                    |       |                                                               |
| <b>Imipramine Hydrochloride</b>                                                                                                                             |                                                                                                                                                                            |                                                               |
| tablets                                                                                                                                                     |       |                                                               |
| <b>Lofepramine</b>                                                                                                                                          |                                                                                                                                                                            | 1 <sup>st</sup> line use                                      |
| tablets; oral suspension                                                                                                                                    |       |                                                               |
| <b>Nortriptyline</b>                                                                                                                                        |                                                                                                                                                                            |                                                               |
| tablets                                                                                                                                                     |       |                                                               |
| <b>Trimipramine</b>                                                                                                                                         |                                                                                                                                                                            |                                                               |
| DNP                                                                                                                                                         |       |                                                               |
| tablets; capsules                                                                                                                                           |       |                                                               |
| Tricyclic-related antidepressants                                                                                                                           |                                                                                                                                                                            |                                                               |
| <b>Mianserin Hydrochloride</b>                                                                                                                              |                                                                                                                                                                            | RESTRICTED<br>initiation by Psychiatrist                      |
| tablets                                                                                                                                                     |     |                                                               |
| <b>Trazodone Hydrochloride</b>                                                                                                                              |                                                                                                                                                                            | RESTRICTED<br>initiation by Psychiatrist                      |
| capsules; tablets; oral solution                                                                                                                            |   |                                                               |
| 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)                                                                                                                  |                                                                                                                                                                            |                                                               |
| <b>Isocarboxazid</b>                                                                                                                                        |                                                                                                                                                                            | RESTRICTED<br>initiation by Psychiatrist                      |
| Red                                                                                                                                                         |   |                                                               |
| tablets                                                                                                                                                     |   |                                                               |
| <b>Phenelzine</b>                                                                                                                                           |                                                                                                                                                                            | RESTRICTED<br>initiation by Psychiatrist                      |
| Red                                                                                                                                                         |   |                                                               |
| 15mg tablets                                                                                                                                                |   |                                                               |
| <b>Tranylcypromine</b>                                                                                                                                      |                                                                                                                                                                            | RESTRICTED<br>initiation by Psychiatrist                      |
| Red                                                                                                                                                         |   |                                                               |
| 10mg tablets                                                                                                                                                |   |                                                               |
| Reversible Monoamine-Oxidase Inhibitors (MAOIs)                                                                                                             |                                                                                                                                                                            |                                                               |
| <b>Moclobemide</b>                                                                                                                                          |                                                                                                                                                                            | RESTRICTED 2 <sup>nd</sup> line<br>initiation by Psychiatrist |
| Green                                                                                                                                                       |   |                                                               |
| 150mg; 300mg tablets                                                                                                                                        |   |                                                               |
| 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)                                                                                                      |                                                                                                                                                                            |                                                               |
| MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |                                                                                                                                                                            |                                                               |
| <b>Fluoxetine</b>                                                                                                                                           |                                                                                                                                                                            |                                                               |
| capsules; tablets; dispersible tablets; oral solution                                                                                                       |   |                                                               |
| <b>Citalopram</b>                                                                                                                                           |                                                                                                                                                                            |                                                               |
| tablets; oral drops                                                                                                                                         |   |                                                               |
| MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use         |                                                                                                                                                                            |                                                               |
| MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation                                                                     |                                                                                                                                                                            |                                                               |
| <b>Sertraline</b>                                                                                                                                           |                                                                                                                                                                            |                                                               |
| tablets; oral suspension                                                                                                                                    |   |                                                               |
| <b>Fluvoxamine maleate</b>                                                                                                                                  |                                                                                                                                                                            |                                                               |
| tablets                                                                                                                                                     |   |                                                               |
| <b>Paroxetine</b>                                                                                                                                           |                                                                                                                                                                            |                                                               |
| tablets; oral suspension                                                                                                                                    |   |                                                               |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| <b>Escitalopram</b><br><br>tablets<br><br>                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Mental Health Trust initiation only |
| MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation                                                                                                                                                                                                                                                                                                                                                                                  |                                                          |
| <b>4.3.4 Other Antidepressant Drugs</b>                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                          |
| <b>Venlafaxine</b><br><br><br>M/R capsules; tablets; M/R tablets<br><br>                                                                                                                                            | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Mirtazapine</b><br><br>tablets; orodisperible tablets; oral solution<br><br>                                                                                                                                    | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Duloxetine</b><br><br><br>gastro-resistant tablets<br><br>                                                                                                                                                       | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Flupentixol</b><br><br>tablets<br><br>                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Reboxetine</b><br><br>tablets<br><br>                                                                                                                                                                           | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Tryptophan</b><br><br>capsules<br><br>                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>initiation by Psychiatrist          |
| <b>Vortioxetine</b><br><br><br>tablets<br><br>    | <b>RESTRICTED</b><br>initiation by Psychiatrist          |

| 4.4 CNS stimulants & drugs used for ADHD                                                                                                                                                                                                             |  | GMMMG                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------|
| 4.4 CNS stimulants & drugs used for ADHD GMMMG                                                                                                                                                                                                       |  | NICE NG87                                                                                 |
| <b>Atomoxetine</b><br>Amber<br>capsules<br>NICE MMC BNF emc                                                                                                                                                                                          |  | <b>RESTRICTED</b><br>on Paediatric / Psychiatric advice                                   |
| MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate<br>MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents                            |  |                                                                                           |
| <b>Dexamfetamine</b><br>Amber CD Red<br>tablets<br>NICE BNF emc                                                                                                                                                                                      |  | <b>RESTRICTED</b><br>on Paediatric / Psychiatric advice                                   |
| <b>Guanfacine</b><br>Amber<br>Prolonged release tablets<br>NICE MMC BNF emc                                                                                                                                                                          |  | <b>RESTRICTED</b><br>2 <sup>nd</sup> line use for ADHD                                    |
| <b>Lisdexamfetamine</b><br>Amber CD<br>capsules<br>NICE MMC BNF GMMMG emc                                                                                                                                                                            |  | <b>RESTRICTED</b><br>2 <sup>nd</sup> line use for ADHD                                    |
| <b>Methylphenidate</b><br>Amber CD<br>tablets; M/R tablets; capsules; M/R capsules<br>NICE MMC BNF emc                                                                                                                                               |  | <b>RESTRICTED</b><br>on Paediatric / Psychiatric advice<br><b>PRESCRIBE BY BRAND NAME</b> |
| MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations<br>MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD |  |                                                                                           |
| <b>Modafinil</b><br>Green DNP Red<br>tablets<br>BNF emc                                                                                                                                                                                              |  | <b>RESTRICTED</b><br>on Paediatric / Psychiatric advice                                   |
| MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy<br>MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy                                  |  |                                                                                           |
| <b>Solriamfetol hydrochloride</b><br>Red £<br>Sunosi® tablets<br>NICE MMC BNF emc                                                                                                                                                                    |  | <b>RESTRICTED</b><br>Sleep Centre only in line with NICE                                  |

## 4.5 Drugs used in the treatment of obesity



### 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract

**NICE CG43**

#### Orlistat

**RESTRICTED**
**Consultant initiation - Paeds. only**

capsules



MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines

| 4.6 Drugs used in nausea & vertigo                                                                                                                                               |                                                                                                                                                                                                                                                                             | GMMMG                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| <b>Antihistamines</b>                                                                                                                                                            |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Cyclizine</b>                                                                                                                                                                 |                                                                                                                                                                                                                                                                             | 1 <sup>st</sup> line use                                        |
| tablets; injection                                                                                                                                                               | <br>BNF                                                                                                 |                                                                 |
| <b>Promethazine Hydrochloride</b>                                                                                                                                                |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets; oral solution (see also section 3.4.1)                                                                                                                                  | <br>BNF                                                                                                 |                                                                 |
| <b>Promethazine Teoclate</b>                                                                                                                                                     |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets                                                                                                                                                                          | <br>BNF                                                                                                 |                                                                 |
| <b>Phenothiazines &amp; Related Drugs</b>                                                                                                                                        |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Prochlorperazine</b>                                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets; buccal tablet; injection                                                                                                                                                | <br>BNF                                                                                                 |                                                                 |
| <b>Droperidol</b>                                                                                                                                                                |                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b><br>Consultant initiation only for PONV        |
| injection                                                                                                                                                                        | <br>MMC <br>BNF        |                                                                 |
| <b>Domperidone &amp; Metoclopramide</b>                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Domperidone</b>                                                                                                                                                               |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets; oral suspension (see also section 1.2)                                                                                                                                  | <br>BNF                                                                                                 |                                                                 |
| MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents                     |                                                                                                                                                                                                                                                                             |                                                                 |
| MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects                                                                          |                                                                                                                                                                                                                                                                             |                                                                 |
| MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects                                                                                                     |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Metoclopramide Hydrochloride</b>                                                                                                                                              |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets; oral suspension; injection (see also section 1.2)                                                                                                                       | <br>BNF                                                                                                 |                                                                 |
| MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects                                                                                           |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>5HT<sub>3</sub>-receptor antagonists</b>                                                                                                                                      |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Ondansetron</b>                                                                                                                                                               |                                                                                                                                                                                                                                                                             | <b>RESTRICTED - Chemotherapy induced &amp; post-op vomiting</b> |
|  Red  Green | <br>BNF                                                                                             |                                                                 |
| tablets; orodispersible tablets; injection; oral solution; orodispersible film                                                                                                   |                                                                                                                                                                                                                                                                             |                                                                 |
| MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation                                                                       |                                                                                                                                                                                                                                                                             |                                                                 |
| MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction                                                                               |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Neurokinin 1-receptor antagonist</b>                                                                                                                                          |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Aprepitant</b>                                                                                                                                                                |                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b><br>highly / moderately emetogenic CINV        |
| 80mg; 125mg capsules; 25mg/mL oral suspension                                                                                                                                    | <br>MMC <br>BNF  |                                                                 |
| <b>Cannabinoids</b>                                                                                                                                                              |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Nabilone</b>                                                                                                                                                                  |                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b><br>highly emetogenic CINV                     |
|  Red                                                                                           | <br>MMC <br>BNF  |                                                                 |
| 0.25mg; 1mg capsules                                                                                                                                                             |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Hyoscine</b>                                                                                                                                                                  |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Hyoscine Hydrobromide</b>                                                                                                                                                     |                                                                                                                                                                                                                                                                             |                                                                 |
| patches; tablets (for Hyoscine Butylbromide see section 1.2)                                                                                                                     | <br>MMC <br>BNF  |                                                                 |
| MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia                                                    |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Other Drugs for Ménière's Disease</b>                                                                                                                                         |                                                                                                                                                                                                                                                                             |                                                                 |
| <b>Betahistine Dihydrochloride</b>                                                                                                                                               |                                                                                                                                                                                                                                                                             |                                                                 |
| tablets                                                                                                                                                                          | <br>BNF                                                                                             |                                                                 |

| 4.7 Analgesics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |  | GMMMG                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------|
| 4.7.1 Non-Opioid Analgesics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | (see also Chapter 10 for NSAIDs)                                        |
| <b>Paracetamol</b><br>tablets; soluble tablets; infusion; injection; oral suspension; suppositories<br>                                                                                                                                                                                                                                                                                                    |  | <b>1<sup>st</sup> line use</b>                                          |
| <b>Sucrose 24% solution</b><br>Sweet-Ease® oral solution<br>                                                                                                                                                                                                                                                                                                                                               |  | <b>RESTRICTED</b><br>Pain relief in neonates                            |
| Compound Analgesic Preparations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |                                                                         |
| <b>Paracetamol and codeine (Co-codamol®)</b><br>tablets; effervescent tablets<br>                                                                                                                                                                                                                                                                                                                          |  |                                                                         |
| <b>Paracetamol and dihydrocodeine (Co-dydramol®)</b><br>tablets<br>                                                                                                                                                                                                                                                                                                                                        |  |                                                                         |
| 4.7.2 Opioid Analgesics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |                                                                         |
| MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  |                                                                         |
| <b>Buprenorphine</b><br><br><b>NOT patch</b><br>                                                                                                                                                                                                                                                                           |  | <b>RESTRICTED</b>                                                       |
| <b>Codeine Phosphate</b><br>tablets; syrup; injection<br>                                                                                                                                                                                                                                                                                                                                                  |  |                                                                         |
| MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  |                                                                         |
| MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |  |                                                                         |
| <b>Diamorphine Hydrochloride</b><br><br>injection<br>                                                                                                                                                                                                                                                                      |  |                                                                         |
| <b>Difelikefalin</b><br><br>Kaprivia® injection<br>      |  | <b>RESTRICTED</b><br>Renal Consultants in line with NICE                |
| <b>Dihydrocodeine Tartrate</b> standard release preparations only<br>tablets<br>                                                                                                                                                                                                                                                                                                                     |  |                                                                         |
| <b>Fentanyl</b><br> <br><b>NOT lozenge</b><br>                                                                                               |  | <b>Spray RESTRICTED</b> palliative care & haematology initiation (Wd44) |
| MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  |                                                                         |
| MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                         |
| <b>Methadone Hydrochloride</b><br><br>oral solution<br>                                                                                                                                                                         |  | <b>RESTRICTED</b><br>palliative care & substance misuse                 |
| <b>Morphine Sulphate</b><br><br>tablets; M/R tablets; capsules; M/R capsules; oral solution; injection<br>                                                                                                                                                                                                         |  |                                                                         |
| <b>Morphine Sulphate</b><br> <br>Actimorph® orodispersible tablets<br>                                                                       |  | <b>RESTRICTED</b><br>palliative care / GMMMG                            |
| <b>Oxycodone Hydrochloride</b><br><br>capsules; liquid; tablets; M/R tablets; injection<br>                                                                                                                                     |  | <b>RESTRICTED</b><br>2 <sup>nd</sup> line for morphine intolerance      |
| <b>Pethidine Hydrochloride</b><br><br>injection; tablets<br>                                                                                                                                                                                                                                                       |  |                                                                         |
| <b>Tapentadol Hydrochloride MR</b><br><br>tablets<br>                                                                                                                                                                           |  | <b>RESTRICTED</b><br>3 <sup>rd</sup> line - Pain Team Consultants only  |
| MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                         |
| <b>Tramadol Hydrochloride</b><br><br>capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection<br>                                                                                                                                                                                                  |  |                                                                         |

|                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| 4.7.3 Neuropathic Pain                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Amitriptyline                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; oral solution                                                                                                                                   |                                                                                                                                                                                                                                                                   |                                                                                           |
| Carbamazepine                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; M/R tablets; oral solution; suppositories                                                                                                       |                                                                                                                                                                                                                                                                   |                                                                                           |
| MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions                             |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Gabapentin                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| capsules; oral suspension                                                                                                                                |                                                                                                                                                                                                                                                                   |                                                                                           |
| MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Pregabalin                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                       | 3 <sup>rd</sup> / 4 <sup>th</sup> line use if gabapentin contraindicated or not tolerated |
| capsules; oral solution                                                                                                                                  |                                                                                                                                                                                  |                                                                                           |
| MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| 4.7.4 Antimigraine Drugs                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| 4.7.4.1 Treatment Of Acute Migraine                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Analgesics                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Aspirin                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; dispersible tablets; E/C tablets; suppositories                                                                                                 |                                                                                                                                                                                                                                                                   |                                                                                           |
| Paracetamol                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; soluble tablets; oral suspension; infusion; suppositories                                                                                       |                                                                                                                                                                                                                                                                   |                                                                                           |
| Ibuprofen                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; M/R tablets; oral suspension; sachets                                                                                                           |                                                                                                                                                                                                                                                                |                                                                                           |
| 5HT <sub>1</sub> receptor agonists                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Sumatriptan                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets; nasal spray; injection                                                                                                                          |                                                                                                                                                                                                                                                               |                                                                                           |
| 4.7.4.2 Prophylaxis of Migraine                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| Botulinum Toxin Type A                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                       | RESTRICTED<br>Specialist use only<br>in line with NICE                                    |
| Botox® injection                                                                                                                                         |      |                                                                                           |
| Clonidine Hydrochloride                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets                                                                                                                                                  |                                                                                                                                                                                                                                                               |                                                                                           |
| Erenumab                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                       | RESTRICTED<br>Specialist use only<br>NOT STOCKED                                          |
| injection                                                                                                                                                |                                                                                         |                                                                                           |
| Eptinezumab                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                       | RESTRICTED<br>Specialist use only<br>NOT STOCKED                                          |
| injection                                                                                                                                                |                                                                                         |                                                                                           |
| Fremanezumab                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                       | RESTRICTED<br>Specialist use only<br>NOT STOCKED                                          |
| injection                                                                                                                                                |                                                                                         |                                                                                           |
| Galcanezumab                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                       | RESTRICTED<br>Specialist use only<br>NOT STOCKED                                          |
| injection                                                                                                                                                |                                                                                         |                                                                                           |
| Pizotifen                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                           |
| tablets                                                                                                                                                  |                                                                                                                                                                                                                                                               |                                                                                           |

| 4.8 Antiepileptic drugs                                                                                                                                               |  | GMMMG                                                      |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------|--|
| 4.8.1 Control of the Epilepsies                                                                                                                                       |  | NICE NG217                                                 |  |
| <b>Carbamazepine</b><br><div>Green</div>                                                                                                                              |  |                                                            |  |
| tablets; M/R tablets; oral solution; suppositories                                                                                                                    |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions                                          |  |                                                            |  |
| <b>Phenobarbital</b><br><div>Green</div> <div>CD</div>                                                                                                                |  |                                                            |  |
| tablets; oral solution; injection                                                                                                                                     |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| <b>Phenytoin Sodium</b><br><div>Green</div>                                                                                                                           |  |                                                            |  |
| capsules; oral suspension; injection                                                                                                                                  |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| <b>Sodium Valproate</b><br><div>Green</div>                                                                                                                           |  |                                                            |  |
| tablets; M/R tablets; oral solution; M/R granules; injection                                                                                                          |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines                                                                    |  |                                                            |  |
| MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate                                                        |  |                                                            |  |
| MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements...                                                       |  |                                                            |  |
| MHRA Drug Safety Update (Jan-20): Valproate (Epilem ▼, Depakote ▼) pregnancy prevention programme: updated educational materials                                      |  |                                                            |  |
| MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance...                   |  |                                                            |  |
| MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilem ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met |  |                                                            |  |
| MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended                                                                     |  |                                                            |  |
| <b>Cenobamate</b><br><div>Green</div>                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only in line with NICE |  |
| Ontozry® tablets                                                                                                                                                      |  | <div>NICE</div> <b>MMC</b> <div>BNF</div> <div>emc</div>   |  |
| <b>Clobazam</b><br><div>Green</div>                                                                                                                                   |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral suspension                                                                                                                                              |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| <b>Clonazepam</b><br><div>Green</div>                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral solution; injection                                                                                                                                     |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| <b>Eslicarbazepine</b><br><div>Green</div>                                                                                                                            |  | <b>RESTRICTED</b><br>Specialist use only in line with NICE |  |
| tablets; oral suspension                                                                                                                                              |  | <div>NICE</div> <b>MMC</b> <div>BNF</div> <div>emc</div>   |  |
| MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions                                          |  |                                                            |  |
| <b>Ethosuximide</b><br><div>Green</div>                                                                                                                               |  | <b>RESTRICTED</b><br>Paediatrics only                      |  |
| capsules; oral solution                                                                                                                                               |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| <b>Fenfluramine Hydrochloride</b><br><div>Red</div>                                                                                                                   |  | <b>RESTRICTED</b><br>Specialist use only in line with NICE |  |
| Fintepla® oral solution                                                                                                                                               |  | <div>NICE</div> <b>MMC</b> <div>BNF</div> <div>emc</div>   |  |
| <b>Gabapentin</b><br><div>Green</div> <div>CD</div>                                                                                                                   |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| capsules; oral suspension                                                                                                                                             |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April              |  |                                                            |  |
| MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression                                                                       |  |                                                            |  |
| Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin                                                                                  |  |                                                            |  |
| <b>Lacosamide</b><br><div>Green</div>                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral solution; infusion                                                                                                                                      |  | <div>NICE</div> <b>MMC</b> <div>BNF</div> <div>emc</div>   |  |
| <b>Lamotrigine</b><br><div>Green</div>                                                                                                                                |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; dispersible tablets                                                                                                                                          |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review                                              |  |                                                            |  |
| <b>Levetiracetam</b><br><div>Green</div>                                                                                                                              |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral solution; infusion; granules                                                                                                                            |  | <div>NICE</div> <b>MMC</b> <div>BNF</div> <div>emc</div>   |  |
| MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review                                              |  |                                                            |  |
| <b>Oxcarbazepine</b><br><div>Green</div>                                                                                                                              |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral suspension                                                                                                                                              |  | <div>NICE</div> <div>BNF</div> <div>emc</div>              |  |
| MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions                                          |  |                                                            |  |
| <b>Perampanel</b><br><div>Green</div>                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only                   |  |
| tablets; oral suspension                                                                                                                                              |  | <b>MMC</b> <div>BNF</div> <div>emc</div>                   |  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| <b>Pregabalin</b><br> <br>capsules; oral solution<br>MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression<br>MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April<br>Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Primidone</b><br><br>tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Rufinamide</b><br><br>tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b> Specialist use only<br>Lennox-Gastaut Syndrome       |
| <b>Stiripentol</b><br><br>capsules; sachets                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Tiagabine</b><br><br>tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Topiramate</b><br><br>tablets; capsules                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Vigabatrin</b><br><br>tablets; sachets                                                                                                                                                                                                                                                                                                                                                                                                                                                 | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Zonisamide</b><br><br>capsules                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>Specialist use only                               |
| <b>Cannabidiol (CBD)</b><br> <br>Epidyolex®                                                                                                                                                                                                                                                                                                                                                              | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA614 / 615 |
| <b>4.8.2 Drugs Used in Status Epilepticus</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                        |
| <b>Lorazepam</b><br>tablets; injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                        |
| <b>Diazepam</b><br>tablets; liquid; injection; rectal tube                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                        |
| MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                        |
| <b>Clonazepam</b><br><br>tablets; oral solution; injection                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                        |
| MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                        |
| <b>Midazolam</b><br> <br>oromucosal solution; injection; infusion                                                                                                                                                                                                                                                                                                                                    |                                                                        |
| MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                        |
| <b>Paraldehyde</b><br>injection; rectal solution                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                        |
| <b>Phenytoin Sodium</b><br><br>capsules; oral suspension; injection                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                        |
| <b>Sulthiame</b><br><br>Ospolot® 50mg tablets                                                                                                                                                                                                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Consultant Neurologist use only                   |

| 4.9 Drugs used in Parkinsonism & related disorders                                                      |                    | GMMMG                                                                    |
|---------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------|
| 4.9.1 Dopaminergic Drugs Used in Parkinsonism                                                           |                    | NICE NG71                                                                |
| <b>Amantadine Hydrochloride</b><br>Green<br>capsules; oral solution                                     | NICE BNF emc       | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Apomorphine Hydrochloride</b><br>Amber<br>injection; infusion                                        | NICE MMC BNF emc   | <b>RESTRICTED</b><br>Specialist use only                                 |
| MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects |                    |                                                                          |
| <b>Cabergoline</b><br>Green<br>tablets                                                                  | NICE MMC BNF emc   | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Co-beneldopa</b><br>Green<br>capsules; M/R capsules; dispersible tablets                             | NICE BNF emc       | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Co-careldopa</b><br>Green<br>tablets; M/R tablets                                                    | PbR X NICE BNF emc | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Entacapone</b><br>Green<br>tablets                                                                   | MMC BNF emc        | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Opicapone</b><br>Green<br>capsules                                                                   | MMC BNF emc        | <b>RESTRICTED</b> 2 <sup>nd</sup> line<br>Specialist use only            |
| <b>Pramipexole</b><br>Green<br>tablets; M/R tablets                                                     | MMC BNF emc        | <b>RESTRICTED</b> 3 <sup>rd</sup> line add-on use<br>Specialist use only |
| <b>Rasagiline</b><br>Green<br>tablets                                                                   | MMC BNF emc        | <b>RESTRICTED</b> patients with end of<br>dose fluctuations              |
| <b>Ropinirole</b><br>Green<br>tablets; M/R tablets                                                      | BNF emc            | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Rotigotine</b><br>Green<br>transdermal patches                                                       | NICE MMC BNF emc   | <b>RESTRICTED</b><br>Specialist use only. NBM patients                   |
| <b>Safinamide</b><br>Green<br>tablets                                                                   | MMC BNF emc        | <b>RESTRICTED</b><br>Specialist use only                                 |
| <b>Selegiline</b><br>Green<br>tablets                                                                   | BNF emc            | <b>RESTRICTED</b><br>Specialist use only                                 |
| 4.9.2 Antimuscarinic Drugs Used in Parkinsonism                                                         |                    |                                                                          |
| <b>Orphenadrine Hydrochloride</b><br>oral solution                                                      | BNF emc            |                                                                          |
| <b>Procyclidine (Oral &amp; IM)</b><br>tablets; oral solution; injection                                | BNF emc            |                                                                          |
| <b>Trihexyphenidyl Hydrochloride (Benzhexol Hydrochloride)</b><br>tablet; syrup                         | MMC BNF emc        |                                                                          |

**4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders****Propranolol**

tablets; M/R capsules; oral solution; injection

**Haloperidol**

Green

tablets; capsules; oral solution



MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

**Piracetam**

tablets; oral solution

**Tetrabenazine**

tablets

**Torsion Dystonias & Other Involuntary Movements****The dose of botulinum toxin is specific to each individual preparation and is NOT interchangeable.****The doses for different indications vary - consult product literature & specialist guidance****Botulinum Toxin Type A**

Red

Botox® injection

**Botulinum Toxin Type A**

Red

Dysport® injection

**Botulinum Toxin Type A**

Red

Xeomin® injection

**RESTRICTED**  
Specialist use only  
**see decision tables****RESTRICTED**  
Specialist use only**RESTRICTED**  
Specialist use only  
**see decision tables**

| 4.10 Drugs used in substance dependence                                                                                |                  | GMMMG                                                                                 |
|------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------------------|
| <b>4.10.1 Alcohol dependence</b>                                                                                       |                  |                                                                                       |
| <b>Nalmefene</b><br>Green                                                                                              | NICE MMC BNF emc | <b>RESTRICTED</b> - Specialist use only in line with NICE TA325<br><b>NOT STOCKED</b> |
| <b>4.10.2 Nicotine dependence</b>                                                                                      |                  | NICE NG92                                                                             |
| <b>Nicotine Replacement Therapy</b><br><br>patches, lozenges, inhalator, microtabs                                     | BNF emc          | 1 <sup>st</sup> line use                                                              |
| <b>Bupropion Hydrochloride</b><br><br>tablets                                                                          | NICE BNF emc     |                                                                                       |
| MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs |                  |                                                                                       |
| <b>Varenicline</b><br><br>tablets                                                                                      | NICE MMC BNF emc |                                                                                       |
| <b>4.10.3 Opioid Dependence</b>                                                                                        |                  | NICE CG52                                                                             |
| MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction                                            |                  |                                                                                       |
| <b>Buprenorphine</b><br>Green                                                                                          | NICE BNF emc     | <b>RESTRICTED</b> Initiation by substance misuse specialist                           |
| sublingual tablets                                                                                                     |                  |                                                                                       |
| <b>Methadone Hydrochloride</b><br>                                                                                     | NICE BNF emc     | <b>RESTRICTED</b> Initiation by substance misuse specialist                           |
| oral solution                                                                                                          |                  |                                                                                       |
| <b>Naltrexone Hydrochloride</b><br>Red Amber                                                                           | NICE MMC BNF emc | <b>RESTRICTED</b><br>Gastro Consultant - cholestatic itch                             |
| tablets                                                                                                                |                  |                                                                                       |

| 4.11 Drugs for dementia                                                                                                                                                                                                                                                                                                                                                                                                   |  | GMMMG                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------|
| 4.11 Drugs for Dementia                                                                                                                                                                                                                                                                                                                                                                                                   |  | NICE NG97                                |
| <b>Donepezil Hydrochloride</b><br>Green<br>tablets; orodispersible tablets<br>      |  | <b>RESTRICTED</b><br>Specialist use only |
| <b>Galantamine</b><br>Green<br>M/R capsules; tablets<br>                                                                                                             |  | <b>RESTRICTED</b><br>Specialist use only |
| MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals                                                                                                                                                                                                                                                                                                                                                |  |                                          |
| <b>Memantine Hydrochloride</b><br>Green<br>tablets; oral solution<br>               |  | <b>RESTRICTED</b><br>Specialist use only |
| <b>Rivastigmine</b><br>Green<br>capsules; oral solution; transdermal patches<br>    |  | <b>RESTRICTED</b><br>Specialist use only |
| Dementia - as per NICE TA217 & NG97 Green (following specialist initiation)                                                                                                                                                                                                                                                                                                                                               |  | Green                                    |

## Section 5: Infections

Supported by the  
formulary ([click here](#))



### 5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulphonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

### 5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

### 5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

### 5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

### 5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

## Trust Guidelines

Adult medicines and prescribing guidelines  
 MFT Adult Antimicrobial guidelines  
 Paediatric medicines and prescribing guidelines  
 MFT Paediatric Antimicrobial guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Bacterial meningitis and meningococcal septicaemia (CG102)  
 Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)  
 Hepatitis B (Chronic) (CG165)  
 Tuberculosis (NG33)  
 Sinusitis (acute): antimicrobial prescribing (NG79)  
 Sore throat (acute): antimicrobial prescribing (NG84)  
 Otitis media (acute): antimicrobial prescribing (NG91)  
 Cough (acute): antimicrobial prescribing (NG120)  
 Surgical site infections: prevention and treatment (NG125)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Hepatitis B: Entecavir (TA153)  
 Hepatitis B: Telbivudine (TA154)  
 Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)  
 Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)  
 Hepatitis B: Tenofovir disoproxil (TA173)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Sofosbuvir for treating chronic hepatitis C (TA330)  
 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)  
 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)  
 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)  
 Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)  
 Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)  
 Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)  
 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)  
 Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)  
 Cabotegravir with rilpivirine for treating HIV-1 (TA757)  
 Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)  
 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)  
 Bulevirtide for treating chronic hepatitis D (TA896)

## GMMM Formulary

Formulary Homepage  
 Chapter 5: Infections (Complete)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List

**RESTRICTED USE ANTIBIOTICS**

1. Must be recommended / approved for use by consultant medical microbiologist
2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
3. Only available from Pharmacy

**RESERVED USE ANTIBIOTICS**

1. Can be used only in accordance with the restrictions outlined below.
2. Indication must be clearly documented on the prescription chart.
3. If being used outside of guidelines Microbiology approval must be sought as above.

**UNRESTRICTED USE ANTIBIOTICS**

1. Can be used according to CMFT Trust guidelines, (those drugs not marked Restricted or Reserved)

| <b>5.1 Antibacterial drugs</b>                                    |                                                                                                                                                                                                                                                                |       |
|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| <b>5.1.1 Penicillins</b>                                          |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>5.1.1.1 Benzylpenicillin &amp; Phenoxymethylpenicillin</b>     |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Benzylpenicillin Sodium (Penicillin G)</b>                     |                                                                                                                                                                                                                                                                |                                                                                          |
| 600mg injection                                                   |                                                                                           |                                                                                          |
| <b>Phenoxymethylpenicillin (Penicillin V)</b>                     |                                                                                                                                                                                                                                                                |                                                                                          |
| tablets                                                           |                                                                                           |                                                                                          |
| <b>Benzathine Benzylpenicillin</b>                                |                                                                                           | <b>RESTRICTED</b><br>unlicensed treatment for syphilis                                   |
| injection                                                         |                                                                                           |                                                                                          |
| <b>5.1.1.2 Penicillinase-Resistant Penicillins</b>                |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Flucloxacillin</b>                                             |                                                                                                                                                                                                                                                                |                                                                                          |
| capsules; injection; oral solution                                |          |                                                                                          |
| <b>Temocillin</b>                                                 |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b> infection caused by<br>multi-resistant coliforms.<br><b>Micro only</b> |
| 1g injection                                                      |          |                                                                                          |
| <b>5.1.1.3 Broad Spectrum Penicillins</b>                         |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Amoxicillin</b>                                                |                                                                                                                                                                                                                                                                |                                                                                          |
| capsules; oral suspension; injection                              |                                                                                       |                                                                                          |
| <b>Co-amoxiclav</b>                                               |                                                                                                                                                                                                                                                                |                                                                                          |
| tablets; oral suspension; injection                               |                                                                                       |                                                                                          |
| <b>5.1.1.4 Antipseudomonal Penicillins</b>                        |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Piperacillin with Tazobactam</b>                               |                                                                                                                                                                                                                                                                | <b>RESERVED</b><br>serious / resistant infections                                        |
| injection                                                         |    |                                                                                          |
| <b>Ticarcillin with Clavulanic Acid</b>                           |                                                                                                                                                                                                                                                                | <b>RESERVED</b><br>serious / resistant infections                                        |
| Timentin® 3.2g injection                                          |    |                                                                                          |
| <b>5.1.1.5 Mecillinams</b>                                        |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Pivmecillinam Hydrochloride</b>                                |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b> UTIs caused by<br>resistant coliforms                                  |
| 200mg tablets                                                     |    |                                                                                          |
| <b>5.1.2 Cephalosporins, Carbapenems &amp; other Beta-Lactams</b> |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>5.1.2.1 Cephalosporins</b>                                     |                                                                                                                                                                                                                                                                |                                                                                          |
| <b>Cefalexin</b>                                                  |                                                                                                                                                                                                                                                                |                                                                                          |
| capsules; tablets; oral suspension                                |                                                                                       |                                                                                          |
| <b>Cefazolin</b>                                                  |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b><br>on Micro. advice only                                               |
| injection                                                         |    |                                                                                          |
| <b>Cefotaxime</b>                                                 |                                                                                                                                                                                                                                                                | <b>RESERVED</b><br>as per guidelines for children                                        |
| injection                                                         |                                                                                       |                                                                                          |
| <b>Ceftriaxone</b>                                                |                                                                                                                                                                                                                                                                | <b>RESERVED</b><br>as per guidelines for children                                        |
| injection                                                         |                                                                                       |                                                                                          |
| <b>Cefuroxime</b>                                                 |                                                                                                                                                                                                                                                                | <b>RESERVED</b><br>as per guidelines for children                                        |
| injection                                                         |                                                                                       |                                                                                          |

|                                                                                                                                                                                                     |                                                                                                                                                                               |                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| <b>Cefixime</b>                                                                                                                                                                                     |                                                                                                                                                                               | <b>RESERVED</b><br>GU infections only                                                               |
| tablets                                                                                                                                                                                             | MMC       |                                                                                                     |
| <b>Ceftazidime</b>                                                                                                                                                                                  |                                                                                                                                                                               | <b>RESERVED</b><br>pseudomonas infection in CF                                                      |
| injection                                                                                                                                                                                           | MMC       |                                                                                                     |
| <b>Cetazidime / Avibactam</b>                                                                                                                                                                       |                                                                                                                                                                               | <b>RESERVED for</b><br>gram negative organisms<br><b>Micro. Consultant only</b>                     |
| Zavicefta® infusion                                                                                                                                                                                 | MMC       |                                                                                                     |
| <b>Ceftolozane sulfate / Tazobactam sodium</b>                                                                                                                                                      |                                                                                                                                                                               | <b>RESERVED for</b><br>gram negative organisms<br><b>Micro. Consultant only</b>                     |
| Zerbaxa® infusion                                                                                                                                                                                   | MMC       |                                                                                                     |
| <b>Ceftaroline Fosamil</b>                                                                                                                                                                          |                                                                                                                                                                               | <b>RESERVED</b><br>CAP & cSSTI treatment.<br><b>Micro. Consultant only</b>                          |
| Zinforo® infusion                                                                                                                                                                                   | MMC       |                                                                                                     |
| <b>Cefoxitin</b>                                                                                                                                                                                    |                                                                                                                                                                               | <b>RESERVED for treatment of</b><br>mycobacterium abscessus in CF.<br><b>Micro. Consultant only</b> |
| injection                                                                                                                                                                                           | MMC       |                                                                                                     |
| <b>Cefiderocol</b>                                                                                                                                                                                  |                                                                                                                                                                               | <b>RESERVED for</b><br>gram negative organisms<br><b>Micro. Consultant only</b>                     |
| Fetroja® infusion                                                                                                                                                                                   | MMC       |                                                                                                     |
| <b>5.1.2.2 Carbapenems</b>                                                                                                                                                                          |                                                                                                                                                                               |                                                                                                     |
| <b>Ertapenem</b>                                                                                                                                                                                    |                                                                                                                                                                               | <b>RESTRICTED</b><br>Outpatient therapy only                                                        |
| infusion                                                                                                                                                                                            | MMC       |                                                                                                     |
| <b>Imipenem with Cilastatin</b>                                                                                                                                                                     |                                                                                                                                                                               | <b>RESTRICTED</b><br>Non-Tuberculous Mycobacteria in CF                                             |
| infusion                                                                                                                                                                                            | MMC       |                                                                                                     |
| <b>Imipenem / Cilastatin / Relebactam</b>                                                                                                                                                           |                                                                                                                                                                               | <b>RESTRICTED</b>                                                                                   |
|  Recarbrio® infusion                                                                                               | MMC    | <b>Micro. Consultant only</b>                                                                       |
| <b>Meropenem</b>                                                                                                                                                                                    |                                                                                                                                                                               | <b>RESERVED</b><br>as per guidelines                                                                |
| injection                                                                                                                                                                                           | MMC   |                                                                                                     |
| <b>Meropenem with Vaboractam</b>                                                                                                                                                                    |                                                                                                                                                                               | <b>RESTRICTED</b>                                                                                   |
| Vaborem® infusion                                                                                                                                                                                   | MMC   | <b>Micro. Consultant only</b>                                                                       |
| <b>5.1.2.3 Other Beta-Lactam antibiotics</b>                                                                                                                                                        |                                                                                                                                                                               |                                                                                                     |
| <b>Aztreonam</b>                                                                                                                                                                                    |                                                                                                                                                                               | <b>RESTRICTED</b><br>gram negative organisms                                                        |
| injection                                                                                                                                                                                           |       |                                                                                                     |
| <b>Aztreonam lysine</b>                                                                                                                                                                             |                                                                                                                                                                               | <b>RESTRICTED 3<sup>rd</sup> line CF patients with</b><br>chronic pulmonary infection               |
|   Cayston® nebuliser solution | MMC   |                                                                                                     |
| <b>5.1.3 Tetracyclines</b>                                                                                                                                                                          |                                                                                                                                                                               |                                                                                                     |
| <b>Doxycycline</b>                                                                                                                                                                                  |                                                                                                                                                                               |                                                                                                     |
| capsules; tablets; dispersible tablets                                                                                                                                                              | MMC   |                                                                                                     |
| <b>Oxytetracycline</b>                                                                                                                                                                              |                                                                                                                                                                               |                                                                                                     |
| tablets                                                                                                                                                                                             |       |                                                                                                     |
| <b>Demeclocycline Hydrochloride</b>                                                                                                                                                                 |                                                                                                                                                                               | <b>RESTRICTED</b><br>SIADH only                                                                     |
| capsules                                                                                                                                                                                            | MMC   |                                                                                                     |
| <b>Lymecycline</b>                                                                                                                                                                                  |                                                                                                                                                                               | <b>RESTRICTED</b><br>Non-Formulary<br><b>MMC approved for GP referral</b>                           |
| capsules                                                                                                                                                                                            | MMC   |                                                                                                     |
| <b>Minocycline</b>                                                                                                                                                                                  |                                                                                                                                                                               |                                                                                                     |
| capsules; tablets                                                                                                                                                                                   | MMC   |                                                                                                     |
| <b>Tigecycline</b>                                                                                                                                                                                  |                                                                                                                                                                               | <b>RESERVED</b><br>as per guidelines                                                                |
| infusion                                                                                                                                                                                            | MMC   |                                                                                                     |

| 5.1.4 Aminoglycosides                                                                                                                                                |                                          |                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|---------------------------------------------------------------------------------------|
| MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin & neomycin): increased risk of deafness in patients with mitochondrial mutations |                                          |                                                                                       |
| <b>Amikacin</b>                                                                                                                                                      |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| injection                                                                                                                                                            | PbR X <b>MMC</b> <b>BNF</b> <b>emc</b> + |                                                                                       |
| <b>Gentamicin</b>                                                                                                                                                    |                                          |                                                                                       |
| injection                                                                                                                                                            | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| <b>Tobramycin</b>                                                                                                                                                    |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| Amber Red ££                                                                                                                                                         |                                          |                                                                                       |
| injection; inhalation powder; nebuliser liquid                                                                                                                       | NICE <b>MMC</b> <b>BNF</b> <b>emc</b> +  |                                                                                       |
| <b>Neomycin Sulfate</b>                                                                                                                                              |                                          | <b>RESTRICTED</b><br>Gastro team only - op prep                                       |
| oral solution                                                                                                                                                        | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| 5.1.5 Macrolides                                                                                                                                                     |                                          |                                                                                       |
| <b>Clarithromycin</b>                                                                                                                                                |                                          |                                                                                       |
| tablets; oral suspension; infusion                                                                                                                                   | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| <b>Azithromycin</b>                                                                                                                                                  |                                          | <b>RESERVED</b><br>GU only or specialist use                                          |
| tablets; oral suspension                                                                                                                                             | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| <b>Erythromycin</b>                                                                                                                                                  |                                          | <b>RESERVED</b><br>in pregnancy or neonates                                           |
| tablets; oral suspension; injection                                                                                                                                  | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban                  |                                          |                                                                                       |
| MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis                                                      |                                          |                                                                                       |
| 5.1.6 Clindamycin                                                                                                                                                    |                                          |                                                                                       |
| <b>Clindamycin</b>                                                                                                                                                   |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| capsules; oral suspension; injection; 2% vaginal cream                                                                                                               | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| 5.1.7 Some other Antibacterials                                                                                                                                      |                                          |                                                                                       |
| <b>Chloramphenicol</b>                                                                                                                                               |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| capsules; injection                                                                                                                                                  | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years                             |                                          |                                                                                       |
| <b>Dalbavancin</b>                                                                                                                                                   |                                          | <b>RESTRICTED Consultant only</b>                                                     |
| <b>Dalbavancin</b>                                                                                                                                                   |                                          | <b>Micro. approval required</b>                                                       |
| 500mg infusion                                                                                                                                                       | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |
| <b>Fidaxomicin</b>                                                                                                                                                   |                                          | <b>RESTRICTED</b><br>clostridium difficile associated diarrhoea<br><b>Micro. only</b> |
| Green ££                                                                                                                                                             |                                          |                                                                                       |
| 200mg tablets; 40mg/mL granules for oral suspension                                                                                                                  | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |
| <b>Fusidic Acid</b>                                                                                                                                                  |                                          |                                                                                       |
| <b>Sodium Fusidate</b>                                                                                                                                               |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| Green                                                                                                                                                                |                                          |                                                                                       |
| tablets; oral suspension; 2% cream                                                                                                                                   | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins                                                                                 |                                          |                                                                                       |
| Glycopeptides                                                                                                                                                        |                                          |                                                                                       |
| <b>Vancomycin</b>                                                                                                                                                    |                                          |                                                                                       |
| Green                                                                                                                                                                |                                          |                                                                                       |
| injection; capsules; oral suspension                                                                                                                                 | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |
| <b>Teicoplanin</b>                                                                                                                                                   |                                          | <b>RESERVED</b><br>as per guidelines                                                  |
| injection                                                                                                                                                            | <b>BNF</b> <b>emc</b> +                  |                                                                                       |
| <b>Daptomycin</b>                                                                                                                                                    |                                          |                                                                                       |
| <b>Daptomycin</b>                                                                                                                                                    |                                          | <b>RESTRICTED</b><br>as per guidelines                                                |
| Red                                                                                                                                                                  |                                          |                                                                                       |
| infusion                                                                                                                                                             | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |
| <b>Linezolid</b>                                                                                                                                                     |                                          |                                                                                       |
| <b>Linezolid</b>                                                                                                                                                     |                                          | <b>RESTRICTED</b><br>as per guidelines                                                |
| Red                                                                                                                                                                  |                                          |                                                                                       |
| tablets; infusion                                                                                                                                                    | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |
| <b>Quinupristin with Dalfopristin</b>                                                                                                                                |                                          |                                                                                       |
| <b>Synercid®</b>                                                                                                                                                     |                                          | <b>RESTRICTED</b><br>as per guidelines. Non-formulary                                 |
| injection                                                                                                                                                            | <b>MMC</b> <b>BNF</b> <b>emc</b> +       |                                                                                       |

|                                                                                                                                                                                                                                                                                                                               |                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| <b>Polymyxins</b>                                                                                                                                                                                                                                                                                                             |                                                                                  |
| <b>Colistimethate Sodium</b><br> <br>injection                                                                                                               | <b>RESTRICTED</b><br>as per guidelines                                           |
| <b>Colistimethate Sodium (DPI)</b><br> <br>Colobreathe® inhalation powder                                                                                    | <b>RESTRICTED</b><br>as per guidelines                                           |
| MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use                                                                                                                                                                          |                                                                                  |
| <b>Pristinamycin</b>                                                                                                                                                                                                                                                                                                          |                                                                                  |
| <b>Pristinamycin</b><br> <br>500mg tablets                                                                                                                   | <b>RESTRICTED</b><br>as per BASHH guidelines for<br><i>Mycoplasma genitalium</i> |
| <b>Rifaximin</b>                                                                                                                                                                                                                                                                                                              |                                                                                  |
| <b>Rifaximin</b><br><br>550mg tablets                                                                                                                                                                                                         | <b>RESTRICTED</b><br>as per guidelines                                           |
| <b>Spectinomycin</b>                                                                                                                                                                                                                                                                                                          |                                                                                  |
| <b>Spectinomycin</b><br><br>Kirin® injection                                                                                                                                                                                                  | <b>RESTRICTED</b><br>cephalosporin resistant gonorrhoea                          |
| <b>Taurolidine</b>                                                                                                                                                                                                                                                                                                            |                                                                                  |
| <b>Taurolidine citrate 4%</b><br><br>TauroLock® 4% ampoules                                                                                                                                                                                                                                                                   | <b>RESTRICTED</b><br>as per CVC guidelines                                       |
| <b>5.1.8 Sulphonamides &amp; Trimethoprim</b>                                                                                                                                                                                                                                                                                 |                                                                                  |
| <b>Trimethoprim</b>                                                                                                                                                                                                                                                                                                           |                                                                                  |
| tablets; oral suspension                                                                                                                                                                                                                                                                                                      |                                                                                  |
| <b>Co-trimoxazole</b><br>                                                                                                                                                                                                                     | <b>RESERVED</b><br>as per guidelines                                             |
| tablets; oral suspension; infusion                                                                                                                                                                                                                                                                                            |                                                                                  |
| <b>Sulfadiazine</b>                                                                                                                                                                                                                                                                                                           |                                                                                  |
| tablets                                                                                                                                                                                                                                                                                                                       |                                                                                  |
| <b>5.1.9 Antituberculosis Drugs</b>  until patient stabilised then   | <b>NICE NG33</b>                                                                 |
| <b>Bedaquiline</b><br><br>tablets                                                                                                                                                                                                           | <b>RESTRICTED</b><br>MDR TB only                                                 |
| <b>Ethambutol Hydrochloride</b><br>                                                                                                                                                                                                         |                                                                                  |
| tablets                                                                                                                                                                                                                                                                                                                       |                                                                                  |
| <b>Isoniazid</b><br>                                                                                                                                                                                                                        |                                                                                  |
| tablets; oral solution; injection                                                                                                                                                                                                                                                                                             |                                                                                  |
| <b>Prothionamide</b><br><br>tablets                                                                                                                                                                                                         | <b>RESTRICTED</b><br>MDR TB only                                                 |
| <b>Pyrazinamide</b><br><br>tablets                                                                                                                                                                                                          |                                                                                  |
| <b>Rifampicin</b><br>                                                                                                                                                                                                                       |                                                                                  |
| capsules; oral solution; infusion                                                                                                                                                                                                                                                                                             |                                                                                  |
| <b>Rifabutin</b><br>                                                                                                                                                                                                                        | <b>2<sup>nd</sup> line</b><br>where rifampicin not suitable                      |
| capsules                                                                                                                                                                                                                                                                                                                      |                                                                                  |
| <b>Rifater®</b><br><br>Rifampicin / Isoniazid / Pyrazinamide tablets                                                                                                                                                                        |                                                                                  |
| <b>Rifinah®</b><br><br>Rifampicin / Isoniazid tablets                                                                                                                                                                                       |                                                                                  |
| <b>Voractiv®</b><br><br>Rifampicin / Isoniazid / Pyrazinamide / Ethambutol Hydrochloride tablets                                                                                                                                            |                                                                                  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| <b>Capreomycin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                      | <b>RESTRICTED</b><br>MDR TB only<br><b>Not stocked</b>               |
| <b>Cycloserine</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| capsules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                       | <b>RESTRICTED</b><br>MDR TB only<br><b>Not stocked</b>               |
| <b>Delamanid</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
|  tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                      | <b>RESTRICTED</b><br>MDR TB only                                     |
| <b>Streptomycin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
|  injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                      | <b>RESTRICTED</b><br>MDR TB only<br><b>Not stocked</b>               |
| <b>Moxifloxacin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets; injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |     | <b>RESTRICTED</b>                                                    |
| <b>Para aminosalicylic acid (PAS)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| granules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |     | <b>RESTRICTED</b><br>MDR TB only<br><b>Not stocked</b>               |
| <b>5.1.10 Antitubercular Drugs</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>Clofazimine</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
|  capsules                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                      | <b>RESTRICTED</b><br>MDR TB only                                     |
| <b>Dapsone</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
|  tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                      | <b>RESERVED</b>                                                      |
| <b>5.1.11 Metronidazole &amp; Tinidazole</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>Metronidazole</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets; oral suspension; infusion; suppositories; vaginal gel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                      |                                                                      |
| <b>Tinidazole</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                   | <b>RESTRICTED</b>                                                    |
| <b>5.1.12 Quinolones</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>Ciprofloxacin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                   | <b>RESERVED</b><br>as per guidelines                                 |
| <b>Levofloxacin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets; infusion (see also section 11.3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                | <b>RESTRICTED</b><br>MDR TB only<br><b>Not stocked</b>               |
| <b>Moxifloxacin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets; infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                | <b>RESTRICTED</b><br>MDR TB only                                     |
| <b>Nalidixic acid</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                   | <b>RESTRICTED</b><br>Urology use in children only                    |
| <b>Ofloxacin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets (see also section 11.3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                   | <b>RESTRICTED</b><br>GU infections only                              |
| MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour<br>MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects<br>MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk<br>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection<br>MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects<br>MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>5.1.13 Urinary-tract Infections</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>Nitrofurantoin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| M/R capsules; capsules; tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                   |                                                                      |
| MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions<br>MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m <sup>2</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| <b>Fosfomycin</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| sachets; infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                | <b>RESTRICTED</b><br>Micro recommendation only                       |
| <b>Methenamine Hippurate</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                            |                                                                      |
| tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                | <b>RESTRICTED</b> Urology Consultants<br>only as part of ALTAR trial |

| 5.2 Antifungal drugs                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                      | GMMMG                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| 5.2.1 Triazole Antifungals                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| <b>Fluconazole</b>                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| capsules; infusion; oral suspension.                                                                                                                                                                                | BNF  emc                                                                                                                                                                                        |                                                                      |
| <b>Isavuconazole</b>                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| capsules; infusion                                                                                                                                                                                                  | PbR X  MMC  BNF  emc          |                                                                      |
| <b>Itraconazole</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| capsules; oral solution; infusion                                                                                                                                                                                   | BNF  emc                                                                                                                                                                                        |                                                                      |
| <b>Posaconazole</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| Red  ££ <br>G/R tablets; oral suspension; infusion | PbR X  MMC  BNF  emc          |                                                                      |
| MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable                                                                                              |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| <b>Voriconazole</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| Red  ££ <br>tablets; oral suspension; infusion     | PbR X  MMC  BNF  emc          |                                                                      |
| 5.2.3 Polyene Antifungals                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| <b>Nystatin</b>                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| 100,000 units/mL oral suspension                                                                                                                                                                                    | BNF  emc                                                                                                                                                                                        |                                                                      |
| <b>Amphotericin (liposomal)</b>                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| ££ <br>AmBisome® infusion (systemic use)                                                                                            | PbR X  MMC  BNF  emc          |                                                                      |
| <b>Amphotericin</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| ££ <br>Fungizone®                                                                                                                   | PbR X  MMC  BNF  emc          |                                                                      |
| 5.2.4 Echinocandin Antifungals                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| <b>Anidulafungin</b>                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                      | <b>1<sup>st</sup> line RESTRICTED</b><br>micro / specialist use only |
| Red  ££ <br>Ecalta® infusion                   | PbR X  MMC  BNF  emc  |                                                                      |
| <b>Micafungin</b>                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / specialist use only                     |
| Red  ££ <br>Mycamine® infusion                 | PbR X  MMC  BNF  emc  |                                                                      |
| 5.2.5 Other Antifungals                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |
| <b>Griseofulvin</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                      | <b>2<sup>nd</sup> line</b><br>following topical therapy              |
| tablets                                                                                                                                                                                                             | MMC  BNF  emc                                                                                            |                                                                      |
| <b>Terbinafine</b>                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                      | <b>2<sup>nd</sup> line</b><br>following topical therapy              |
| tablets                                                                                                                                                                                                             | BNF  emc                                                                                                                                                                                    |                                                                      |
| <b>Flucytosine</b>                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>micro / Neonates only                           |
| infusion                                                                                                                                                                                                            | BNF  emc                                                                                                                                                                                    |                                                                      |
| MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                      |                                                                      |

| 5.3 Antiviral drugs                                                                                                                                                                                                                                         |  |  | GMMMG                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Casirivimab with Imdevimab</b><br> <br>Ronapreve® infusion                              |  |  | <b>RESTRICTED</b><br>                                       |
| <b>Molnupiravir</b><br> <br>Lagevrio® 200mg capsules                                       |  |  | <b>RESTRICTED CMDU</b><br><b>see COVID-19 guidance</b><br>                                                                                   |
| <b>Nirmatrelvir with Ritonavir</b><br> <br>Paxlovid® 150mg/100mg tablets                   |  |  | <b>RESTRICTED</b><br><b>see COVID-19 guidance</b><br>       |
| MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir                                                                                                                             |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Remdesivir</b><br> <br>Veklury® infusion                                                |  |  | <b>RESTRICTED</b><br><b>see COVID-19 guidance</b><br>       |
| <b>Sotrovimab</b><br> <br>Veklury® infusion                                                |  |  | <b>RESTRICTED</b><br><b>see COVID-19 guidance</b><br>       |
| <b>Tecovirimat monohydrate</b><br><br>Tecovirimat SIGA® 200mg capsules                                                                                                      |  |  | <b>RESTRICTED patients hospitalised due to monkeypox</b><br>                                                                                 |
| <b>5.3.1 HIV Infection</b>                                                                                                                                                 |  |  | <b>BHIVA treatment guidelines</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b>                                                                                                                                                                                                  |  |  | <b>CHIVA PEP 2023</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Abacavir</b><br> <br>tablets; oral solution                                             |  |  |                                                                                                                                                                                                                                 |
| <b>Bictegravir / Emtricitabine / Tenofovir Alafenamide</b><br> <br>Biktarvy® tablets       |  |  |                                                                                                                                                                                                                                |
| <b>Emtricitabine</b><br> <br>capsules                                                    |  |  |                                                                                                                                                                                                                       |
| <b>Lamivudine</b><br> <br>tablets; oral solution                                       |  |  |                                                                                                                                                                                                                                                                                                          |
| <b>Tenofovir Disoproxil</b><br> <br>tablets; granules                                  |  |  |                                                                                                                                    |
| <b>Tenofovir Alafenamide</b><br> <br>Descovy® / Odefsey® / Genvoya® tablets            |  |  | <b>RESTRICTED</b><br><b>patients requiring new formulation</b><br>                                                               |
| <b>Tenofovir Disoproxil / Efavirenz / Emtricitabine</b><br> <br>Atripla® tablets       |  |  |                                                                                                                                                                                                                       |
| <b>Tenofovir / Cobicistat / Elvitegravir / Emtricitabine</b><br> <br>Stribild® tablets |  |  |                                                                                                                                  |
| <b>Tenofovir / Emtricitabine</b><br> <br>Truvada® tablets                              |  |  |                                                                                                                                                                                                                       |
| <b>Emtricitabine / Rilpivirine / Tenofovir</b><br> <br>Eviplera® tablets               |  |  |                                                                                                                                                                                                                       |
| <b>Zidovudine / Lamivudine</b><br> <br>Combivir® tablets                               |  |  |                                                                                                                                                                                                                                                                                                          |
| <b>Didanosine</b><br> <br>Videx® capsules (to be DISCONTINUED Q1 2020)                 |  |  |                                                                                                                                                                                                                       |
| <b>Stavudine</b><br> <br>Zerit® capsules (to be DISCONTINUED Q1 2020)                  |  |  |                                                                                                                                                                                                                                                                                                          |

| Protease Inhibitors                                                                                                                                                                                                                      |  | BHIVA treatment guidelines |                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------|-----------------------------------------------------------------------------------------------|
| <b>Atazanavir</b><br>                                                   |  |                            |                                                                                               |
| capsules                                                                                                                                                                                                                                 |  | PbR X                      | MMC BNF    |
| <b>Atazanavir / Cobicistat</b><br>                                      |  |                            |                                                                                               |
| Evotaz® tablets                                                                                                                                                                                                                          |  | PbR X                      | MMC BNF    |
| <b>Darunavir</b><br>                                                    |  |                            |                                                                                               |
| tablets; oral suspension                                                                                                                                                                                                                 |  | PbR X                      | MMC BNF    |
| MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1                                                                 |  |                            |                                                                                               |
| <b>Darunavir / Cobicistat</b><br>                                       |  |                            |                                                                                               |
| Rezolsta® tablets                                                                                                                                                                                                                        |  | PbR X                      | MMC BNF    |
| MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1                                                                 |  |                            |                                                                                               |
| <b>Darunavir / Cobicistat / Emtricitabine &amp; Tenofovir</b><br>       |  |                            |                                                                                               |
| Symtuza® tablets                                                                                                                                                                                                                         |  | PbR X                      | MMC BNF    |
| MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1                                                                 |  |                            |                                                                                               |
| <b>Fosamprenavir</b><br>                                                |  |                            |                                                                                               |
| Telzir® tablets                                                                                                                                                                                                                          |  | PbR X                      | MMC BNF    |
| <b>Fostemsavir tromethamine</b><br>                                     |  |                            |                                                                                               |
| Rukobia® tablets                                                                                                                                                                                                                         |  | PbR X                      | MMC BNF    |
| <b>Lopinavir / Ritonavir</b><br>                                        |  |                            |                                                                                               |
| Kaletra® tablets; oral solution                                                                                                                                                                                                          |  | PbR X                      | BNF        |
| MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels                                                                                           |  |                            |                                                                                               |
| <b>Ritonavir</b><br>                                                    |  |                            |                                                                                               |
| tablets; powder for oral suspension                                                                                                                                                                                                      |  | PbR X                      | BNF      |
| MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels                                                                                           |  |                            |                                                                                               |
| <b>Saquinavir</b><br>                                               |  |                            |                                                                                               |
| tablets                                                                                                                                                                                                                                  |  | PbR X                      | BNF      |
| <b>Tipranavir</b><br>                                               |  |                            |                                                                                               |
| capsules                                                                                                                                                                                                                                 |  | PbR X                      | MMC BNF  |
| Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)                                                                                                                                                                              |  | BHIVA treatment guidelines |                                                                                               |
| <b>Doravirine</b><br>                                               |  |                            |                                                                                               |
| Pifeltro® tablets                                                                                                                                                                                                                        |  | PbR X                      | MMC BNF  |
| <b>Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate</b><br>  |  |                            |                                                                                               |
| Delstrigo® tablets                                                                                                                                                                                                                       |  | PbR X                      | MMC BNF  |
| <b>Efavirenz</b><br>                                                |  |                            |                                                                                               |
| tablets; capsules                                                                                                                                                                                                                        |  | PbR X                      | BNF      |
| <b>Etravirine</b><br>                                               |  |                            |                                                                                               |
| Intelence® tablets                                                                                                                                                                                                                       |  | PbR X                      | MMC BNF  |
| <b>Nevirapine</b><br>                                               |  |                            |                                                                                               |
| tablets; oral suspension; M/R tablets                                                                                                                                                                                                    |  | PbR X                      | MMC BNF  |
| <b>Rilpivirine</b><br>                                              |  |                            |                                                                                               |
| Edurant® tablets / Rekambys® injection                                                                                                                                                                                                   |  | PbR X NICE                 | MMC BNF  |
| Other Antiretrovirals                                                                                                                                                                                                                    |  | BHIVA treatment guidelines |                                                                                               |
| <b>Cabotegravir</b><br>                                             |  |                            |                                                                                               |
| Vocabria® injection                                                                                                                                                                                                                      |  | PbR X NICE                 | MMC BNF  |
| <b>Dolutegravir</b><br>                                             |  |                            |                                                                                               |
| Tivicay® tablets                                                                                                                                                                                                                         |  | PbR X                      | MMC BNF  |
| MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects                                                                                                    |  |                            |                                                                                               |
| MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...                                                                          |  |                            |                                                                                               |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Dolutegravir / Abacavir / Lamivudine</b><br> <br><i>Triumeq</i> ® tablets<br>                                                                                                                                                                |  |                                                                             |
| MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                                                                                                                |
| <b>Dolutegravir / Lamivudine</b><br> <br><i>Dovato</i> ® tablets<br>                                                                                                                                                                            |  |                                                                             |
| MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                                                                                                                |
| <b>Dolutegravir / Rilpivirine</b><br> <br><i>Juluca</i> ® tablets<br>                                                                                                                                                                           |  |                                                                             |
| MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                                                                                                                |
| <b>Enfuvirtide</b><br> <br><i>Fuzeon</i> ® injection<br>                                                                                                                                                                                        |  |                                                                                                                                                                |
| <b>Maraviroc</b><br> <br><i>Celsentri</i> ® tablets<br>                                                                                                                                                                                         |  |                                                                                                                                                                |
| <b>Raltegravir</b><br> <br>tablets; chewable tablets; granules<br>                                                                                                                                                                                                                                                               |  |                                                                                                                                                                |
| <b>Pharmacokinetic enhancers of antiretrovirals</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  |                                                                                                                                                                |
| <b>Cobicistat</b><br> <br><i>Tyboost</i> ® tablets<br>                                                                                                                                                                                          |  |                                                                             |
| <b>5.3.2 Herpesvirus Infection</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |                                                                                                                                                                |
| <b>5.3.2.1 Herpes Simplex &amp; Varicella-Zoster Infection</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                |
| <b>Aciclovir</b><br>tablets; oral suspension; infusion (see also section 13.10.3)<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                                                                                |
| <b>Valaciclovir</b><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b><br>Specialist use only<br>Haematology / Renal                                                                                                |
| <b>5.3.2.2 Cytomegalovirus (CMV) Infection</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                |
| <b>Cidofovir</b><br> <br>infusion<br>                                                                                                                                                                                                                                                                                  |  | <b>RESERVED</b><br>Specialist use only                                                                                                                         |
| <b>Foscarnet Sodium</b><br> <br>infusion<br>                                                                                                                                                                                        |  | <b>RESERVED</b> Specialist use only;<br>also for aggressive CMV retinitis                                                                                      |
| <b>Ganciclovir</b><br> <br>infusion (see also eye gel section 11.3.3)<br>                                                                                                                                                                                                                                              |  | <b>RESERVED</b><br>Specialist use only                                                                                                                         |
| <b>Letermovir</b><br> <br><i>Prevymis</i> ® tablets<br>                                                                                          |  | <b>RESERVED</b><br>Specialist use only in line with NICE                                                                                                       |
| <b>Maribavir</b><br> <br><i>Livtency</i> ® tablets<br>      |  | <b>RESERVED</b><br>Specialist use only in line with NICE                                                                                                       |
| <b>Valganciclovir</b><br> <br>tablets; oral solution<br>                                                                                                                                                                                                                                                               |  | <b>RESERVED</b><br>Specialist use only                                                                                                                         |
| <b>5.3.3 Viral Hepatitis</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                                                                                                                |
| <b>5.3.3.1 Chronic hepatitis B</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |                                                                                                                                                                |
| <b>Adefovir Dipivoxil</b><br> <br><i>Hepsera</i> ® tablets<br>                                                                                   |  | <b>NICE CG165</b>                                                                                                                                              |
| <b>Entecavir</b><br> <br><i>Baraclude</i> ® tablets<br>                                                                                          |  | <b>NHSE Hepatitis C</b>                                                   |
| MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |                                                                                                                                                                |
| MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                                                                                |
| <b>Dasabuvir</b><br> <br><i>Exviera</i> ® tablets<br>                                                                                          |  | <b>RESTRICTED</b> Specialist use only<br>in line with NHSE Commissioning  |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Elbasvir / Grazoprevir</b><br> <br><i>Zepatier</i> ® tablets<br>                     | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA413                                                                                                  |
| <b>Glecaprevir / Pibrentasvir</b><br> <br><i>Maviret</i> ® tablets<br>                  | <b>RESTRICTED</b> Specialist use only<br>in line with NHSE and NICE TA499                                                                                         |
| <b>Ombitasvir / Paritaprevir / Ritonavir</b><br> <br><i>Viekirax</i> ® tablets<br>      | <b>RESTRICTED</b> Specialist use only<br>in line NICE / NHSE Commissioning<br> |
| MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                   |
| <b>Sofosbuvir</b><br> <br><i>Sovaldi</i> ® tablets<br>                                  | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA330<br>           |
| MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                   |
| <b>Sofosbuvir / Ledipasvir</b><br> <br><i>Harvoni</i> ® tablets<br>                     | <b>RESTRICTED</b> Specialist use only<br>in line NHSE Commissioning<br>        |
| MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                   |
| <b>Sofosbuvir / Velpatasvir</b><br> <br><i>Epclusa</i> ® tablets<br>                    | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA430                                                                                                  |
| <b>Sofosbuvir / Velpatasvir / Voxilaprevir</b><br> <br><i>Vosevi</i> ® tablets<br>      | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA507                                                                                                  |
| <b>5.3.3.3 Hepatitis D</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                   |
| <b>Bulevirtide</b><br> <br><i>Hepcludex</i> ® injection<br>                             | <b>RESTRICTED</b> Specialist use only<br>in line with NICE TA896                                                                                                  |
| <b>5.3.4 Influenza</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                   |
| <b>Oseltamivir</b><br><br><i>Tamiflu</i> ® capsules; oral suspension<br>                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                   |
| MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                   |
| <b>Zanamivir</b><br><br><i>Relenza</i> ® inhalation powder<br>                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                   |
| <b>Zanamivir</b><br><br><i>Dectova</i> ® 10mg/mL infusion<br>                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br>Virology approval only                                                                                                                       |
| <b>5.3.5 Respiratory Syncytial Virus (RSV)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                   |
| <b>Palivizumab</b><br> <br><i>Synagis</i> ® 100mg/mL injection<br>                                                                                         | <b>RESTRICTED</b><br>Specialist use only<br>                                 |
| <b>Ribavirin</b><br> <br>capsules; tablets<br>                                                                                                               | <b>RESTRICTED</b><br>Specialist use only                                                                                                                          |

| 5.4 Antiprotozoal drugs                                                                                                                                                                                                                                                                          |  | GMMMG                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------|
| <b>Nitazoxanide</b><br> Red <br>500mg tablets; 100mg/5mL oral suspension                                                        |  | <b>RESTRICTED</b><br>Specialist use only                         |
| 500mg tablets; 100mg/5mL oral suspension    |  |                                                                  |
| 5.4.1 Antimalarials                                                                                                                                                                                                                                                                              |  |                                                                  |
| <b>Artesunate</b><br><br>injection                                                                                                                                                                               |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| <b>Artemether with Lumefantrine</b><br><br>tablets                                                                                                                                                               |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                             |  |                                                                  |
| <b>Chloroquine</b><br><br>tablets                                                                                                                                                                                |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions<br>MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment |  |                                                                  |
| <b>Mefloquine</b><br><br>tablets                                                                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| <b>Primaquine</b><br><br>tablets                                                                                                                                                                                 |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| <b>Proguanil Hydrochloride</b><br><br>tablets                                                                                                                                                                    |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| <b>Proguanil Hydrochloride / Atovaquone</b><br><br>Malarone® tablets                                                                                                                                             |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                              |  |                                                                  |
| <b>Pyrimethamine</b><br><br>tablets                                                                                                                                                                              |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                       |  |                                                                  |
| <b>Pyrimethamine with Sulfadoxine</b><br><br>tablets                                                                                                                                                           |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                          |  |                                                                  |
| <b>Quinine Dihydrochloride</b><br> Red<br>injection                                                                                                                                                            |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                          |  |                                                                  |
| MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions                                                                                                                                                                                |  |                                                                  |
| <b>Quinine Sulfate</b><br><br>tablets                                                                                                                                                                          |  | <b>RESTRICTED</b><br>Specialist use only                         |
|                                                                                                                          |  |                                                                  |
| MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions                                                                                                                                                                                |  |                                                                  |
| 5.4.2 Amoebicides                                                                                                                                                                                                                                                                                |  |                                                                  |
| <b>Metronidazole</b><br>(see also section 5.1.11)                                                                                                                                                                                                                                                |  |                                                                  |
|                                                                                                                          |  |                                                                  |
| <b>Tinidazole</b><br>Fasigyn® tablets                                                                                                                                                                                                                                                            |  | <b>RESERVED</b><br>Specialist use only                           |
|                                                                                                                          |  |                                                                  |
| <b>Diloxanide Furoate</b><br>tablets                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b><br>Non-formulary<br>micro. recommendation only |
|                                                                                                                          |  |                                                                  |
| 5.4.3 Trichomonacides                                                                                                                                                                                                                                                                            |  |                                                                  |
| <b>Metronidazole</b><br>(see also section 5.1.11)                                                                                                                                                                                                                                                |  |                                                                  |
|                                                                                                                          |  |                                                                  |
| 5.4.4 Antigiardial drugs                                                                                                                                                                                                                                                                         |  |                                                                  |
| <b>Metronidazole</b><br>(see also section 5.1.11)                                                                                                                                                                                                                                                |  |                                                                  |
|                                                                                                                          |  |                                                                  |

|                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                      |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--|
| <b>5.4.5 Leishmaniacides</b>                                                                                                                                                                                                                                                                                                                                                                 |                                                                                      |  |
| <b>Paromomycin</b><br> Red<br>tablets<br>               | <b>RESTRICTED</b><br>treatment of Cryptosporidiosis                                  |  |
| <b>Sodium Stibogluconate</b><br> Red<br>injection<br>   | <b>RESTRICTED</b><br>treatment of Leishmaniacides                                    |  |
| <b>5.4.7 Drugs for toxoplasmosis</b>                                                                                                                                                                                                                                                                                                                                                         |                                                                                      |  |
| <b>Sulfadiazine</b><br> Red<br>tablets<br>                                                                                               | <b>RESTRICTED</b><br>treatment of toxoplasmosis<br><b>micro. recommendation only</b> |  |
| <b>5.4.8 Drugs for pneumocystis pneumonia</b>                                                                                                                                                                                                                                                                                                                                                |                                                                                      |  |
| <b>Atovaquone</b><br> Red<br>oral suspension<br>                                                                                         | <b>RESTRICTED</b><br>Specialist use only                                             |  |
| <b>Pentamidine Isethionate</b><br> Red<br>injection<br>                                                                                  | <b>RESTRICTED</b><br>Specialist use only                                             |  |

| 5.5 Anthelmintics                                                                                                        |                                                                                                                       | GMMMG                                            |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| 5.5.1 Drugs for Threadworms (pinworms, <i>Enterobius vermicularis</i> )                                                  |                                                                                                                       |                                                  |
| <b>Albendazole</b><br><br>tablets        | <br><b>MMC</b> <b>BNF</b> <b>emc</b> | <b>RESTRICTED</b><br>Specialist use only         |
| <b>Mebendazole</b><br><br>chewable tablets; oral suspension                                                              | <br><b>BNF</b> <b>emc</b>            |                                                  |
| 5.5.2 Ascaricides                                                                                                        |                                                                                                                       |                                                  |
| <b>Levamisole</b><br><br>tablets         | <br><b>MMC</b> <b>BNF</b> <b>emc</b> | <b>RESTRICTED</b><br>Specialist use only         |
| 5.5.5 Schistosomicides (bilharziasis)                                                                                    |                                                                                                                       |                                                  |
| <b>Praziquantel</b><br><br>tablets       | <br><b>MMC</b> <b>BNF</b> <b>emc</b> | <b>RESTRICTED</b><br>Schistosomicides / tapeworm |
| 5.5.6 Filaricides                                                                                                        |                                                                                                                       |                                                  |
| <b>Diethylcarbamazine</b><br><br>tablets | <br><b>MMC</b> <b>BNF</b> <b>emc</b> | <b>RESTRICTED</b><br>Specialist use only         |

## Section 6: Endocrine System

Supported by the  
formulary ([click here](#))



### 6.1 Drugs used in diabetes

#### 6.1.1 Insulins

##### 6.1.1.1 Short-acting insulins

##### 6.1.1.2 Intermediate & long-acting insulins

##### Biphasic insulins

#### 6.1.2 Antidiabetic drugs

##### 6.1.2.1 Sulphonylureas

##### 6.1.2.2 Biguanides

##### 6.1.2.3 Other antidiabetic drugs

##### Alpha glucosidase inhibitors

##### Dipeptidyl peptidase-4 (DPP-4) inhibitors

##### Rapid acting insulin secretagogues (meglitinides)

##### Glucagon-like peptide-1 (GLP-1) receptor agonists

##### Sodium-glucose co-transporter 2 (SGLT2) inhibitors

##### Thiazolidinediones

#### 6.1.4 Treatment of hypoglycaemia

### 6.2 Thyroid & antithyroid drugs

#### 6.2.1 Thyroid hormones

#### 6.2.2 Antithyroid drugs

### 6.3 Corticosteroids

#### 6.3.1 Replacement therapy

#### 6.3.2 Glucocorticoid therapy

### 6.4 Sex hormones

#### 6.4.1 Female sex hormones and their modulators

##### 6.4.1.1 Oestrogens & HRT

##### 6.4.1.2 Progestogens and progesterone receptor modulators

#### 6.4.2 Male sex hormones & antagonists

### 6.5 Hypothalamic and pituitary hormones & anti-oestrogens

#### 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

#### 6.5.2 Posterior pituitary hormones & antagonists

### 6.6 Drugs affecting bone metabolism

#### 6.6.1 Calcitonin & parathyroid hormone

#### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

### 6.7 Other endocrine drugs

#### 6.7.1 Bromocriptine & other dopaminergic drugs

#### 6.7.2 Drugs affecting gonadotrophins

#### 6.7.3 Metyrapone

#### 6.7.4 Somatomedins

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Safer insulin prescribing (KTT20)  
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)  
 Type 1 diabetes in adults: diagnosis and management (NG17)  
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)  
 Diabetic foot problems: prevention and management (NG19)  
 Type 2 diabetes in adults: management (NG28)  
 Heavy menstrual bleeding: assessment and management (NG88)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Human growth hormone - adults (TA64)  
 Diabetes (type 1) - insulin pump therapy (TA151)  
 Osteoporosis - Primary Prevention (TA160)  
 Osteoporosis - Secondary Prevention (TA161)  
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)  
 Osteoporotic Fractures - denosumab (TA204)  
 Bone metastases from solid tumours - denosumab (TA265)  
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)  
 Diabetes (type 2) - canagliflozin (TA315)  
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)  
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)  
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)  
 Bisphosphonates for treating osteoporosis (TA464)  
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)  
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)  
 Dapagliflozin with insulin for treating type 1 diabetes (TA597)  
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)  
 Liraglutide for managing overweight and obesity (TA664)  
 Dapagliflozin for treating chronic kidney disease (TA775)  
 Romosozumab for treating severe osteoporosis (TA791)  
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)  
 Somatogron for treating growth disturbance in people 3 years and over (TA863)  
 Tirzepatide for treating type 2 diabetes (TA924)

## GMMMG Formulary

Formulary Homepage  
 Chapter 6: Endocrine system (Complete)  
 GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 6.1 Drugs used in diabetes



### 6.1.1 Insulins

**Insulins must ONLY be initiated by practitioners experienced in their use**

**Insulins must be prescribed by BRAND NAME**

MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error

NICE NG3

NICE NG17

NICE NG18

NICE NG19

NICE NG28

#### 6.1.1.1 Short-acting insulins

##### Human

##### Actrapid®

Human Insulin



##### Apidra®

Insulin Glulisine



##### Fiasp®

Insulin Aspart



##### Humalog®

Insulin Lispro



##### Humulin R®



Human Insulin



##### Humulin S®

Human Insulin



##### Insulin Lispro Sanofi®

Insulin Lispro



##### Lyumjev®

Green

Insulin Lispro



##### NovoRapid®

Insulin Aspart



##### Trurapi®

Green

Insulin Aspart



##### Animal

##### Hypurin® Bovine Neutral

Insulin Bovine



##### Hypurin® Porcine Neutral

Insulin Porcine



#### 6.1.1.2 Intermediate & long-acting insulins

##### Human

##### Humulin I® Insulin

Isophane Insulin



##### Insulatard®

Isophane Insulin



##### Animal

##### Hypurin® Bovine Isophane

Isophane Insulin



##### Hypurin® Porcine Isophane

Isophane Insulin



| <b>Long-acting insulins</b>                                                                                            |                                                                                                                           |                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| <b>Human</b>                                                                                                           |                                                                                                                           |                                                                                                               |
| <b>Levemir®</b>                                                                                                        |                                                                                                                           |                                                                                                               |
| Insulin Detemir                                                                                                        | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕   |                                                                                                               |
| <b>Lantus®</b>                                                                                                         |                                                                                                                           | <b>2<sup>nd</sup> line use</b><br>in patients where normal basal insulins<br>cause nocturnal hypoglycaemia    |
| Insulin Glargine                                                                                                       | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕   |                                                                                                               |
| <b>Abasaglar®</b>                                                                                                      |                                                                                                                           |                                                                                                               |
| Insulin Glargine biosimilar                                                                                            | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕   |                                                                                                               |
| <b>Toujeo®</b>                                                                                                         |                                                                                                                           |                                                                                                               |
| Insulin Glargine HIGH STRENGTH                                                                                         | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕   |                                                                                                               |
| <b>Tresiba®</b>                                                                                                        |                                                                                                                           | <b>RESTRICTED</b><br><b>3<sup>rd</sup> line after Levemir &amp; Lantus</b><br><b>Diabetes Consultant only</b> |
| Insulin Degludec                                                                                                       | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕   |                                                                                                               |
| MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength                |                                                                                                                           |                                                                                                               |
| <b>Animal</b>                                                                                                          |                                                                                                                           |                                                                                                               |
| <b>Hypurin® Bovine Lente</b>                                                                                           |                                                                                                                           |                                                                                                               |
| Insulin Zinc suspension                                                                                                | <br><b>BNF</b> <b>emc</b> ⊕              |                                                                                                               |
| <b>Biphasic insulins</b>                                                                                               |                                                                                                                           |                                                                                                               |
| <b>Human</b>                                                                                                           |                                                                                                                           |                                                                                                               |
| <b>Humalog® Mix 25</b>                                                                                                 |                                                                                                                           |                                                                                                               |
| Biphasic Insulin Lispro                                                                                                | <br><b>BNF</b> <b>emc</b> ⊕              |                                                                                                               |
| <b>Humalog® Mix 50</b>                                                                                                 |                                                                                                                           |                                                                                                               |
| Biphasic Insulin Lispro                                                                                                | <br><b>BNF</b> <b>emc</b> ⊕              |                                                                                                               |
| <b>Humulin M3®</b>                                                                                                     |                                                                                                                           |                                                                                                               |
| Biphasic Isophane Insulin                                                                                              | <br><b>BNF</b> <b>emc</b> ⊕            |                                                                                                               |
| <b>Insuman® Comb 25</b>                                                                                                |                                                                                                                           |                                                                                                               |
| Biphasic Isophane Insulin                                                                                              | <br><b>BNF</b> <b>emc</b> ⊕            |                                                                                                               |
| <b>NovoMix® 30</b>                                                                                                     |                                                                                                                           |                                                                                                               |
| Biphasic Insulin Aspart                                                                                                | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕ |                                                                                                               |
| <b>Animal</b>                                                                                                          |                                                                                                                           |                                                                                                               |
| <b>Hypurin® Porcine 30/70 Mix Insulin</b>                                                                              |                                                                                                                           |                                                                                                               |
| Biphasic Isophane Insulin                                                                                              | <br><b>BNF</b> <b>emc</b> ⊕            |                                                                                                               |
| <b>6.1.2 Antidiabetic drugs</b>                                                                                        |                                                                                                                           |                                                                                                               |
| <b>6.1.2.1 Sulfonylureas</b>                                                                                           |                                                                                                                           |                                                                                                               |
| <b>Gliclazide</b>                                                                                                      |                                                                                                                           |                                                                                                               |
| tablets                                                                                                                | <br><b>BNF</b> <b>emc</b> ⊕            |                                                                                                               |
| <b>Glipizide</b>                                                                                                       |                                                                                                                           | <b>RESTRICTED</b><br><b>Not for initiation</b>                                                                |
| tablets                                                                                                                | <br><b>BNF</b> <b>emc</b> ⊕            |                                                                                                               |
| <b>6.1.2.2 Biguanides</b>                                                                                              |                                                                                                                           |                                                                                                               |
| <b>Metformin Hydrochloride</b>                                                                                         |                                                                                                                           |                                                                                                               |
|                                      |                                                                                                                           |                                                                                                               |
| oral solution; tablets                                                                                                 | <br><b>MMC</b> <b>BNF</b> <b>emc</b> ⊕ |                                                                                                               |
| MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk |                                                                                                                           |                                                                                                               |
| MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns                               |                                                                                                                           |                                                                                                               |

| 6.1.2.3 Other antidiabetic drugs                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                  | NICE NG28                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| <b>Alpha glucosidase inhibitors</b>                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Acarbose</b>                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| tablets                                                                                                                                                  |                                                                                                                                                                               |                                                                                                      |
| <b>Dipeptidyl peptidase 4 (DPP 4) inhibitors</b>                                                                                                         |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis                                                           |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Alogliptin</b>                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
|                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Linagliptin</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
|                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Saxagliptin</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | 2 <sup>nd</sup> line to improve glycaemic control in adults with metformin                           |
|                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Sitagliptin</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
|                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Rapid acting insulin secretagogues (meglitinides)</b>                                                                                                 |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Nateglinide</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | 2 <sup>nd</sup> line                                                                                 |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Repaglinide</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | 2 <sup>nd</sup> line                                                                                 |
| tablets                                                                                                                                                  |                                                                                              |                                                                                                      |
| <b>Glucagon-like peptide-1 (GLP-1) receptor agonists</b>                                                                                                 |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Dulaglutide</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b><br>1 <sup>st</sup> line weekly preparation<br><b>Diabetes Consultants only</b>     |
|                                                                          |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| injection                                                                                                                                                |                                                                                           |                                                                                                      |
| <b>Exenatide</b>                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                  | 2 <sup>nd</sup> line patients with poor glycaemic control                                            |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| injection                                                                                                                                                |     |                                                                                                      |
| <b>Bydureon®</b>                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                  | 3 <sup>rd</sup> line after failure / inadequate response to oral therapy                             |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| Exenatide prolonged release (once weekly injection)                                                                                                      |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
|                                                                                                                                                          |                                                                                        |                                                                                                      |
| <b>Liraglutide (Victoza®)</b>                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                  | 2 <sup>nd</sup> line to achieve glycaemic control with metformin or a sulphonylurea                  |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| 6mg/mL pre-filled pen                                                                                                                                    |     | <b>PRESCRIBE BY BRAND NAME</b>                                                                       |
| <b>Liraglutide (Saxenda®)</b>                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b><br>in line with NICE TA664<br><b>PRESCRIBE BY BRAND NAME</b>                       |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| 6mg/mL pre-filled pen                                                                                                                                    |     |                                                                                                      |
| MHRA Drug Safety Update (Nov-23): Ozempic ▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products    |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>GLP-1 receptor agonists (continued)</b>                                                                                                               |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Lixisenatide</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b><br>3 <sup>rd</sup> line as per by GMMMG & NICE<br><b>Diabetes Consultants only</b> |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| injection                                                                                                                                                |                                                                                        |                                                                                                      |
| <b>Semaglutide</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | 1 <sup>st</sup> line weekly preparation                                                              |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| Ozempic® injection                                                                                                                                       |                                                                                        |                                                                                                      |
| MHRA Drug Safety Update (Nov-23): Ozempic ▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products    |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| <b>Semaglutide</b>                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b><br>as per by GMMMG                                                                 |
|                                                                        |                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |
| Rybelsus® tablets                                                                                                                                        |     |                                                                                                      |

| Sodium-glucose co-transporter 2 (SGLT2) inhibitors                                                                                                                  |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)                             |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)                                         |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis                                                             |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Canagliflozin                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                           | RESTRICTED<br>in line with NICE<br><br>Diabetes Consultants only |
| tablets                                                                                                                                                             |     |                                                                  |
| MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients  |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Dapagliflozin                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                           | RESTRICTED<br>in line with NICE                                  |
| <br>tablets                                                                         |     |                                                                  |
| MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus                                           |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Empagliflozin                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                           | RESTRICTED<br>in line with NICE                                  |
| <br>tablets                                                                         |     |                                                                  |
| Ertugliflozin                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                           | RESTRICTED<br>in line with NICE<br><br>Diabetes Consultants only |
| tablets                                                                                                                                                             |     |                                                                  |
| Sotagliflozin                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                           | RESTRICTED<br>in line with NICE<br><br>Diabetes Consultants only |
| Zynquista® 200mg tablets                                                                                                                                            |     |                                                                  |
| Thiazolidinediones                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Pioglitazone                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                           | 2 <sup>nd</sup> line add-on with metformin or a sulphonylurea    |
| tablets                                                                                                                                                             |                                                                                      |                                                                  |
| MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer                                                                                              |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| 6.1.4 Treatment of hypoglycaemia                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Glucagon                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| 1mg injection                                                                                                                                                       |                                                                                                                                                                     |                                                                  |
| Glucose gel                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| 40% oral gel                                                                                                                                                        |                                                                                                                                                                   |                                                                  |
| Diazoxide                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                           | Hyperinsulinaemic Hypoglycaemia                                  |
| <br>tablets                                                                       |                                                                                |                                                                  |

## 6.2 Thyroid & antithyroid drugs



### 6.2.1 Thyroid hormones

#### Levothyroxine Sodium

oral solution; tablets



MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products

#### Liothyronine Sodium

Red Green

injection; tablets



**2<sup>nd</sup> line use (I.V. RESTRICTED to hypothyroid coma)**

### 6.2.2 Antithyroid drugs

#### Carbimazole

tablets



MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis

#### Iodine (Aqueous Iodine Oral Solution)



Lugol's Iodine



#### Potassium Iodide

tablets



#### Propylthiouracil

Green

tablets



## 6.3 Corticosteroids



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

### 6.3.1 Replacement therapy

#### Fludrocortisone

tablets



### 6.3.2 Glucocorticoid therapy

#### Prednisolone



#### Dexamethasone



#### Hydrocortisone



MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks

#### Hydrocortisone M/R

5mg tablets



**RESTRICTED**  
2<sup>nd</sup> line use in adrenal insufficiency

#### Hydrocortisone

Green

Alkindi® granules in capsules



**RESTRICTED**  
2<sup>nd</sup> line use in adrenal insufficiency

MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules

#### Betamethasone



**RESTRICTED**  
Specialist use only

#### Methylprednisolone



MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy

#### Triamcinolone

(see also section 10.1.2.2)



**RESTRICTED**  
Specialist use only

| 6.4 Sex hormones                                                                                                                                                  |                  | GMMMG                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------------|
| 6.4.1 Female sex hormones and their modulators                                                                                                                    |                  |                                                                             |
| 6.4.1.1 Oestrogens & HRT                                                                                                                                          |                  |                                                                             |
| Conjugated oestrogens with progestogen                                                                                                                            |                  |                                                                             |
| <b>Premique®</b>                                                                                                                                                  |                  | <b>2<sup>nd</sup> line use oral</b><br>(continuous combined HRT)            |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| Estradiol with Progestogen                                                                                                                                        |                  |                                                                             |
| <b>Elleste-Duet®</b>                                                                                                                                              |                  | <b>1<sup>st</sup> line use oral</b><br>(sequential HRT)                     |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| <b>Femoston®</b>                                                                                                                                                  |                  | <b>2<sup>nd</sup> line use oral</b><br>(sequential HRT)                     |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| <b>Kliovance®</b>                                                                                                                                                 |                  | <b>1<sup>st</sup> line use oral</b><br>(continuous combined HRT)            |
| tablets                                                                                                                                                           | MMC BNF emc      |                                                                             |
| <b>Evorel Conti®</b>                                                                                                                                              |                  | <b>RESTRICTED</b><br>(Continuous combined HRT)<br>when oral contraindicated |
| patch                                                                                                                                                             | BNF emc          |                                                                             |
| Estradiol only                                                                                                                                                    |                  |                                                                             |
| <b>Elleste Solo®</b>                                                                                                                                              |                  | <b>1<sup>st</sup> line use oral</b><br>(oestrogen only HRT)                 |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| <b>Estradot®</b>                                                                                                                                                  |                  | <b>RESTRICTED</b><br>(Oestrogen only HRT)<br>when oral contraindicated.     |
| patch                                                                                                                                                             | BNF emc          |                                                                             |
| <b>Evorel®</b>                                                                                                                                                    |                  | <b>RESTRICTED</b><br>Paed. Endocrine Consultants                            |
| patch                                                                                                                                                             | MMC BNF emc      |                                                                             |
| Ethinylestradiol, raloxifene & tibolone                                                                                                                           |                  |                                                                             |
| <b>Ethinylestradiol</b>                                                                                                                                           |                  | 2 microgram tablets (unlicensed)<br>for amenorrhoea                         |
| tablets                                                                                                                                                           | MMC BNF emc      |                                                                             |
| <b>Raloxifene Hydrochloride</b>                                                                                                                                   |                  | <b>RESTRICTED</b><br>Specialist Med. Consultant only                        |
| tablets                                                                                                                                                           | NICE MMC BNF emc |                                                                             |
| <b>Tibolone</b>                                                                                                                                                   |                  | <b>3<sup>rd</sup> line use oral</b><br>(continuous combined HRT)            |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| 6.4.1.2 Progestogens and progesterone receptor modulators                                                                                                         |                  |                                                                             |
| <b>Dydrogesterone</b>                                                                                                                                             |                  |                                                                             |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| <b>Medroxyprogesterone Acetate</b>                                                                                                                                |                  |                                                                             |
| Depo-Provera® 150mg/mL injection                                                                                                                                  | BNF emc          |                                                                             |
| <b>Medroxyprogesterone Acetate</b>                                                                                                                                |                  |                                                                             |
| Sayana Press® 104mg/0.65 mL injection                                                                                                                             | MMC BNF emc      |                                                                             |
| <b>Norethisterone</b>                                                                                                                                             |                  |                                                                             |
| tablets                                                                                                                                                           | BNF emc          |                                                                             |
| <b>Progesterone</b>                                                                                                                                               |                  |                                                                             |
| Red (suppositories in IVF)                                                                                                                                        |                  |                                                                             |
| pessaries; vaginal capsules; injection                                                                                                                            | MMC BNF emc      |                                                                             |
| <b>Ulipristal Acetate</b>                                                                                                                                         |                  | <b>RESTRICTED</b><br>Specialist use only uterine fibroids                   |
| Red                                                                                                                                                               |                  |                                                                             |
| Esmya® 5mg tablets                                                                                                                                                | MMC BNF emc      |                                                                             |
| MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury                                        |                  |                                                                             |
| MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment |                  |                                                                             |
| MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users |                  |                                                                             |

|                                                                                                                                                                                                                                                                                                                                            |                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| <b>6.4.2 Male sex hormones &amp; antagonists</b>                                                                                                                                                                                                                                                                                           |                                                                 |
| <b>Testosterone &amp; Esters</b>                                                                                                                                                                                                                                                                                                           |                                                                 |
| <b>Oral</b>                                                                                                                                                                                                                                                                                                                                |                                                                 |
| <b>Testosterone</b><br><span>Green</span> <span>Amber</span><br>injection & implants only<br>                                                                           | <b>RESTRICTED</b><br>Specialist use only                        |
| <b>Transdermal preparations</b>                                                                                                                                                                                                                                                                                                            |                                                                 |
| <b>Androstanolone (aka Dihydrotestosterone (DHT))</b><br><br>Andractim® 2.5% gel<br>   | <b>RESTRICTED</b><br>Specialist use only - 3 <sup>rd</sup> line |
| MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure                                                                                                                                                                                                                  |                                                                 |
| <b>Testosterone</b><br><br>Tostran® 2% gel<br>                                         | <b>RESTRICTED</b><br>Specialist use only                        |
| MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure                                                                                                                                                                                                                  |                                                                 |
| <b>Anti-androgens</b>                                                                                                                                                                                                                                                                                                                      |                                                                 |
| <b>Cyproterone Acetate</b><br><span>Green</span><br>tablets ( <a href="#">see also section 8.3.4.2</a> )<br>                                                            | <b>RESTRICTED</b><br>Specialist use only                        |
| <b>Finasteride</b><br><span>Amber</span><br>tablets<br>                                                                                                                 | <b>RESTRICTED</b><br>Specialist use only                        |
| MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts                                                                                                                                                                                                                                            |                                                                 |

## 6.5 Hypothalamic & pituitary hormones & anti-oestrogens



### 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

#### Anti-oestrogens

##### Clomifene Citrate

Red

tablets

BNF emc

#### Anterior pituitary hormones (Corticotrophins)

##### Tetracosactide

Red

injection

BNF emc

##### Corticotropin releasing hormone

Red

injection

BNF emc

#### Anterior pituitary hormones (Gonadotrophins)

##### Human Chorionic Gonadotrophin (hCG)

Red



Gonasi® injection

MMC BNF emc

##### Recombinant human follicle stimulating hormone (r-hFSH)

Red

Ovaleap® injection

MMC BNF emc

#### Anterior pituitary hormones (Growth Hormone)

##### Somatropin

Red

Amber

££

injection

PbR X NICE MMC BNF emc

##### Somatogon

Red

££

Ngenla® injection

PbR X NICE MMC BNF emc

Growth hormone for children

Amber

Growth hormone for primary and secondary hypopituitarism

Green

Growth hormone for adults except in proven primary and secondary hypopituitarism

Red

#### Anterior pituitary hormones (Growth Hormone receptor antagonists)

##### Pegvisomant

Red

££

injection

PbR X MMC BNF blueveq emc

#### Hypothalamic hormones

##### Gonadorelin (GnRH; LHRH)

Red

injection

BNF emc

##### Protirelin (TRH)

Red

injection

BNF emc

### 6.5.2 Posterior pituitary hormones & antagonists

#### Desmopressin

injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)

MMC BNF emc

#### Terlipressin Acetate

injection

BNF emc

MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure &amp; septic shock in patients with type 1 hepatorenal syndrome

#### Tolvaptan

Red

££

tablets

PbR X NICE MMC BNF emc

#### Vasopressin

injection

BNF emc

#### Antidiuretic hormone antagonists

##### Demeclocycline Hydrochloride

Red

capsules (see also section 5.1.3)

MMC BNF emc

**RESTRICTED**  
test for adrenocortical insufficiency

**RESTRICTED**  
Specialist use only

**RESTRICTED**  
Specialist use only

**RESTRICTED**  
Specialist use only

**RESTRICTED**  
as per NICE

**RESTRICTED**  
as per NICE

**RESTRICTED**  
acromegaly on named patient basis  
**NOT STOCKED**

**RESTRICTED**  
Specialist use only

**RESTRICTED**  
Specialist use only

**RESTRICTED**  
Haematology Consultants only



**RESTRICTED**  
adjunct in oesophageal varices

**RESTRICTED Adult.**  
Endocrine / Renal Consultant only



**RESTRICTED**  
pituitary diabetes insipidus

**RESTRICTED**  
SIADH only

| 6.6 Drugs affecting bone metabolism                                                                                                                                      |                        | GMMMG                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------------------|
| <b>6.6.1 Calcitonin &amp; parathyroid hormone</b>                                                                                                                        |                        |                                                                                                 |
| <b>Calcitonin (salmon) / Salcatonin (<i>Miacalcic</i>®)</b>                                                                                                              |                        | <b>RESTRICTED</b> osteoporosis patients with acute fracture pain.                               |
| injection                                                                                                                                                                | MMC BNF emc            |                                                                                                 |
| MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.                                                 |                        |                                                                                                 |
| <b>Parathyroid hormone</b>                                                                                                                                               |                        | <b>RESTRICTED</b> postmenopausal osteoporosis if failure or non-compliance with bisphosphonates |
| Red                                                                                                                                                                      | ff                     |                                                                                                 |
| injection                                                                                                                                                                | PbR X MMC BNF emc      |                                                                                                 |
| <b>Teriparatide (<i>Forsteo</i>®)</b>                                                                                                                                    |                        | <b>RESTRICTED</b> as per NICE/NHSE                                                              |
| Red                                                                                                                                                                      | ff                     |                                                                                                 |
| 250 micrograms / mL injection                                                                                                                                            | PbR X NICE MMC BNF emc | Paeds. see decision tables                                                                      |
| <b>Teriparatide (<i>Movymia</i>®)</b>                                                                                                                                    |                        | <b>RESTRICTED</b> as per forsteo for new patients                                               |
| Red                                                                                                                                                                      | ff                     |                                                                                                 |
| 250 micrograms / mL injection                                                                                                                                            | PbR X NICE MMC BNF emc | NHS England                                                                                     |
| <b>6.6.2 Bisphosphonates &amp; other drugs affecting bone metabolism</b>                                                                                                 |                        |                                                                                                 |
| MHRA Guidance (Dec-14): Bisphosphonates: use and safety                                                                                                                  |                        |                                                                                                 |
| MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal                                                     |                        |                                                                                                 |
| MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures                                                                                            |                        |                                                                                                 |
| MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw                                                                                              |                        |                                                                                                 |
| <b>Alendronic Acid</b>                                                                                                                                                   |                        | <b>1<sup>st</sup> line use</b>                                                                  |
| tablets                                                                                                                                                                  | NICE MMC BNF emc       |                                                                                                 |
| <b>Risedronate Sodium</b>                                                                                                                                                |                        | <b>2<sup>nd</sup> line</b><br>Osteoporosis & Paget's disease                                    |
| tablets                                                                                                                                                                  | NICE MMC BNF emc       |                                                                                                 |
| <b>Strontium Ranelate</b>                                                                                                                                                |                        | <b>3<sup>rd</sup> line</b> osteoporosis patients unable to take bisphosphonates                 |
| Red                                                                                                                                                                      |                        |                                                                                                 |
| oral suspension                                                                                                                                                          | MMC BNF emc            |                                                                                                 |
| <b>Ibandronic Acid</b>                                                                                                                                                   |                        | <b>RESTRICTED</b> monthly treatment when daily/weekly dosing contraindicated; NICE TA464        |
| Red                                                                                                                                                                      | injection              | Green tablets                                                                                   |
| tablets; injection                                                                                                                                                       | NICE MMC BNF emc       |                                                                                                 |
| <b>Denosumab</b>                                                                                                                                                         |                        | <b>RESTRICTED</b><br>specialist use / NICE TA204                                                |
| Amber                                                                                                                                                                    |                        |                                                                                                 |
| <i>Prolia</i> ® injection                                                                                                                                                | NICE MMC BNF emc       |                                                                                                 |
| MHRA Drug Safety Update (May-22): Denosumab 60mg ( <i>Prolia</i> ): should not be used in patients under 18 years due to the risk of serious hypercalcaemia              |                        |                                                                                                 |
| MHRA Drug Safety Update (Aug-20): Denosumab 60mg ( <i>Prolia</i> ): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment          |                        |                                                                                                 |
| MHRA Drug Safety Update (Jun-17): Denosumab ( <i>Xgeva</i> ▼, <i>Prolia</i> ): reports of osteonecrosis of the external auditory canal                                   |                        |                                                                                                 |
| MHRA Drug Safety Update (Jul-15): Denosumab ( <i>Xgeva</i> ▼, <i>Prolia</i> ): intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk   |                        |                                                                                                 |
| <b>Denosumab</b>                                                                                                                                                         |                        | <b>RESTRICTED</b><br>specialist use / NICE TA265                                                |
| Red                                                                                                                                                                      |                        |                                                                                                 |
| <i>Xgeva</i> ® injection                                                                                                                                                 | NICE MMC BNF emc       |                                                                                                 |
| MHRA Drug Safety Update (Jun-18): Denosumab ( <i>Xgeva</i> ▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently... |                        |                                                                                                 |
| MHRA Drug Safety Update (Jun-18): Denosumab ( <i>Xgeva</i> ▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation     |                        |                                                                                                 |
| MHRA Drug Safety Update (Jun-17): Denosumab ( <i>Xgeva</i> ▼, <i>Prolia</i> ): reports of osteonecrosis of the external auditory canal                                   |                        |                                                                                                 |
| MHRA Drug Safety Update (Jul-15): Denosumab ( <i>Xgeva</i> ▼, <i>Prolia</i> ): intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk   |                        |                                                                                                 |
| <b>Zoledronic Acid</b>                                                                                                                                                   |                        | <b>RESTRICTED</b><br>see decision tables; also NICE TA464                                       |
| Red                                                                                                                                                                      |                        |                                                                                                 |
| infusion                                                                                                                                                                 | NICE MMC BNF emc       |                                                                                                 |
| <b>Burosumab</b>                                                                                                                                                         |                        | <b>RESTRICTED</b><br>specialist use only XLH / TIO                                              |
| Red                                                                                                                                                                      |                        |                                                                                                 |
| infusion                                                                                                                                                                 | NICE MMC BNF emc       |                                                                                                 |
| <b>Romosozumab</b>                                                                                                                                                       |                        | <b>RESTRICTED</b><br>specialist use NICE TA791                                                  |
| Red                                                                                                                                                                      |                        |                                                                                                 |
| <i>Evenity</i> ® injection                                                                                                                                               | NICE MMC BNF emc       |                                                                                                 |

| 6.7 Other endocrine drugs                                                                                                                       |  | GMMMG                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------|
| 6.7.1 Bromocriptine & other dopaminergic drugs                                                                                                  |  |                       |
| <b>Bromocriptine</b>                                                                                                                            |  |                       |
| 1mg; 2.5mg tablets                                                                                                                              |  | MMC BNF emc           |
| <b>Cabergoline</b>                                                                                                                              |  |                       |
| 500 microgram tablets                                                                                                                           |  | BNF emc               |
| <b>6.7.2 Drugs affecting gonadotrophins</b>                                                                                                     |  |                       |
| <b>Danazol</b>                                                                                                                                  |  |                       |
| capsules                                                                                                                                        |  | BNF emc               |
| <b>Buserelin</b>                                                                                                                                |  |                       |
| Red                                                                                                                                             |  |                       |
| injection (see also section 8.3.4.2)                                                                                                            |  | MMC BNF emc           |
| <b>Buserelin Acetate</b>                                                                                                                        |  |                       |
| Red                                                                                                                                             |  |                       |
| Suprecur® nasal spray                                                                                                                           |  | MMC BNF emc           |
| <b>Goserelin</b>                                                                                                                                |  |                       |
| Amber Red                                                                                                                                       |  | BNF emc               |
| implant (also section 8.3.4.2)                                                                                                                  |  | BNF emc               |
| <b>Leuporelin Acetate</b>                                                                                                                       |  |                       |
| Amber Red                                                                                                                                       |  | BNF emc               |
| injection (also section 8.3.4.2)                                                                                                                |  | MMC BNF emc           |
| <b>Triptorelin</b>                                                                                                                              |  |                       |
| Amber Red                                                                                                                                       |  | BNF emc               |
| injection (also section 8.3.4.2)                                                                                                                |  | MMC BNF emc           |
| <b>Cetrorelix acetate</b>                                                                                                                       |  |                       |
| Red                                                                                                                                             |  |                       |
| injection                                                                                                                                       |  | MMC BNF emc           |
| <b>Ganirelix</b>                                                                                                                                |  |                       |
| Red                                                                                                                                             |  |                       |
| injection                                                                                                                                       |  | MMC BNF emc           |
| <b>Relugolix with estradiol &amp; norethisterone acetate</b>                                                                                    |  |                       |
| Green                                                                                                                                           |  |                       |
| Ryeqo® 40mg/1mg/0.5mg tablets                                                                                                                   |  | NICE MMC BNF emc      |
| Goserelin/Leuporelin - Licensed Indications (Pre-op management prior to endometrial ablation/fibroid surgery)                                   |  | Amber                 |
| Goserelin/Leuporelin/Triptorelin - Licensed Indications (Prostate cancer for all and breast cancer for Goserelin)                               |  | Amber                 |
| Goserelin/Leuporelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuporelin) |  | Red                   |
| Goserelin/Leuporelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)                                    |  | Red                   |
| <b>6.7.3 Metypapone</b>                                                                                                                         |  |                       |
| <b>Metypapone</b>                                                                                                                               |  |                       |
| Red                                                                                                                                             |  |                       |
| 250mg capsules                                                                                                                                  |  | BNF emc               |
| <b>6.7.4 Somatomedins</b>                                                                                                                       |  |                       |
| <b>Mecasernin</b>                                                                                                                               |  |                       |
| ££                                                                                                                                              |  |                       |
| 10mg/mL injection                                                                                                                               |  | PbR X BNF bluefeg emc |
| MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia                                               |  |                       |

## Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the  
formulary ([click here](#))



### 7.1 Drugs used in Obstetrics

#### 7.1.1 Prostaglandins & oxytocics

##### 7.1.1.1 Ductus arteriosus

#### 7.1.2 Mifepristone

#### 7.1.3 Myometrial relaxants

### 7.2 Treatment of vaginal & vulval conditions

#### 7.2.1 Preparations for vaginal & vulval changes

#### 7.2.2 Vaginal & vulval infections

### 7.3 Contraceptives

#### 7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

#### 7.3.2 Progestogen-only contraceptives

##### 7.3.2.1 Oral progestogen-only contraceptives

##### 7.3.2.2 Parenteral progestogen-only contraceptives

##### 7.3.2.3 Intra-uterine progestogen-only device

#### 7.3.5 Emergency contraception

### 7.4 Drugs for genito-urinary disorders

#### 7.4.1 Drugs for urinary retention

#### 7.4.2 Drugs for urinary, enuresis & incontinence

#### 7.4.3 Drugs used in urological pain

#### 7.4.4 Bladder instillations & urological surgery

#### 7.4.5 Drugs for erectile dysfunction

#### 7.4.6 Drugs for premature ejaculation

## Trust Guidelines

Adult medicines and prescribing guidelines  
Paediatric medicines and prescribing guidelines  
Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Long-acting reversible contraception (CG30)  
Lower urinary tract symptoms (CG97)  
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)  
Antenatal and postnatal mental health: clinical management and service guidance (CG192)  
Heavy menstrual bleeding: assessment and management (NG88)  
Urinary incontinence and pelvic organ prolapse in women: management (NG123)  
Caesarean birth (NG192)  
Antenatal care for uncomplicated pregnancies (NG201)  
Inducing labour (NG207)  
Intrapartum care for healthy women and babies (NG235)  
Overactive bladder - mirabegron (TA290)  
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

## GMMMG Formulary

Formulary Homepage  
Chapter 7: Obstetrics, gynaecology & urinary tract disorders (Complete)  
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 7.1 Drugs used in Obstetrics                                                                   |  | GMMMG                                             |
|------------------------------------------------------------------------------------------------|--|---------------------------------------------------|
| 7.1.1 Prostaglandins & oxytocics                                                               |  | NICE NG207                                        |
| <b>Carbetocin</b><br>Red<br><i>Pabal</i> ® injection<br>MMC BNF emc                            |  | <b>RESTRICTED</b><br>Obs & Gynae Consultants only |
| <b>Carboprost</b><br>Red<br>injection<br>BNF emc                                               |  |                                                   |
| <b>Ergometrine Maleate</b><br>Red<br>injection<br>BNF emc                                      |  |                                                   |
| <b>Gemeprost</b><br>Red<br>pessaries<br>BNF emc                                                |  |                                                   |
| <b>Oxytocin</b><br>Red<br>injection<br>BNF emc                                                 |  |                                                   |
| <b>Dinoprostone</b><br>Red<br>injection; pessaries; vaginal gel; vaginal tablet<br>MMC BNF emc |  | <b>RESTRICTED</b><br>Obs & Gynae Consultants only |
| 7.1.1.1 Drugs affecting the ductus arteriosus                                                  |  | (see also BNFC)                                   |
| Maintenance of patency                                                                         |  |                                                   |
| <b>Alprostadil</b><br>Red<br><i>Prostin VR</i> ® infusion<br>MMC BNF emc                       |  |                                                   |
| Closure of the ductus arteriosus                                                               |  |                                                   |
| <b>Indometacin</b><br>Red<br>injection<br>BNF emc                                              |  |                                                   |
| 7.1.2 Mifepristone                                                                             |  |                                                   |
| <b>Mifepristone</b><br>Red<br>tablets<br>BNF emc                                               |  |                                                   |
| 7.1.3 Myometrial relaxants                                                                     |  |                                                   |
| Atosiban                                                                                       |  |                                                   |
| <b>Atosiban</b><br>Red<br>infusion; injection<br>MMC BNF emc                                   |  | <b>RESTRICTED</b><br>Obs & Gynae Consultants only |
| Beta <sub>2</sub> agonists                                                                     |  |                                                   |
| <b>Salbutamol</b><br>Red<br>injection (see also section 3.1.1.1)<br>BNF emc                    |  |                                                   |
| <b>Terbutaline Sulfate</b><br>Red<br>injection (see also section 3.1.1.1)<br>BNF emc           |  |                                                   |

| 7.2 Treatment of vaginal & vulval conditions               |             | GMMMG                                                                    |
|------------------------------------------------------------|-------------|--------------------------------------------------------------------------|
| <b>7.2.1 Preparations for vaginal &amp; vulval changes</b> |             |                                                                          |
| <b>Oestrogens, topical</b>                                 |             |                                                                          |
| <b>Estradiol</b>                                           |             |                                                                          |
| Vagifem® 10 microgram pessaries                            | BNF emc     |                                                                          |
| <b>Estriol</b>                                             |             |                                                                          |
| 0.01% cream                                                | BNF emc     |                                                                          |
| <b>Estradiol vaginal ring</b>                              |             | <b>RESTRICTED</b><br>Obs & Gynae Consultants only                        |
| Estring® 7.5 microgram / 24 hours ring                     | BNF emc     |                                                                          |
| <b>7.2.2 Vaginal &amp; vulval infections</b>               |             |                                                                          |
| <b>Preparations for vaginal &amp; vulval candidiasis</b>   |             |                                                                          |
| <b>Clotrimazole</b>                                        |             |                                                                          |
| cream; pessaries                                           | BNF emc     |                                                                          |
| <b>Miconazole</b>                                          |             |                                                                          |
| vaginal cream                                              | BNF emc     |                                                                          |
| <b>Preparations for other vaginal infections</b>           |             |                                                                          |
| <b>Clindamycin</b>                                         |             |                                                                          |
| 2% vaginal cream                                           | BNF emc     |                                                                          |
| <b>Nystatin</b>                                            |             |                                                                          |
| vaginal cream; pessaries                                   | BNF emc     |                                                                          |
| <b>Metronidazole</b>                                       |             | <b>RESTRICTED</b><br>Obs & Gynae Consultants only                        |
| Zidoval® 0.75% vaginal gel                                 | MMC BNF emc |                                                                          |
| <b>Boric acid</b>                                          |             | <b>RESTRICTED</b><br>specialist use only for<br>vulvovaginal candidiasis |
| Red U<br>vaginal pessary                                   | MMC emc     |                                                                          |

## 7.3 Contraceptives



MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?

### 7.3.1 Combined hormonal contraceptives

NICE CG30

MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism

#### Ethinylestradiol with Desogestrel

**Munalea®**

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Mercilon®**

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with Gestodene

**Femodene®**

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Aidulan®**

20microgram / 75 microgram tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with Levonorgestrel

NICE NG88

**TriRegol®**

tablets



**Microgynon 30®**

tablets



**Ovranette®**

tablets



#### Ethinylestradiol with Norelgestromin

**Evra®**

patch



**RESTRICTED**  
in line with GMMMG and SmPC

#### Ethinylestradiol with Norethisterone

**Loestrin 20®**

tablets



**Loestrin 30®**

tablets



**Norimin®**

tablets



#### Ethinylestradiol with Norgestimate

**Cilest®**

tablets



#### Mestranol with Norethisterone

**Norinyl-1®**

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

### 7.3.2 Progestogen-only contraceptives

#### 7.3.2.1 Oral progestogen-only contraceptives

**Desogestrel**

Cerazette® 75 microgram tablets



**Levonorgestrel**

Norgeston® 35 microgram tablets



**Norethisterone**

Noriday® 350 microgram tablets



| 7.3.2.2 Parenteral progestogen-only contraceptives                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Injectable preparations                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                           |
| <b>Medroxyprogesterone Acetate</b><br><br><i>Depo-Provera</i> ® 150mg/mL intramuscular injection                                                                                                                                                                                                                                                                                  |                                                                                                                                                                       |
| <b>Medroxyprogesterone Acetate</b><br><br><i>Sayana Press</i> ® 160mg/mL subcutaneous injection                                                                                                                                                                                                                                                                                   |                                                                                      |
| Implants                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                           |
| <b>Etonogestrel</b><br><br><i>Nexplanon</i> ® 68mg subdermal implant<br><br>MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury & implant migration<br>MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung | <b>2<sup>nd</sup> line as per MMC</b><br><br>                                        |
| 7.3.2.3 Intra-uterine progestogen-only device                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                           |
| <b>Levonorgestrel</b><br><br><i>Mirena</i> ® 20micrograms/24 hours IUD<br><br>MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name                                                                                                                                                                                            |                                                                                                                                                                       |
| <b>Levonorgestrel</b><br><br><i>Jaydess</i> ® 13.5mg IUD<br><br>MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name                                                                                                                                                                                                          | <b>RESTRICTED</b><br><b>Specialist use Tertiary Services only</b><br><br>            |
| <b>Levonorgestrel</b><br><br><i>Kyleena</i> ® 19.5mg IUD<br><br>MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name                                                                                                                                                                                                          | <b>RESTRICTED</b><br><b>Specialist use Tertiary Services only</b><br><br>            |
| 7.3.5 Emergency contraception                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                           |
| <b>Levonorgestrel</b><br><br><i>Levonelle</i> ® 1500 microgram tablets<br><br>MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers...<br>MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women                      |                                                                                                                                                                     |
| <b>Ulipristal Acetate</b><br><br><i>ellaOne</i> ® 30mg tablets<br><br>MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women                                                                                                                                                                                      | <b>RESTRICTED</b><br><b>emergency contraception (SARC)</b><br><br>             |
| Assisted Reproductive Technology (ART) cycles                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                           |
| <b>Progesterone</b><br><br><i>Utrogestan</i> ® 100mg; 200mg vaginal capsules                                                                                                                                                                                                                                                                                                      | <b>RESTRICTED</b><br><b>ART cycles</b><br><b>2<sup>nd</sup> line</b><br><br>   |

| 7.4 Drugs for genito-urinary disorders                                                                                                 |                  | GMMMG                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------------------------------|
| 7.4.1 Drugs for urinary retention                                                                                                      |                  | NICE CG97                                                     |
| Alpha blockers                                                                                                                         |                  | NICE CG111                                                    |
|                                                                                                                                        |                  | NICE NG123                                                    |
| <b>Alfuzosin Hydrochloride</b>                                                                                                         |                  |                                                               |
| tablets                                                                                                                                | BNF emc          |                                                               |
| <b>Tamsulosin Hydrochloride</b>                                                                                                        |                  | 1 <sup>st</sup> line                                          |
| capsules, tablets                                                                                                                      | MMC BNF emc      |                                                               |
| 7.4.2 Drugs for urinary, enuresis & incontinence                                                                                       |                  | NICE NG123                                                    |
| Urinary incontinence                                                                                                                   |                  |                                                               |
| <b>Oxybutynin Hydrochloride</b>                                                                                                        |                  | 1 <sup>st</sup> line in OAB                                   |
| oral solution; patch; tablets                                                                                                          | NICE MMC BNF emc |                                                               |
| <b>Darifenacin Hydrobromide</b>                                                                                                        |                  | 1 <sup>st</sup> line in OAB                                   |
| tablets                                                                                                                                | NICE MMC BNF emc |                                                               |
| <b>Tolterodine Tartrate</b>                                                                                                            |                  | 1 <sup>st</sup> line in OAB                                   |
| capsules, tablets                                                                                                                      | NICE MMC BNF emc |                                                               |
| <b>Solifenacin Succinate</b>                                                                                                           |                  | 2 <sup>nd</sup> line in OAB                                   |
| tablets                                                                                                                                | MMC BNF emc      | patients failed / intolerant to oxybutynin                    |
| <b>Duloxetine</b>                                                                                                                      |                  |                                                               |
| capsules                                                                                                                               | MMC BNF emc      |                                                               |
| <b>Trospium Chloride</b>                                                                                                               |                  | RESTRICTED<br>1 <sup>RY</sup> Care referral only              |
| capsules; tablets                                                                                                                      | MMC BNF emc      |                                                               |
| <b>Mirabegron</b>                                                                                                                      |                  | RESTRICTED<br>in line with TA290 / Paeds 3 <sup>rd</sup> line |
| tablets                                                                                                                                | NICE MMC BNF emc |                                                               |
| MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga▼): risk of severe hypertension and associated cerebrovascular and cardiac events |                  |                                                               |
| Nocturnal enuresis                                                                                                                     |                  |                                                               |
| <b>Amitriptyline</b>                                                                                                                   |                  |                                                               |
| oral solution; tablets (see also section 4.3.1)                                                                                        | BNF emc          |                                                               |
| <b>Desmopressin</b>                                                                                                                    |                  | RESTRICTED<br>Haematology Consultants only                    |
| injection; nasal spray; tablets (see also section 6.5.2)                                                                               | MMC BNF emc      |                                                               |
| 7.4.3 Drugs used in urological pain                                                                                                    |                  |                                                               |
| <b>Methionine</b>                                                                                                                      |                  | RESTRICTED<br>resistant calcium phosphate lithiasis           |
| tablets                                                                                                                                | BNF emc          | EAU European Association of Urology                           |
| <b>Pentosan polysulfate sodium</b>                                                                                                     |                  | RESTRICTED<br>Urology Cons. in line with NICE                 |
| capsules                                                                                                                               | NICE MMC BNF emc |                                                               |
| MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy                           |                  |                                                               |
| <b>Potassium Citrate</b>                                                                                                               |                  |                                                               |
| tablets                                                                                                                                | BNF emc          |                                                               |

| 7.4.4 Bladder instillations & urological surgery                                                                                                        |                                                                                                                                                                      |  |                          |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------|
| <b>Chlorhexidine</b>                                                                                                                                    |                                                                                                                                                                      |  |                          |
| 0.02% irrigation solution                                                                                                                               |   |  |                          |
| <b>Dimethyl Sulfoxide</b>                                                                                                                               |                                                                                                                                                                      |  |                          |
|  50% solution                                                           |   |  |                          |
| <b>Glycine</b>                                                                                                                                          |                                                                                                                                                                      |  |                          |
| 1.5% irrigation solution                                                                                                                                |   |  |                          |
| <b>Sodium Chloride</b>                                                                                                                                  |                                                                                                                                                                      |  |                          |
| 0.9% irrigation solution                                                                                                                                |   |  |                          |
| <b>Sodium Citrate</b>                                                                                                                                   |                                                                                                                                                                      |  |                          |
| 3% irrigation solution                                                                                                                                  |   |  |                          |
| <b>Sodium Hyaluronate</b>                                                                                                                               |                                                                                                                                                                      |  | <b>RESTRICTED</b>        |
|  Cystistat® 40mg/50mL bladder instillation                              |   |  | Urology Consultants only |
| <b>Sodium Hyaluronate with sodium chondroitin sulfate</b>                                                                                               |                                                                                                                                                                      |  | <b>RESTRICTED</b>        |
|  iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation |   |  | Urology Consultants only |

| 7.4.5 Drugs for erectile dysfunction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| <b>Alprostadil</b><br><br>cream; injection; urethral sticks                                                                                                                                         | <b>RESTRICTED</b><br>Urology Consultants only           |
| <b>Aviptadil with Phentolamine</b><br><br>Invicorp® injection                                                                                                                                       | <b>RESTRICTED</b><br>Urology Consultants only           |
| <b>Sildenafil</b><br> or  PAH<br>injection; oral suspension; tablets ( <a href="#">see also section 2.5.1</a> )    | <b>RESTRICTED</b><br>1 <sup>RY</sup> Care referral only |
| MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction                                                                                                                                                                                                                                                                                                                                                                     |                                                         |
| <b>Tadalafil</b><br> or  PAH<br>tablets ( <a href="#">see also section 2.5.1</a> )                                 | <b>RESTRICTED</b><br>1 <sup>RY</sup> Care referral only |
| <b>Vardenafil</b><br>tablets                                                                                                                                                                                                                                                        | <b>RESTRICTED</b><br>1 <sup>RY</sup> Care referral only |
| 7.4.6 Drugs for premature ejaculation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                         |
| <b>NOT STOCKED</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <b>NOT STOCKED</b>                                      |

## Section 8: Malignant disease & immunosuppression

Supported by the  
formulary ([click here](#))



### 8.1 Cytotoxic drugs

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

### 8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

### 8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
  - 8.3.4.1 Breast Cancer
  - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
  - 8.3.4.3 Somatostatin analogues

### 8.4 Miscellaneous preparations

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Advanced breast cancer (CG81)  
 Familial breast cancer (CG164)  
 Hepatitis B (chronic) (CG165)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)  
 Early and locally advanced breast cancer: diagnosis and management (NG101)  
 Lung cancer: diagnosis and management (NG122)  
 Prostate cancer: diagnosis and management (NG131)  
 Colorectal cancer (NG151)  
 Temozolomide for malignant glioma (TA23)  
 Leukaemia (lymphocytic) - fludarabine (TA29)  
 Trastuzumab for advanced breast cancer (TA34)  
 Paclitaxel for ovarian cancer (TA55)  
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)  
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)  
 Docetaxel for prostate cancer (hormone-refractory) (TA101)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Paclitaxel for early breast cancer (TA108)  
 Docetaxel for early breast cancer (TA109)  
 Gemcitabine for Breast Cancer (TA116)  
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)  
 Leukaemia (lymphocytic) - fludarabine (TA119)  
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)  
 Pemetrexed for lung cancer (non small cell) (TA124)  
 Multiple sclerosis - natalizumab (TA127)  
 Bortezomib for relapsed multiple myeloma (TA129)  
 Pemetrexed for mesothelioma (TA135)  
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)  
 Head and neck cancer - cetuximab (TA145)  
 Renal cell carcinoma - sunitinib (TA169)  
 Lenalidomide - multiple myeloma (TA171)  
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)  
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)  
 Renal Cell Carcinoma (TA178)  
 Sunitinib for gastrointestinal stromal tumours (TA179)  
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)  
 Cervical cancer (recurrent) - topotecan (TA183)  
 Lung cancer (small cell) - topotecan (TA184)  
 Soft tissue sarcoma - trabectedin (TA185)  
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)  
 Gastric cancer (advanced) - capecitabine (TA191)  
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)  
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)  
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)  
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)  
 Colorectal cancer (metastatic) - bevacizumab (TA212)  
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)  
 Renal cell carcinoma (1<sup>st</sup> line metastatic) - pazopanib (TA215)  
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)  
 Myelodysplastic syndrome - azacitidine (TA218)  
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)  
 Multiple myeloma (1<sup>st</sup> line) - bortezomib and thalidomide (TA228)  
 Osteosarcoma - mifamurtide (TA235)  
 Follicular lymphoma - rituximab (review TA110) (TA243)  
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)  
 Bevacizumab in combination with paclitaxel & carboplatin for 1<sup>st</sup> line treatment of advanced ovarian cancer (TA284)  
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Multiple sclerosis (relapsing) - teriflunomide (TA303)  
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)

Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)

Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)

Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Ibrutinib for treating Waldenström's macroglobulinaemia (TA491)

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)

Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Tivozanib for treating advanced renal cell carcinoma (TA512)

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)

Cabozantinib for treating medullary thyroid cancer (TA516)

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)  
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)  
 Midostaurin for untreated acute myeloid leukaemia (TA523)  
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)  
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)  
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)  
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)  
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)  
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)  
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)  
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)  
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)  
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)  
 Dinutuximab beta for treating neuroblastoma (TA538)  
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)  
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)  
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)  
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)  
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)  
 Padeliporfin for untreated localised prostate cancer (TA546)  
 Vandetanib for treating medullary thyroid cancer (TA550)  
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)  
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)  
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)  
 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)  
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)  
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)  
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)  
 Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567)  
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)  
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)  
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)  
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)  
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)  
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)  
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)  
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)  
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)  
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)  
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)  
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)  
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)  
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)  
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)  
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)  
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)  
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)  
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)  
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)  
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)  
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)  
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)  
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)  
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)  
 Entrectinib for treating NTRK fusion-positive solid tumours (TA644)  
 Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)  
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)  
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)  
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)  
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)  
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)  
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)  
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)  
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)  
 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)  
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)  
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)  
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)  
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)  
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)  
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)  
 Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)  
 Avelumab for untreated metastatic Merkel cell carcinoma (TA691)  
 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)  
 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)  
 Ofatumumab for treating relapsing multiple sclerosis (TA699)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)  
 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)  
 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)  
 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)  
 Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)  
 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)  
 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)  
 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)  
 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)  
 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)  
 Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)  
 Midostaurin for treating advanced systemic mastocytosis (TA728)  
 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)  
 Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)  
 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)  
 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)  
 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)  
 Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)  
 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)  
 Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)  
 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)  
 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)  
 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)  
 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)  
 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)  
 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)  
 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)  
 Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)  
 Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)  
 Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)  
 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)  
 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)  
 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)  
 Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)  
 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)  
 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)  
 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)  
 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)  
 Ibrutinib for treating Waldenström's macroglobulinaemia (replacing TA491) (TA795)  
 Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)  
 Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)  
 Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)  
 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)  
 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)  
 Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)  
 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)  
 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)  
 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)  
 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)  
 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)  
 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)  
 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)  
 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)  
 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)  
 Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)  
 Zanubrutinib for treating Waldenström's macroglobulinaemia (TA833)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)  
 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)  
 Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)  
 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)  
 Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)  
 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)  
 Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)  
 Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)  
 Regorafenib for previously treated metastatic colorectal cancer (TA866)  
 Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)  
 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)  
 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)  
 Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)  
 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)  
 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)  
 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)  
 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)  
 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)  
 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)  
 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)  
 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)  
 Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)  
 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)  
 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)  
 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)  
 Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)  
 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)  
 Ruxolitinib for treating polycythaemia vera (TA921)  
 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)  
 Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

## GMMM Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression (Complete)

GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMM Paediatric **Red/Amber/Green** Drug List

| 8.1 Cytotoxic drugs                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                               |                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| 8.1 Cytotoxic drugs                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                               |                                                                                                                                       |
| <b>Dexrazoxane</b><br>                                                                                                                                        |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only  |
| infusion                                                                                                                                                                                                                                                                                                                       |  <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                          |                                                                                                                                       |
| <b>Folinic Acid</b> (as calcium folinate)<br>                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| tablets; injection                                                                                                                                                                                                                                                                                                             |  <b>BNF</b> <b>emc</b>                                                                                                     |                                                                                                                                       |
| <b>Mesna</b><br>                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| tablets; injection                                                                                                                                                                                                                                                                                                             |  <b>BNF</b> <b>emc</b>                                                                                                     |                                                                                                                                       |
| <b>Palifermin</b><br>                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection                                                                                                                                                                                                                                                                                                                      | <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                                                                                                            |                                                                                                                                       |
| 8.1.1 Alkylating drugs                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                               |                                                                                                                                       |
| <b>Busulfan</b><br>                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion                                                                                                                                                                                                                                                                                                                       | <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                                                                                                            |                                                                                                                                       |
| <b>Bendamustine</b><br>                                                                                                                                       |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion                                                                                                                                                                                                                                                                                                                       |   <b>MMC</b> <b>BNF</b> <b>emc</b>        |                                                                                                                                       |
| MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML)<br>MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation |                                                                                                                                                                                                                                                                                               |                                                                                                                                       |
| <b>Carmustine</b><br>                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion                                                                                                                                                                                                                                                                                                                       |  <b>BNF</b> <b>emc</b>                                                                                                     |                                                                                                                                       |
| <b>Chlorambucil</b><br>                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| tablets                                                                                                                                                                                                                                                                                                                        |  <b>BNF</b> <b>emc</b>                                                                                                   |                                                                                                                                       |
| <b>Cyclophosphamide</b><br>                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection; tablets; oral suspension                                                                                                                                                                                                                                                                                            | <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                                                                                                          |                                                                                                                                       |
| <b>Ifosfamide</b><br>                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection                                                                                                                                                                                                                                                                                                                      | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Lomustine</b><br>                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| capsules                                                                                                                                                                                                                                                                                                                       | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Melphalan</b><br>                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection; tablets                                                                                                                                                                                                                                                                                                             | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Treosulfan</b><br>                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b> Adult Haematology /<br>Paediatric Haematology / Oncology                                                            |
| injection                                                                                                                                                                                                                                                                                                                      |  <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                      |                                                                                                                                       |
| 8.1.2 Anthracyclines & other cytotoxic antibiotics                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                               |                                                                                                                                       |
| <b>Bleomycin</b><br>                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection                                                                                                                                                                                                                                                                                                                      | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Daunorubicin</b><br>                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| injection                                                                                                                                                                                                                                                                                                                      | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Doxorubicin Hydrochloride</b><br>                                                                                                                      |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion; injection                                                                                                                                                                                                                                                                                                            |   <b>MMC</b> <b>BNF</b> <b>emc</b>  |                                                                                                                                       |
| <b>Idarubicin</b><br>                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| capsules; injection                                                                                                                                                                                                                                                                                                            | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Mitomycin</b><br>                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Consultants only                                                                                                 |
| injection                                                                                                                                                                                                                                                                                                                      | <b>MMC</b> <b>BNF</b> <b>emc</b>                                                                                                                                                                          |                                                                                                                                       |
| <b>Mitoxantrone</b><br>                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion                                                                                                                                                                                                                                                                                                                       | <b>BNF</b> <b>emc</b>                                                                                                                                                                                     |                                                                                                                                       |
| <b>Pixantrone</b><br>                                                                                                                                     |                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                     |
| infusion                                                                                                                                                                                                                                                                                                                       |   <b>MMC</b> <b>BNF</b> <b>emc</b>  |                                                                                                                                       |

| 8.1.3 Antimetabolites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |  | NICE CG81                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | NICE NG151                                                                                                                                                                                                                                                                                                                               |
| <b>Azacitidine</b><br> <br>injection                                                                                                                                                                                                                                                                                                                     |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                     |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Capecitabine</b><br><br>tablets                                                                                                                                                                                                                                                                                                                                                                                                        |  |     |
| MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity<br>MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment                                                                                                                                                                                                                                  |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Cladribine</b><br> <br>infusion; injection                                                                                                                                                                                                                                                                                                            |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                   |  |                                                                                                                                                                                                                                                                                                                                          |
| MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury<br>MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Clofarabine</b><br> <br>infusion                                                                                                                                                                                                                                                                                                                      |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                     |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Cytarabine</b><br><br>injection                                                                                                                                                                                                                                                                                                                                                                                                        |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                       |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Cytarabine / Daunorubicin</b><br> <br>Vyxeos® 100mg/44mg infusion                                                                                                                                                                                                                                                                                     |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                   |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Fludarabine</b><br><br>injection; tablets                                                                                                                                                                                                                                                                                                                                                                                              |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                       |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Fluorouracil</b><br><br>injection                                                                                                                                                                                                                                                                                                                                                                                                      |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                      |  |                                                                                                                                                                                                                                                                                                                                          |
| MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity                                                                                                                                                                                                                                                                                                                                           |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Gemcitabine</b><br><br>infusion                                                                                                                                                                                                                                                                                                                                                                                                      |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                              |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Mercaptopurine</b><br><br>oral suspension; tablets (see also section 1.5.3)                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                    |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Methotrexate</b><br><br>infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)                                                                                                                                                                                                                                                                                                                            |  |                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                 |  |                                                                                                                                                                                                                                                                                                                                          |
| MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions                                                                                                                                                                                                                                                                                                                                                                                        |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Pemetrexed</b><br> <br>injection                                                                                                                                                                                                                                                                                                                  |  | <b>RESTRICTED</b> Respiratory<br>Consultants only in line with TA402                                                                                                                                                                                                                                                                     |
|       |  |                                                                                                                                                                                                                                                                                                                                          |
| 8.1.4 Vinca alkaloids & etoposide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Etoposide</b><br><br>capsules; infusion                                                                                                                                                                                                                                                                                                                                                                                              |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                    |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Vinblastine Sulfate</b><br><br>injection                                                                                                                                                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                    |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Vincristine Sulfate</b><br><br>injection                                                                                                                                                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                                                                                                    |  |                                                                                                                                                                                                                                                                                                                                          |
| 8.1.5 Other antineoplastic drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Acalabrutinib</b><br> <br>infusion                                                                                                                                                                                                                                                                                                                |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|       |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Arsenic Trioxide</b><br> <br>infusion                                                                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b> Haem. Consultants only<br>/ also in line with NICE TA526                                                                                                                                                                                                                                                               |
|       |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Asciminib</b><br> <br>Scemblix® 20mg/40mg tablets                                                                                                                                                                                                                                                                                                 |  | <b>RESTRICTED</b> Haem. Consultants in<br>line with NICE TA813                                                                                                                                                                                                                                                                           |
|       |  |                                                                                                                                                                                                                                                                                                                                          |
| <b>Asparaginase e-coli</b><br><br>infusion                                                                                                                                                                                                                                                                                                                                                                                              |  | <b>RESTRICTED</b><br>Haematology Consultants only                                                                                                                                                                                                                                                                                        |
|                                                                                                                                                                                                                                                                 |  |                                                                                                                                                                                                                                                                                                                                          |

|                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| <b>Autologous anti-CD19-transduced CD3+ cells</b><br> <br><i>Tecartus</i> ® infusion |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Haem. Consultants in line with NICE TA677                              |
| <b>Axicabtagene ciloleucel</b><br> <br><i>Yescarta</i> ® infusion                    |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> in line with NICE TA872                                                |
| <b>Bevacizumab</b><br> <br><i>Avastin</i> ® 100mg in 4mL vial                        |  <b>MMC</b> <b>BNF</b>                                                                                                                                                                         | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Bortezomib</b><br> <br>injection                                                  |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Brentuximab Vedotin</b><br> <br>infusion                                          |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Brexucabtagene autoleucel</b><br> <br><i>Tecartus</i> ® infusion                  |  <b>MMC</b> <b>BNF</b>                                                                                                                                                                         | <b>RESTRICTED</b> Haem. Consultants only in line with CDF                                |
| <b>Cabozantinib</b><br> <br>tablets; capsules                                        |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Specialist Consultant use only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Carfilzomib</b><br> <br>infusion                                                  |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Haematology Consultants only in line with NICE                         |
| <b>Ceritinib</b><br> <br>capsules                                                    |   <b>MMC</b> <b>BNF</b>                                                                                       | <b>RESTRICTED</b> Respiratory Consultants only in line with NICE<br><b>NOT STOCKED</b>   |
| <b>Cetuximab</b><br> <br>infusion                                                    |   <b>MMC</b> <b>BNF</b>                                                                                  | <b>RESTRICTED</b> Haematology Consultants only in line with NICE                         |
| <b>Crisantaspase</b><br> <br>injection                                           |                                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Dacarbazine</b><br><br>injection                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Durvalumab</b><br> <br>infusion                                               |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Respiratory Consultants only in line with NICE<br><b>NOT STOCKED</b>   |
| <b>Entrectinib</b><br> <br>injection                                             |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Specialist Consultant use only in line with NICE                       |
| <b>Eribulin</b><br> <br>injection                                                |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Specialist Consultant use only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Erlotinib</b><br> <br>tablets                                                 |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Respiratory Consultants only in line with NICE<br><b>NOT STOCKED</b>   |
| <b>Everolimus</b><br> <br>tablets                                                |   <b>MMC</b>     | <b>RESTRICTED</b> Specialist Consultant use only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Hydroxycarbamide</b><br><br>capsules; tablets ( <a href="#">see below</a> )                                                                                      |                                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b> Haematology Consultants only                                           |
| <b>Ipilimumab</b><br> <br>infusion                                               |   <b>MMC</b>     | <b>RESTRICTED</b> Dermatology Consultants only in line with NICE<br><b>NOT STOCKED</b>   |
| MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                          |
| <b>Ixazomib</b><br> <br>capsules                                                 |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Haematology Consultants only in line with NICE                         |
| <b>Lorlatinib</b><br> <br><i>Lorviqua</i> ® tablets                              |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Respiratory Consultants only in line with NICE                         |
| <b>Midostaurin</b><br> <br><i>Rydapt</i> ® capsules                              |   <b>MMC</b> <b>BNF</b>                                                                             | <b>RESTRICTED</b> Haematology Consultants only in line with NICE                         |

|                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| <b>Nintedanib esilate</b><br> <br>Ofev® capsules            |                   | <b>RESTRICTED Respiratory</b><br>Consultants only in line with NICE                       |
| <b>Nintedanib esilate</b><br> <br>Vargatef® capsules        |                   | <b>RESTRICTED Respiratory</b><br>Consultants only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Niraparib</b><br> <br>Zejula® capsules                   |                   | <b>RESTRICTED Gynaecology</b><br>Consultants only in line with NICE<br><b>NOT STOCKED</b> |
| MHRA Drug Safety Update (Oct-20): Niraparib (Zejula▼): reports of severe hypertension & PRES, particularly in early treatment                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
| <b>Panitumumab</b><br> <br>infusion                         |                   | <b>RESTRICTED Haematology</b><br>Consultants only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Panobinostat</b><br> <br>capsules                        |                                                                                                      | <b>RESTRICTED Haematology</b><br>Consultants only in line with TA380                      |
| <b>Pegaspargase</b><br> <br>Oncaspar® injection             |                   | <b>RESTRICTED</b><br>Haematology Consultants only                                         |
| <b>Pembrolizumab</b><br> <br>infusion                       |                   | <b>RESTRICTED Specialist use only in line with NICE / NHSE</b>                            |
| MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
| <b>Pentostatin</b><br> <br>infusion                         |                                                                                                                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>Haematology Consultants only                                         |
| <b>Pertuzumab</b><br> <br>infusion                          |                   | <b>RESTRICTED Specialist Consultant use only in line with NICE</b><br><b>NOT STOCKED</b>  |
| <b>Procarbazine</b><br> <br>capsules                      |                                                                                                                                                                                                                                                                                                                                                     | <b>RESTRICTED</b><br>Haematology Consultants only                                         |
| <b>Sacituzumab govitecan</b><br> <br>Trodelvy® infusion |       | <b>RESTRICTED Specialist Consultant use only in line with NICE</b><br><b>NOT STOCKED</b>  |
| <b>Sorafenib</b><br> <br>tablets                        |       | <b>RESTRICTED Haematology</b><br>Consultants only in line with NICE                       |
| MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
| <b>Sotorasib</b><br> <br>Lumykras® tablets              |       | <b>RESTRICTED PulmonaryOnc Consultants only in line with NICE TA781</b>                   |
| <b>Talimogene Laherparepvec</b><br> <br>injection       |       | <b>RESTRICTED Dermatology</b><br>Consultants only in line with TA410                      |
| <b>Tisagenlecleucel</b><br> <br>Kymriah® infusion       |       | <b>RESTRICTED in line with CDF criteria and NICE TA554 / TA567</b>                        |
| <b>Trastuzumab</b><br> <br>infusion; injection          |       | <b>RESTRICTED Specialist use only in line with NICE</b>                                   |
| <b>Venetoclax</b><br> <br>tablets                       |       | <b>RESTRICTED Specialist use only in line with NICE / NHSE</b>                            |
| MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
| Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |      |
| Hydroxycarbamide - Sickle Cell Disease                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |      |
| Hydroxycarbamide - Chemotherapy                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |      |
| <b>Platinum compounds</b>                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                           |
| <b>Cisplatin</b><br><br>injection                                                                                                          |                                                                                                                                                                                                                                                                                                                                                     | <b>RESTRICTED</b><br>Haematology Consultants only                                         |

| <b>Protein kinase inhibitors</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| <b>Abemaciclib</b><br> <br>Verzenios® tablets<br>  <b>MMC</b>                                             | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>          |
| MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                        |
| <b>Alectinib</b><br> <br>Alecensa® capsules<br>  <b>MMC</b>                                               | <b>RESTRICTED</b> Specialist use only in line with NICE TA536<br><b>NOT STOCKED</b>    |
| <b>Alpelisib</b><br> <br>Piqray® tablets<br>  <b>MMC</b>                                                  | <b>RESTRICTED</b> Specialist use only in line with NICE TA816<br><b>NOT STOCKED</b>    |
| <b>Axitinib</b><br> <br>Inlyta® tablets<br>  <b>MMC</b>                                                   | <b>RESTRICTED</b> Haematology Consultants only in line with NICE<br><b>NOT STOCKED</b> |
| <b>Bosutinib</b><br> <br>Bosulif® tablets<br>  <b>MMC</b>                                                 | <b>RESTRICTED</b> Haematology Consultants only in line with TA401                      |
| MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                        |
| <b>Brigatinib</b><br> <br>Alunbrig® tablets<br>  <b>MMC</b>                                               | <b>RESTRICTED</b> Specialist use only in line with NICE                                |
| <b>Crizotinib</b><br> <br>Xalkori® capsules<br>  <b>MMC</b>                                               | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>          |
| <b>Dabrafenib</b><br> <br>Tafinlar® capsules<br>  <b>MMC</b>                                              | <b>RESTRICTED</b> Specialist use only in line with NICE                                |
| <b>Dacomitinib</b><br> <br>Vizimpro® tablets<br>  <b>MMC</b>                                          | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>          |
| <b>Dasatinib</b><br> <br>Sprycel® tablets; powder for oral suspension<br>  <b>MMC</b>       | <b>RESTRICTED</b> Haematology Consultants only                                         |
| MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                        |
| <b>Encorafenib</b><br> <br>Braftovi® capsules<br>  <b>MMC</b>                               | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>          |
| <b>Fedratinib</b><br> <br>Inrebic® capsules<br>  <b>MMC</b>                                 | <b>RESTRICTED</b> Haematology Consultants only                                         |
| <b>Gefitinib</b><br> <br>tablets<br>  <b>MMC</b>                                            | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>          |
| <b>Gemtuzumab ozogamicin</b><br> <br>Mylotarg® injection<br>  <b>MMC</b>                    | <b>RESTRICTED</b> Haematology Consultants only                                         |
| <b>Gilteritinib fumarate</b><br> <br>Xospata® tablets<br>  <b>MMC</b>                       | <b>RESTRICTED</b> Haematology Consultants only                                         |
| <b>Ibrutinib</b><br> <br>Imbruvica® capsules; tablets<br>  <b>MMC</b>                       | <b>RESTRICTED</b> Haem. Consultants only / also in line with NICE                      |
| MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                        |
| MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                        |
| <b>Idelalisib</b><br> <br>Zydelig® tablets<br>  <b>MMC</b>                                  | <b>RESTRICTED</b> Specialist use only in line with NICE TA359                          |
| MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                        |
| <b>Imatinib</b><br> <br>tablets<br>  <b>MMC</b>                                             | <b>RESTRICTED</b> Haematology Consultants only                                         |
| MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                        |
| <b>Inotuzumab ozogamicin</b><br> <br>Besponsa® 1mg solution for infusion<br>  <b>MMC</b>    | <b>RESTRICTED</b> Haematology Consultants only                                         |
| <b>Larotrectinib sulfate</b><br> <br>Vitrakvi® 20mg/mL oral solution<br>  <b>MMC</b>        | <b>RESTRICTED</b> Consultants only in line with NICE                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| <b>Lenvatinib</b><br> <br><i>Kisplyx</i> ® capsules<br>  <b>MMC</b>                               | <b>RESTRICTED</b> Specialist use only in line with NICE TA498 / 858<br><b>NOT STOCKED</b>   |
| <b>Lenvatinib</b><br> <br><i>Lenvima</i> ® capsules<br>  <b>MMC</b>                               | <b>RESTRICTED</b> Specialist use only in line with NICE TA535 / 551<br><b>NOT STOCKED</b>   |
| MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                             |
| <b>Mobocertinib</b><br> <br><i>Exkivity</i> ® capsules<br>  <b>MMC</b>                            | <b>RESTRICTED</b> Specialist use only                                                       |
| <b>Neratinib</b><br> <br><i>Nerlynx</i> ® tablets<br>  <b>MMC</b>                                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA612<br><b>NOT STOCKED</b>         |
| <b>Nilotinib</b><br> <br><i>Tasigna</i> ® capsules<br>  <b>MMC</b>                                | <b>RESTRICTED</b><br>Haematology Consultants only                                           |
| MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                             |
| <b>Osimertinib</b><br> <br><i>Tagrisso</i> ® tablets<br>  <b>MMC</b>                              | <b>RESTRICTED</b> Specialist use only in line with NICE                                     |
| <b>Palbociclib</b><br> <br><i>Ibrance</i> ® capsules<br>  <b>MMC</b>                              | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>               |
| MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                             |
| <b>Ponatinib</b><br> <br><i>Iclusig</i> ® tablets<br>  <b>MMC</b>                                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA451                               |
| MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection<br>MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome<br>MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation<br>MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events                                                                                                                                                                                                                                   |                                                                                             |
| <b>Regorafenib</b><br> <br><i>Stivarga</i> ® 40mg tablets<br>  <b>MMC</b>           | <b>RESTRICTED</b> Specialist use only in line with NICE TA488 / TA555<br><b>NOT STOCKED</b> |
| MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                             |
| <b>Ribociclib</b><br> <br><i>Kisqali</i> ® 200mg tablets<br>  <b>MMC</b>            | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b>               |
| MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                             |
| <b>Ruxolitinib</b><br> <br><i>Jakavi</i> ® tablets<br>  <b>MMC</b>                  | <b>RESTRICTED</b> Specialist use only in line with NICE / NHSE                              |
| <b>Selpercatinib</b><br> <br><i>Retsevmo</i> ® capsules<br>  <b>MMC</b>             | <b>RESTRICTED</b><br>Specialist use only in line with NICE                                  |
| <b>Selumetinib</b><br> <br><i>Koselugo</i> ® capsules<br>  <b>MMC</b>               | <b>RESTRICTED</b><br>Specialist use only for NF1 in line with NICE HST20                    |
| <b>Sunitinib</b><br> <br><i>Sutent</i> ® capsules<br>  <b>MMC</b>                   | <b>RESTRICTED</b><br>Specialist use only in line with NICE<br><b>NOT STOCKED</b>            |
| MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                             |
| <b>Tepotinib</b><br> <br><i>Tepmetko</i> ® 225mg tablets<br>  <b>MMC</b>            | <b>RESTRICTED</b> Specialist use in line with NICE / NHSE                                   |
| <b>Tivozanib</b><br> <br><i>Fotivda</i> ® capsules<br>  <b>MMC</b>                  | <b>RESTRICTED</b><br>Specialist use only in line with NICE<br><b>NOT STOCKED</b>            |
| <b>Trametinib</b><br> <br><i>Mekinist</i> ® tablets<br>  <b>MMC</b>                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA396<br><b>NOT STOCKED</b>         |
| <b>Zanubrutinib</b><br> <br><i>Brukinsa</i> ® 80mg hard capsules<br>  <b>MMC</b>    | <b>RESTRICTED</b> Specialist use in line with NICE / NHSE                                   |
| <b>Topoisomerase I inhibitors</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Tretinoin</b><br><br>capsules<br>                                                                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>Haematology Consultants only                                           |

| Taxanes                                                                                                                                                                                                          |                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <div><div><div>Paclitaxel</div><div>Red</div></div><div>Infusion</div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>blue<b>teq</b></div><div>emc</div></div></div>                        | <div><div>RESTRICTED</div><div>Haematology Consultants only</div></div> |
| MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error                                                              |                                                                         |
| <div><div><div>Cabazitaxel</div><div>Red</div><div>££</div></div><div>Jevtana® Infusion</div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>blue<b>teq</b></div><div>emc</div></div></div> | <div><div>RESTRICTED</div><div>Haematology Consultants only</div></div> |

## 8.2 Drugs affecting the immune response



### 8.2.1 Antiproliferative immunosuppressants

#### Azathioprine

Amber

tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 &amp; 13.5.3)

#### Mycophenolate Mofetil

Amber

capsules; tablets; oral suspension; infusion

MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients

MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

#### Belatacept

Nulojix® 25mg/mL injection

**RESTRICTED**  
Renal Transplant Consultants only  
**NOT STOCKED**

### 8.2.2 Corticosteroids & other immunosuppressants

#### Antithymocyte immunoglobulin (Rabbit)

injection

#### Basiliximab

Simulect® injection

**RESTRICTED**  
Renal Consultants only

#### Ciclosporin (Deximune®) & I.V. (Sandimmun®)

Amber

capsules; oral solution; injection

#### Sirolimus

Amber

oral solution; tablets

**RESTRICTED**  
Renal Consultants only

#### Tacrolimus

Amber

capsules; tablets; ointment; oral suspension; infusion; sachets

#### Voclosporin

capsules

**RESTRICTED**  
Specialist use only in line with NICE

Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus if no SCP

### 8.2.3 Anti-lymphocyte monoclonal antibodies

#### Alemtuzumab

Lemtrada® infusion

**RESTRICTED** Renal Consultants only  
under Patient Access Scheme

MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions &amp; monitoring requirements following review of serious CV &amp; immune-mediated reactions

MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV &amp; immune-mediated adverse reactions: new restrictions to use &amp; strengthened monitoring requirements

#### Atezolizumab

Tecentriq® infusion; solution for injection

**RESTRICTED** Specialist Consultants  
in line with NICE / NHSE

MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)

#### Avacopan

Tavneos® capsules

**RESTRICTED** Specialist Consultants  
in line with NICE

#### Avelumab

Bavencio® infusion

**RESTRICTED** Specialist Consultants  
in line with NICE

#### Blinatumomab

Blinicyto® infusion

**RESTRICTED** Haematology  
Consultants only in line with NICE

#### Burosumab

Crysvita® injection

**RESTRICTED**  
X-linked hypophosphatemia

#### Daratumumab

Darzalex® infusion

**RESTRICTED** Haematology  
Consultants only in line with  
NICE / NHSE

MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus

#### Glofitamab

Columvi® infusion

**RESTRICTED** Haematology  
Consultants only in line with NICE

#### Isatuximab

infusion

**RESTRICTED** Haematology  
Consultants only in line with EAMS

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Mogamulizumab</b><br> <br><i>Poteligeo</i> ® infusion<br>                    | <b>RESTRICTED</b> Haematology<br>Consultants only in line with NICE<br><b>NOT STOCKED</b>                                                          |
| <b>Obinutuzumab</b><br> <br><i>Gazyvaro</i> ® infusion<br>                      | <b>RESTRICTED</b> Haematology<br>Consultants only in line with NICE                                                                                |
| <b>Ofatumumab</b><br> <br><i>Kesimpta</i> ® injection<br>                       | <b>RESTRICTED</b><br>Consultants only in line with NICE                                                                                            |
| MHRA Drug Safety Update (Aug-14): Ofatumumab▼: reminder of risk of serious and fatal infusion reactions<br>MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                    |
| <b>Pertuzumab</b><br> <br><i>Perjeta</i> ® infusion<br>                         | <b>RESTRICTED</b> Haematology<br>Consultants only in line with NICE                                                                                |
| <b>Polatuzumab vedotin</b><br> <br><i>Polivy</i> ® infusion<br>                 | <b>RESTRICTED</b> Haematology<br>Consultants only in line with NICE                                                                                |
| <b>Rituximab</b><br> <br>injection; infusion (see also section 10.1.3)<br>      | <b>RESTRICTED</b> Consultants only in line with NICE / NHSE<br> |
| MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                    |
| <b>8.2.4 Other immunomodulating drugs</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                    |
| <b>Interferon alfa</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                    |
| <b>Interferon alfa-2a</b><br> <br><i>Roferon-A</i> ® injection<br>                                                                                                                                                                                                                                                                  |                                                                                                                                                    |
| <b>Interferon alfa-2b</b><br> <br><i>IntronA</i> ®<br>                                                                                                                                                                                                                                                                              |                                                                                                                                                    |
| <b>Peginterferon alfa-2a</b><br> <br><i>Pegasys</i> ®<br>          | <b>RESTRICTED</b><br>Gastro Consultants only                                                                                                       |
| <b>Peginterferon alfa-2b</b><br> <br><i>ViraferonPeg</i> ®<br>                                                                                                                                                                         | <b>RESTRICTED</b><br>Gastro Consultants only                                                                                                       |
| <b>Interferon beta</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                    |
| MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                    |
| <b>Interferon beta-1a</b><br> <br>injection<br>                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA527<br><b>NOT STOCKED</b>                                                                |
| <b>Interferon beta-1b</b><br> <br>injection<br>                 | <b>RESTRICTED</b> Specialist use only in line with NICE TA527<br><b>NOT STOCKED</b>                                                                |
| <b>BCG bladder instillation</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                    |
| <b>BCG bladder instillation</b><br><br><i>OncoTICE</i> ®<br>                                                                                                                                                                                                                                                                                                                                                                                                                                    | <b>RESTRICTED</b><br>Specialist use only                                                                                                           |

| Other Agents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Canakinumab</b><br> <br><i>Ilaris</i> ® 150mg/mL injection<br>                                                                                                         | <b>RESTRICTED Specialist use in line with NHSE</b><br> |
| <b>Cemiplimab</b><br> <br><i>Libtayo</i> ® 50mg/mL injection<br>                         | <b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>                                                                              |
| <b>Dimethyl Fumarate</b><br> <br><i>Tecfidera</i> ® capsules<br>                         | <b>RESTRICTED Specialist use only in line with NICE TA320</b>                                                                             |
| MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia<br>MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy<br>MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                           |
| <b>Dinutuximab beta</b><br> <br><i>Qarziba</i> ® 4.5mg/mL injection<br>                  | <b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>                                                                              |
| <b>Diroximel Fumarate</b><br> <br><i>Vumerity</i> ® 231mg capsules<br>                   | <b>RESTRICTED Specialist use in line with NICE TA794</b><br><b>NOT STOCKED</b>                                                            |
| <b>Fingolimod Hydrochloride</b><br> <br><i>Gilenya</i> ® capsules<br>                    | <b>RESTRICTED Specialist use only in line with NICE TA254</b>                                                                             |
| MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                           |
| <b>Glatiramer acetate</b><br> <br>injection<br>                                          | <b>RESTRICTED Specialist use only in line with NICE TA527</b><br><b>NOT STOCKED</b>                                                       |
| <b>Imlifidase</b><br> <br>infusion<br>                                                   | <b>RESTRICTED Specialist use only in line with NICE TA809</b>                                                                             |
| <b>Lenalidomide</b><br> <br><i>Revlimid</i> ® capsules<br>                    | <b>RESTRICTED Haematology Consultants only</b>                                                                                            |
| MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)<br>MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                           |
| <b>Mifamurtide</b><br> <br><i>Mepact</i> ® Intravenous infusion<br>      | <b>RESTRICTED Specialist use only in line with NICE TA235</b><br><b>NOT STOCKED</b>                                                       |
| <b>Natalizumab</b><br> <br><i>Tysabri</i> ® infusion<br>                 | <b>RESTRICTED Specialist use only in line with NICE TA127</b><br><b>NOT STOCKED</b>                                                       |
| MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                           |
| <b>Nivolumab</b><br> <br><i>Opdivo</i> ® 10mg/mL infusion<br>            | <b>RESTRICTED Specialist use only in line with NICE</b>                                                                                   |
| MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation<br>MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                           |
| <b>Ocrelizumab</b><br> <br><i>Ocrevus</i> ® 30mg/mL infusion<br>         | <b>RESTRICTED Specialist use only in line with NICE TA533 / TA585</b><br><b>NOT STOCKED</b>                                               |
| <b>Olaparib</b><br> <br><i>Lynparza</i> ® tablets<br>                    | <b>RESTRICTED Specialist use only in line with NICE</b><br><b>NOT STOCKED</b>                                                             |
| <b>Pomalidomide</b><br> <br>capsules<br>                                 | <b>RESTRICTED Haematology only / also in line with NICE</b>                                                                               |
| MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)<br>MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation<br>MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                           |
| <b>Ponesimod</b><br> <br><i>Ponvory</i> ® tablets<br>                    | <b>RESTRICTED Specialist use only in line with NICE TA767</b><br><b>NOT STOCKED</b>                                                       |
| <b>Rucaparib</b><br> <br>tablets<br>                                     | <b>RESTRICTED Specialist use only in line with NICE TA611</b><br><b>NOT STOCKED</b>                                                       |
| MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                           |
| <b>Teriflunomide</b><br> <br>tablets<br>                                 | <b>RESTRICTED Specialist use only in line with NICE TA303</b><br><b>NOT STOCKED</b>                                                       |

|                                                                                                                                                                                                                                                                                                                                                                               |  |                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------|
| <div><div>Thalidomide</div><div><div>Red</div><div>££</div></div><div>capsules</div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div></div>                                                                                                                                                                                                |  | <div>RESTRICTED Haematology Consultants only</div> |
| <div>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)</div> <div>MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years</div> <div>MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies</div> |  |                                                    |

| 8.3 Sex hormones & hormone antagonists in malignant disease                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                          |    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| <b>8.3.1 Oestrogens</b>                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>Diethylstilbestrol</b>                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                                                                                                       |                                                                                       |
| <b>8.3.2 Progestogens</b>                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>Medroxyprogesterone Acetate</b>                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                                                                                                       |                                                                                       |
| <b>Megestrol Acetate</b>                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                                                                                                       |                                                                                       |
| <b>8.3.3 Androgens</b>                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>Testolactone</b>                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                                                                                                       |                                                                                       |
| <b>8.3.4 Hormone Antagonists</b>                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>8.3.4.1 Breast Cancer</b>                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                          | <b>NICE NG101</b>                                                                     |
| <b>Aminoglutethimide</b>                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                                                                                                       |                                                                                       |
| <b>Anastrozole</b><br>                                                                                               |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |     |                                                                                       |
| <b>Exemestane</b><br>                                                                                                |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |     |                                                                                       |
| <b>Letrozole</b><br>                                                                                                 |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets                                                                                                                                                                                              |                                                                                |                                                                                       |
| <b>Tamoxifen</b><br>                                                                                               |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| tablets; oral solution                                                                                                                                                                               |                                                                                |                                                                                       |
| <b>8.3.4.2 Gonadorelin analogues &amp; gonadotrophin-releasing hormone antagonists</b>                                                                                                               |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>Gonadorelin analogues</b>                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                          |                                                                                       |
| <b>Buserelin</b><br>                                                                                               |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| injection (see also section 6.7.2)                                                                                                                                                                   |                                                                                                                                                                   |                                                                                       |
| <b>Goserelin</b><br>            |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| implant (also section 6.7.2)                                                                                                                                                                         |                                                                                                                                                                   |                                                                                       |
| <b>Leuprorelin Acetate</b><br>  |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| injection (also section 6.7.2)                                                                                                                                                                       |                                                                                |                                                                                       |
| <b>Triptorelin</b><br>          |                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                              |
| injection (also section 6.7.2)                                                                                                                                                                       |                                                                                |                                                                                       |
| Goserelin/Leuprorelin - Licensed Indications (pre-op management prior to endometrial ablation/fibroid surgery)                                                                                       |                                                                                                                                                                                                                                                                                                                                          |  |
| Goserelin/Leuprorelin/Triptorelin - Licensed Indications (prostate cancer (all), breast cancer (goserelin))                                                                                          |                                                                                                                                                                                                                                                                                                                                          |  |
| Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)                                                    |                                                                                                                                                                                                                                                                                                                                          |  |
| Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)                                                                                        |                                                                                                                                                                                                                                                                                                                                          |  |

|                                                                                                                                                                                                                                                                                                             |                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| <b>Anti-androgens</b>                                                                                                                                                                                                                                                                                       |                                                                               |
| <b>Bicalutamide</b><br><br>tablets <div>BNF emc</div>                                                                                                                                                                       | <b>RESTRICTED</b><br>Specialist use only                                      |
| <b>Cyproterone Acetate</b><br><br>tablets (see also section 6.4.2) <div>BNF emc</div>                                                                                                                                       | <b>RESTRICTED</b><br>Specialist use only                                      |
| MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma<br>MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma                                                                                                 |                                                                               |
| <b>Darolutamide</b><br> <br>300mg tablets <div>PbR X NICE MMC BNF blueiq emc</div>                                                         | <b>RESTRICTED</b><br>Specialist use only in line with NICE                    |
| <b>Flutamide</b><br>tablets <div>BNF emc</div>                                                                                                                                                                                                                                                              | <b>RESTRICTED</b><br>Specialist use only                                      |
| <b>Enzalutamide</b><br> <br>tablets <div>PbR X NICE MMC BNF blueiq emc</div>                                                               | <b>RESTRICTED</b><br>Specialist use only<br><b>NOT STOCKED</b>                |
| <b>Abiraterone</b><br> <br>Zytiga® tablets <div>PbR X NICE MMC BNF blueiq emc</div>                                                        | <b>RESTRICTED</b><br>Specialist use only<br><b>NOT STOCKED</b>                |
| <b>Gonadotrophin-releasing hormone antagonists</b>                                                                                                                                                                                                                                                          |                                                                               |
| <b>Degarelix</b><br><br>Firmagon® 80mg; 120mg injection <div>NICE MMC BNF emc</div>                                                                                                                                         | <b>RESTRICTED</b> Specialist use only in line with NICE                       |
| <b>Other</b>                                                                                                                                                                                                                                                                                                |                                                                               |
| <b>Radium-223 dichloride</b><br> <br>Xofigo® 1,100 kBq/mL injection <div>PbR X NICE MMC BNF blueiq emc</div>                               | <b>RESTRICTED</b> Specialist use only in line with NICE                       |
| MHRA Drug Safety Update (Sep-18): Xofigo▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial<br>MHRA Drug Safety Update (Dec-17): ▼Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone |                                                                               |
| <b>8.3.4.3 Somatostatin analogues</b>                                                                                                                                                                                                                                                                       |                                                                               |
| <b>Lanreotide</b><br> <br>injection <div>PbR X MMC BNF emc</div>                                                                       | <b>RESTRICTED</b><br>Consultant only - acromegaly                             |
| <b>Octreotide</b><br> <br>injection <div>PbR X MMC BNF emc</div>                                                                       | <b>RESTRICTED</b> 3 <sup>rd</sup> line use Gastro.<br>Consultant only         |
| <b>Lutetium (<sup>177</sup>Lu) oxodotreotide</b><br> <br>Lutathera® injection <div>PbR X NICE MMC BNF blueiq emc</div>                 | <b>RESTRICTED</b> Specialist use only in line with NICE<br><b>NOT STOCKED</b> |

| 8.4 Miscellaneous preparations                                                                                                                                                                                                |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------|
| <div><div>Glucarpidase</div><div><div><div>U</div><div>EE</div></div><div>Voraxaze® 1,000 unit injection (see also sections 1.10, 10.4 &amp; 13.14)</div></div></div> <div><div>PbR X</div><div>MMC</div><div>emc</div></div> |  | <div>RESTRICTED</div> <div>2<sup>nd</sup> line rescue therapy</div>                |
| <div><div>Trifluridine / Tipiracil hydrochloride</div><div><div>Red</div><div>EE</div></div><div>tablets</div></div> <div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>blueiq</div><div>emc</div></div>    |  | <div>RESTRICTED Specialist use only in line with NICE</div> <div>NOT STOCKED</div> |

## Section 9: Nutrition & blood

Supported by the  
formulary ([click here](#))



### 9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells

### 9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

### 9.3 Intravenous nutrition

### 9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

### 9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

### 9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

### 9.7 Bitters & tonics

### 9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)  
 Nutrition support in adults (CG32)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Chronic kidney disease: assessment and management (NG203)  
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)  
 Migalastat for treating Fabry disease (HST4)  
 Eliglustat for treating type 1 Gaucher disease (HST5)  
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)  
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)  
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)  
 Hyperparathyroidism - cinacalcet (TA117)  
 Thrombocytopenic purpura - romiplostim (TA221)  
 Thrombocytopenic purpura - eltrombopag (TA293)  
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)  
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)  
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)  
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)  
 Patisiran for treating hyperkalaemia (TA623)  
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)  
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)  
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)  
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)  
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)  
 Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)  
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)  
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)  
 Avalglucosidase alfa for treating Pompe disease (TA821)  
 Fostatinib for treating refractory chronic immune thrombocytopenia (TA835)  
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

## GMMM Formulary

Formulary Homepage  
 Chapter 9: Nutrition & Blood (Complete)  
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 9.1 Anaemias and some other blood disorders                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| 9.1.1 Iron deficiency anaemias                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| 9.1.1.1 Oral iron                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Ferrous Sulfate</b>                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>1<sup>st</sup> line use</b>                                                        |
| tablets                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                         | <b>STANDARD PREPARATIONS ONLY</b>                                                     |
| <b>Ferrous Fumarate</b>                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| tablets; oral solution                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                         |                                                                                       |
| <b>Ferric Maltol</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| capsules                                                                                                                                                             |                                                                                                                                                                                                                                                                       |                                                                                       |
| <b>Sodium Feredetate</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| oral solution                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                         | <b>LIQUID PREPARATIONS ONLY</b>                                                       |
| Iron & folic acid                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Ferrous Sulfate</b>                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| M/R tablets                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                         |                                                                                       |
| <b>Ferrous Fumarate</b>                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| capsules; tablets                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                         |                                                                                       |
| 9.1.1.2 Parenteral iron                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Ferric Carboxymaltose</b>                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b>                                                                     |
| <i>Ferinject®</i> injection                                                                                                                                          |                                                                                                                                                                                                                                                                       |                                                                                       |
| MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose ( <i>Ferinject</i> ▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Ferric Derisomaltose</b>                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b>                                                                     |
| <i>Monofer®</i> injection                                                                                                                                            |                                                                                                                                                                                                                                                                    |                                                                                       |
| MHRA: Monofer and Diafer name change (Nov-20)                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Iron Sucrose</b>                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b>                                                                     |
| <i>Venofer®</i> injection                                                                                                                                            |                                                                                                                                                                                                                                                                 |                                                                                       |
| 9.1.2 Drugs used in megaoblastic anaemias                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| MHRA Drug Safety Update (Dec-23): Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Hydroxocobalamin</b>                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>1<sup>st</sup> line use</b>                                                        |
| Intramuscular injection; sachets                                                                                                                                     |                                                                                                                                                                                                                                                                 |                                                                                       |
| <b>Cyanocobalamin</b>                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>See BSH guidance</b>                                                               |
| 50microgram; 1mg tablets                                                                                                                                             |                                                                                                                                                                                                                                                                 |  |
| 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| Erythropoietins                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Darbepoetin alfa</b>                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Renal Consultants only                                           |
| injection                                                                                                                                                            |                                                                                            |                                                                                       |
| <b>Epoetin Alfa</b>                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Renal Consultants only                                           |
| injection                                                                                                                                                            |                                                                                                                                                                               |                                                                                       |
| <b>Epoetin Beta</b>                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Renal Consultants only                                           |
| injection                                                                                                                                                            |                                                                                                                                                                               |                                                                                       |
| MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| Sickle-cell disease                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                       |
| <b>Hydroxycarbamide</b>                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Haematology Consultants only                                     |
| oral solution; capsules                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                     |                                                                                       |
| <b>Crizanlizumab</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Haematology Consultants only<br>in line with NICE / NHSE         |
| <i>Adakveo®</i> infusion                                                                                                                                             |       |                                                                                       |
| <b>Voxelotor</b>                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Haematology Consultants only<br>in line with EAMS / NHSE SSC2339 |
| <i>Oxbryta®</i> 500mg tablets                                                                                                                                        |                                                                                          |                                                                                       |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <b>Iron overload</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                         |
| <b>Deferasirox</b><br> <br>tablets<br>                                                                                                                                                                          | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Deferiprone</b><br> <br>tablets<br>                                                                                                                                                                          | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Desferrioxamine Mesilate</b><br> <br>injection<br>                                                                                                                                                                                                                                            | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                         |
| <b>Roxadustat</b><br> <br>Evrenzo® tablets<br>                                                                                 | <b>RESTRICTED</b><br>Specialist use only in line with NICE              |
| <b>Paroxysmal nocturnal haemoglobinuria &amp; atypical haemolytic uraemic syndrome</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                         |
| <b>Eculizumab</b><br> <br>infusion<br>      | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Ravulizumab</b><br> <br>infusion<br>                                                                                        | <b>RESTRICTED</b><br>Specialist use only in line with NICE              |
| <b>9.1.4 Drugs used in autoimmune thrombocytopenic purpura</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                         |
| <b>Anagrelide</b><br> <br>capsules<br>                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Avatrombopag</b><br> <br>Doptelet® tablets<br>                                                                              | <b>RESTRICTED</b><br>Specialist use only in line with NICE              |
| <b>Caplacizumab</b><br> <br>Cabliivi® injection<br>                                                                         | <b>RESTRICTED</b><br>Specialist use only in line with NICE              |
| <b>Eltrombopag</b><br> <br>Revolade® tablets<br>                                                                 | <b>NOT STOCKED</b><br>Haematology Consultants only                      |
| MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                         |
| <b>Fostamatinib</b><br> <br>Tavlesse® tablets<br>                                                                | <b>RESTRICTED</b><br>Specialist use only                                |
| <b>Lusutrombopag</b><br> <br>Mupleo® tablets<br>                                                                 | <b>RESTRICTED</b><br>Specialist use only                                |
| <b>Romiplostim</b><br> <br>Nplate® injection<br>                                                                 | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>9.1.6 Drugs used in neutropenia</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                         |
| <b>Filgrastim</b><br> <br>injection<br>                                                                                                                                                             | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                         |
| <b>Lenograstim</b><br> <br>injection<br>                                                                                                                                                                                                                                               | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| <b>Pegfilgrastim</b><br> <br>injection<br>                                                                                                                                                          | <b>RESTRICTED</b><br>Haematology Consultants only                       |
| MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                         |
| <b>9.1.7 Drugs used to mobilise stem cells</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                         |
| <b>Plerixafor</b><br> <br>injection<br>                                                                        | <b>RESTRICTED - initiation on advice of Haematology Consultant only</b> |

| 9.2 Fluids and electrolytes                                                                                                                                                                                                                                                                        |                  | GMMMG                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------|
| <b>9.2.1 Oral preparations for fluid &amp; electrolyte imbalance</b>                                                                                                                                                                                                                               |                  |                                                                                |
| <b>9.2.1.1 Oral potassium</b>                                                                                                                                                                                                                                                                      |                  |                                                                                |
| <b>Potassium Chloride</b>                                                                                                                                                                                                                                                                          |                  |                                                                                |
| Sando-K® effervescent tablets; Kay-Cee-L® syrup                                                                                                                                                                                                                                                    | BNF emc          |                                                                                |
| <b>Potassium removal</b>                                                                                                                                                                                                                                                                           |                  |                                                                                |
| <b>Calcium Polystyrene Sulfonate</b>                                                                                                                                                                                                                                                               |                  |                                                                                |
| Calcium Resonium® powder; enema (unlicensed)                                                                                                                                                                                                                                                       | BNF emc          |                                                                                |
| <b>Sodium Zirconium Cyclosilicate</b>                                                                                                                                                                                                                                                              |                  |                                                                                |
| Red                                                                                                                                                                                                                                                                                                | NICE MMC BNF emc |                                                                                |
| Lokelma® powder sachets                                                                                                                                                                                                                                                                            |                  |                                                                                |
| <b>9.2.1.2 Oral sodium and water</b>                                                                                                                                                                                                                                                               |                  |                                                                                |
| <b>Sodium Chloride (Slow Sodium®)</b>                                                                                                                                                                                                                                                              |                  |                                                                                |
| 600mg M/R tablets                                                                                                                                                                                                                                                                                  | BNF emc          |                                                                                |
| <b>Oral Rehydration Therapy (ORT)</b>                                                                                                                                                                                                                                                              |                  |                                                                                |
| <b>Oral Rehydration Salts (ORS)</b>                                                                                                                                                                                                                                                                |                  |                                                                                |
| oral powder                                                                                                                                                                                                                                                                                        | BNF emc          |                                                                                |
| <b>9.2.1.3 Oral bicarbonate</b>                                                                                                                                                                                                                                                                    |                  |                                                                                |
| <b>Sodium Bicarbonate</b>                                                                                                                                                                                                                                                                          |                  |                                                                                |
| 500mg capsules; 8.4% (1mmol/mL) oral solution                                                                                                                                                                                                                                                      | BNF emc          |                                                                                |
| <b>Sodium Hydrogen Carbonate</b>                                                                                                                                                                                                                                                                   |                  |                                                                                |
| Nephrotrans® 50mg gastro-resistant capsules                                                                                                                                                                                                                                                        | MMC BNF emc      | <b>RESTRICTED</b><br>2 <sup>nd</sup> line patients with severe GI side effects |
| <b>9.2.2 Parenteral preparations for fluid &amp; electrolyte imbalance</b>                                                                                                                                                                                                                         |                  |                                                                                |
| <b>9.2.2.1 Electrolytes &amp; water</b>                                                                                                                                                                                                                                                            |                  |                                                                                |
| <b>Intravenous sodium</b>                                                                                                                                                                                                                                                                          |                  |                                                                                |
| <b>Sodium Chloride</b>                                                                                                                                                                                                                                                                             |                  |                                                                                |
| infusion; injection                                                                                                                                                                                                                                                                                | BNF emc          |                                                                                |
| <b>Sodium chloride with other ingredients</b>                                                                                                                                                                                                                                                      |                  |                                                                                |
| <b>Sodium Chloride &amp; Glucose</b>                                                                                                                                                                                                                                                               |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| <b>Sodium Chloride, Calcium Chloride &amp; Potassium Chloride (Ringer's solution)</b>                                                                                                                                                                                                              |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| <b>Sodium Chloride, Calcium Chloride, Potassium Chloride &amp; Sodium Lactate</b>                                                                                                                                                                                                                  |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| <b>Intravenous glucose</b>                                                                                                                                                                                                                                                                         |                  |                                                                                |
| <b>Glucose</b>                                                                                                                                                                                                                                                                                     |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines<br>MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines |                  |                                                                                |
| <b>Intravenous potassium</b>                                                                                                                                                                                                                                                                       |                  |                                                                                |
| <b>Potassium Chloride and Glucose</b>                                                                                                                                                                                                                                                              |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| <b>Potassium Chloride and Sodium Chloride</b>                                                                                                                                                                                                                                                      |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |
| <b>Potassium Chloride, Sodium Chloride &amp; Glucose</b>                                                                                                                                                                                                                                           |                  |                                                                                |
| infusion                                                                                                                                                                                                                                                                                           | BNF emc          |                                                                                |

|                                                          |                                                                                                                                                                               |
|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Bicarbonate and lactate</b>                           |                                                                                                                                                                               |
| <b>Sodium Bicarbonate</b>                                |                                                                                                                                                                               |
| 1.26%, 2.74%, 4.2% & 8.4% injection; infusion            | BNF  emc  |
| <b>Water</b>                                             |                                                                                                                                                                               |
| <b>Water for Injections</b>                              |                                                                                                                                                                               |
| injection                                                | BNF  emc  |
| <b>9.2.2.2 Plasma &amp; plasma substitutes</b>           |                                                                                                                                                                               |
| <b>Dextran</b>                                           |                                                                                                                                                                               |
| <i>Dextran 40</i> - 10% in sodium chloride 0.9% infusion | emc                                                                                        |
| <b>Dextrose Acid Citrate ACDA</b>                        |                                                                                                                                                                               |
| solution                                                 | emc                                                                                        |
| <b>Gelatin</b>                                           |                                                                                                                                                                               |
| <i>Gelofusine</i> ® infusion                             | BNF  emc  |

## 9.3 Intravenous nutrition



**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**

**NICE CG32**

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |  |                                                                                                                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9.4 Oral nutrition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |  |                                                                              |
| Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)                                                                                                                                                                                                                                                                                                                                                                                                                   |  | NICE CG32                                                                                                                                                      |
| 9.4.1 Nutrition in special diets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                                                                                |
| <div>Sapropterin dihydrochloride</div> <div><div>Red</div><div></div></div> <div><div>Kuvan® 100mg soluble tablets</div><div><div>PbR X</div><div></div></div></div> |  | <div>RESTRICTED</div> <div>Tetrahydrobiopterin deficiency</div> <div></div> |
| <div>LaBiNIC® probiotic drops</div> <div><div>Red</div></div> <div><div>LaBiNIC® probiotic drops</div><div></div></div>                                                                                                                                                                                                                  |  | <div>RESTRICTED</div> <div>prevention of NEC</div>                                                                                                             |

| 9.5 Minerals                                                                                                                                          |                                 | GMMMG                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|--------------------------------------|
| <b>9.5.1 Calcium and magnesium</b>                                                                                                                    |                                 |                                      |
| <b>9.5.1.1 Calcium supplements</b>                                                                                                                    |                                 |                                      |
| <b>Oral preparations</b>                                                                                                                              |                                 |                                      |
| <b>Calcium Carbonate</b>                                                                                                                              |                                 |                                      |
| Green                                                                                                                                                 | BNF emc                         |                                      |
| Cacit® effervescent tablets; Calcichew® chewable tablets                                                                                              |                                 |                                      |
| <b>Calcium Carbonate &amp; Calcium Lactate Gluconate</b>                                                                                              |                                 |                                      |
| Green                                                                                                                                                 | BNF emc                         |                                      |
| Sandocal® 1000 effervescent tablets                                                                                                                   |                                 |                                      |
| <b>Parenteral preparations</b>                                                                                                                        |                                 |                                      |
| <b>Calcium Gluconate</b>                                                                                                                              |                                 |                                      |
| 10% injection                                                                                                                                         | BNF emc                         |                                      |
| MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia   |                                 |                                      |
| <b>Calcium Chloride</b>                                                                                                                               |                                 |                                      |
| 10% injection                                                                                                                                         | BNF emc                         |                                      |
| MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia   |                                 |                                      |
| <b>with vitamin D</b>                                                                                                                                 |                                 |                                      |
| see section 9.6.4                                                                                                                                     |                                 | BNF emc                              |
| <b>with risedronate sodium &amp; colecalciferol</b>                                                                                                   |                                 |                                      |
| see section 6.6.2                                                                                                                                     |                                 | BNF emc                              |
| <b>9.5.1.2 Hypercalcaemia &amp; hypercalciuria</b>                                                                                                    |                                 |                                      |
| <b>Cinacalcet</b>                                                                                                                                     |                                 | RESTRICTED<br>as per NICE TA117      |
| Red 2 <sup>ty</sup> HPT Amber 1 <sup>ty</sup> HPT ££                                                                                                  | PbR X NICE MMC BNF emc          |                                      |
| tablets                                                                                                                                               |                                 |                                      |
| <b>Etelcalcetide</b>                                                                                                                                  |                                 | RESTRICTED<br>as per NICE TA448      |
| Red ££                                                                                                                                                | PbR X NICE MMC BNF bluef eq emc |                                      |
| injection                                                                                                                                             |                                 |                                      |
| <b>9.5.1.3 Magnesium</b>                                                                                                                              |                                 | NICE ESUOM4                          |
| <b>Magnesium Aspartate Dihydrate</b>                                                                                                                  |                                 | 1 <sup>st</sup> line use             |
| Magnaspartate® sachets                                                                                                                                | MMC BNF emc                     |                                      |
| <b>Magnesium Glycerophosphate</b>                                                                                                                     |                                 |                                      |
| chewable tablets; capsules; oral solution; tablets                                                                                                    | NICE BNF emc                    |                                      |
| <b>Magnesium Sulfate</b>                                                                                                                              |                                 |                                      |
| injection; infusion                                                                                                                                   | BNF emc                         |                                      |
| MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy |                                 |                                      |
| <b>9.5.2 Phosphorus</b>                                                                                                                               |                                 |                                      |
| <b>9.5.2.1 Phosphate supplements</b>                                                                                                                  |                                 |                                      |
| <b>Phosphate supplements (Phosphate-Sandoz®)</b>                                                                                                      |                                 | Effervescent tabs                    |
| effervescent tablets                                                                                                                                  | BNF emc                         |                                      |
| <b>Phosphates (Polyfusor®)</b>                                                                                                                        |                                 | I.V. preparation                     |
| Red                                                                                                                                                   | BNF emc                         |                                      |
| infusion                                                                                                                                              |                                 |                                      |
| <b>9.5.2.2 Phosphate-binding agents</b>                                                                                                               |                                 | NICE NG203                           |
| <b>Aluminium Hydroxide</b>                                                                                                                            |                                 |                                      |
| Green                                                                                                                                                 | BNF emc                         |                                      |
| capsules                                                                                                                                              |                                 |                                      |
| <b>Calcium Carbonate</b>                                                                                                                              |                                 |                                      |
| Green                                                                                                                                                 | BNF emc                         |                                      |
| tablets (see also section 9.5.1.1)                                                                                                                    |                                 |                                      |
| <b>Calcium Acetate</b>                                                                                                                                |                                 |                                      |
| Green                                                                                                                                                 | MMC BNF emc                     |                                      |
| tablets                                                                                                                                               |                                 |                                      |
| <b>Calcium Acetate / Magnesium Carbonate</b>                                                                                                          |                                 | RESTRICTED<br>Renal Consultants only |
| Green                                                                                                                                                 | MMC BNF emc                     |                                      |
| Osvaren® 435mg/235mg tablets                                                                                                                          |                                 |                                      |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| <b>Lanthanum</b><br> <br>chewable tablets; oral powder<br>                                                                                                                                                           | <b>RESTRICTED</b><br>Renal Consultants only                        |
| <b>Patiromer Calcium</b><br> <br>Veltassa® oral powder<br>                                                                          | <b>RESTRICTED</b> Consultants only<br>in line with NICE TA623      |
| <b>Sevelamer Carbonate</b><br> <br>tablets<br>     | <b>RESTRICTED</b><br>Renal Consultants only                        |
| <b>Sucroferric Oxyhydroxide</b><br> <br>chewable tablets<br>                                                                                                                                                         | <b>RESTRICTED</b><br>Renal Consultants only - 3 <sup>rd</sup> line |
| <b>9.5.3 Fluoride</b><br><b>Sodium Fluoride</b><br>tablets, paediatric drops, dental rinse<br>                                                                                                                                                                                                                                                                                                                                                                         |                                                                    |
| <b>9.5.4 Zinc</b><br><b>Zinc Sulfate</b><br>Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules<br>                                                                                                                                                                                                                                                                                                                                                           |                                                                    |

| 9.6 Vitamins                                                                             |                                                                                                                                                                                                                                                              | GMMMG                    |
|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 9.6.1 Vitamin A                                                                          |                                                                                                                                                                                                                                                              |                          |
| Vitamin A                                                                                |                                                                                           |                          |
| 150,000units/mL drops                                                                    |                                                                                                                                                                                                                                                              |                          |
| Vitamin A Palmitate                                                                      |                                                                                           |                          |
| 100,000units/2mL injection                                                               |                                                                                                                                                                                                                                                              |                          |
| Vitamins A & D                                                                           |                                                                                           |                          |
| capsules                                                                                 |                                                                                                                                                                                                                                                              |                          |
| 9.6.2 Vitamin B group                                                                    |                                                                                                                                                                                                                                                              |                          |
| Pyridoxine Hydrochloride                                                                 |                                                                                           |                          |
| tablets                                                                                  |                                                                                                                                                                                                                                                              |                          |
| Thiamine                                                                                 |                                                                                           |                          |
| tablets                                                                                  |                                                                                                                                                                                                                                                              |                          |
| Vitamin B Compound                                                                       |                                                                                           |                          |
|                                                                                          |                                                                                                                                                                                                                                                              |                          |
| Vitamin B Compound Strong                                                                |                                                                                           |                          |
| tablets                                                                                  |                                                                                                                                                                                                                                                              |                          |
| Vitamins B & C                                                                           |                                                                                           |                          |
| <i>Pabrinex</i> ® Intramuscular (IM) & Intravenous (IV) injection                        |                                                                                                                                                                                                                                                              |                          |
| 9.6.3 Vitamin C (Ascorbic acid)                                                          |                                                                                                                                                                                                                                                              |                          |
| Ascorbic acid                                                                            |                                                                                        |                          |
| tablets                                                                                  |                                                                                                                                                                                                                                                              |                          |
| 9.6.4 Vitamin D                                                                          |                                                                                                                                                                                                                                                              |                          |
| Alfacalcidol                                                                             |                                                                                       |                          |
|  Green |                                                                                                                                                                                                                                                              |                          |
| capsules; injection; oral drops                                                          |                                                                                                                                                                                                                                                              |                          |
| Calcitriol                                                                               |                                                                                       |                          |
| capsules; oral solution                                                                  |                                                                                                                                                                                                                                                              |                          |
| Vitamin D and calcium                                                                    |                                                                                                                                                                                                                                                              |                          |
| Colecalciferol                                                                           |                                                                                                                                                                                                                                                              | 1 <sup>st</sup> line use |
| Calcichew D3® Forte tablets / Adcal D3® chewable tablets                                 |    |                          |
| Calcium & Ergocalciferol                                                                 |                                                                                       |                          |
| calcium 97mg/vitamin D 400units                                                          |                                                                                                                                                                                                                                                              |                          |
| Colecalciferol                                                                           |    |                          |
| <i>Cacif</i> ® D3 effervescent granules; 800 IU capsules                                 |                                                                                                                                                                                                                                                              |                          |
| 9.6.5 Vitamin E (Tocopherols)                                                            |                                                                                                                                                                                                                                                              |                          |
| Alpha Tocopheryl Acetate (Vitamin E)                                                     |                                                                                       |                          |
| 500mg/5mL liquid                                                                         |                                                                                                                                                                                                                                                              |                          |
| Alpha Tocopheryl Acetate (Vitamin E)                                                     |                                                                                       |                          |
| 75 unit capsules                                                                         |                                                                                                                                                                                                                                                              |                          |

|                                                             |                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>9.6.6 Vitamin K</b>                                      |                                                                                                                                                                                                                                                        |
| <b>Phytomenadione</b>                                       |                                                                                                                                                                                                                                                        |
| <i>Konakion® MM &amp; Konakion® MM Paediatric injection</i> |    |
| <b>Menadiol Sodium Phosphate</b>                            |                                                                                                                                                                                                                                                        |
| oral solution; tablets                                      |    |
| <b>9.6.7 Multivitamin preparations</b>                      |                                                                                                                                                                                                                                                        |
| <b>Vitamins B,C</b>                                         | <b>RESTRICTED</b>                                                                                                                                                                                                                                      |
| <i>Renavit® tablets</i>                                     |    |
| <b>Vitamins A,D,E,K</b>                                     | <b>RESTRICTED</b><br>Paediatric CF patients                                                                                                                                                                                                            |
| <i>Paravit-CF® capsules; liquid</i>                         |    |

## 9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use

| 9.8 Metabolic disorders                                                                                                                                                                                                                            |  | GMMMG              |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------|-----|
| 9.8.1 Drugs used in metabolic disorders                                                                                                                                                                                                            |  |                    |     |
| Serine deficiency                                                                                                                                                                                                                                  |  |                    |     |
| <b>L-Serine</b> <br>(Nutricia L-Serine) powder                                                                                                                    |  | MMC                | emc |
| <b>Wilson's Disease</b>                                                                                                                                                                                                                            |  |                    |     |
| <b>Penicillamine</b><br><br>tablets (see also section 10.1.3)                                                                                                      |  | BNF                | emc |
| <b>Trientine Dihydrochloride</b><br> <br>capsules                                 |  | PbR X MMC BNF      | emc |
| <b>Carnitine Deficiency</b>                                                                                                                                                                                                                        |  |                    |     |
| <b>Levocarnitine</b><br><br>injection; oral solution                                                                                                               |  | PbR X BNF          | emc |
| <b>Fabry's disease</b>                                                                                                                                                                                                                             |  |                    |     |
| <b>Agalsidase alfa</b><br><br>Replagal® infusion                                                                                                                  |  | PbR X MMC BNF      | emc |
| <b>Migalastat</b><br> <br>Galafold® capsules                                      |  | PbR X NICE MMC BNF | emc |
| <b>Mucopolysaccharidosis</b>                                                                                                                                                                                                                       |  |                    |     |
| <b>Elosulfase alfa</b><br> <br>Vimizim® infusion                                  |  | PbR X NICE MMC BNF | emc |
| <b>Galsulfase</b><br> <br>Naglazyme® infusion                                   |  | PbR X MMC BNF      | emc |
| <b>Idursulfase</b><br> <br>Elaprase® infusion                                 |  | PbR X MMC BNF      | emc |
| <b>Laronidase</b><br> <br>Aldurazyme® infusion                                |  | PbR X MMC BNF      | emc |
| <b>Vestronidase alfa</b><br> <br>Mepsevii® infusion                           |  | PbR X MMC BNF      | emc |
| <b>Nephropathic cystinosis</b>                                                                                                                                                                                                                     |  |                    |     |
| <b>Cystagon® (Mercaptamine)</b><br> <br>capsules (NB: prescribe as CYSTAGON®) |  | PbR X BNF          | emc |
| <b>Pompe disease</b>                                                                                                                                                                                                                               |  |                    |     |
| <b>Avalglucosidase alfa</b><br> <br>Nexviadyne® infusion                      |  | PbR X NICE MMC BNF | emc |
| <b>Tyrosinemia type I</b>                                                                                                                                                                                                                          |  |                    |     |
| <b>Nitisinone</b><br> <br>capsules; oral suspension                           |  | PbR X MMC BNF      | emc |
| <b>Urea cycle disorders</b>                                                                                                                                                                                                                        |  | BIMDG              |     |
| <b>Arginine</b><br><br>infusion; oral solution                                                                                                                   |  | PbR X MMC BNF      | emc |
| <b>Carglumic acid</b><br> <br>dispersible tablets                             |  | PbR X MMC BNF      | emc |
| <b>Citrulline</b><br><br>powder                                                                                                                                  |  | PbR X MMC BNF      | emc |
| <b>Glycerol Phenylbutyrate</b><br><br>Ravicti® 1.1g/mL oral liquid                                                                                               |  | PbR X MMC BNF      | emc |

|                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| <b>Sodium Phenylbutyrate</b><br> <br>tablets; injection; oral liquid; granules (discontinued)                                                                                         |                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                                                                        |
| <b>Homocystinuria</b><br><b>Betaine</b><br> <br>tablets; oral powder                                                                                                                  |                                                                                                                                                                                                                                                           | <br><b>RESTRICTED</b><br>Specialist use only |
| <b>Sodium Benzoate</b><br>injection; oral solution; tablets; powder                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Specialist use only                                                                                        |
| <b>Uridine</b>                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Specialist use only                                                                                        |
| <b>Other metabolic disorders</b>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                 |
| <b>Asfotase alfa</b><br> <br>Strensiq® injection                                                                                                                                      |       | <b>RESTRICTED</b><br>Specialist use only (NICE HST23)                                                                           |
| <b>Cerliponase alfa</b><br> <br>Brineura® 150mg solution for infusion                                                                                                                 |       | <b>RESTRICTED</b><br>Specialist use only (NICE HST12)                                                                           |
| <b>Eliglustat</b><br> <br>Cerdelga® 84mg capsules                                                                                                                                     |       | <b>RESTRICTED</b><br>Specialist use only (NICE HST5)                                                                            |
| <b>Miglustat</b><br> <br>100mg capsules                                                                                                                                               |                                                                                                                                                                          | <b>RESTRICTED</b><br>Specialist use only                                                                                        |
| <b>Sodium dichloroacetate</b><br>  <br>50 mg/mL powder for reconstitution for oral solution (200 mL) |                                                                                                                                                                                                                                                           | <b>RESTRICTED</b><br>Specialist use only<br>Primary lactic acidosis / PDHC deficiency                                           |
| <b>Velaglucerase alfa</b><br> <br>VPRIV® 400 units vial                                                                                                                             |                                                                                                                                                                  | <b>RESTRICTED</b><br>Specialist use only                                                                                        |
| <b>9.8.2 Acute porphyrias</b>                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                 |
| <b>Haem Arginate</b><br> <br>infusion                                                                                                                                             |                                                                                                                                                                                                                                                     |                                                                                                                                 |

## Section 10: Musculoskeletal & Joint Diseases

Supported by the  
formulary ([click here](#))



### 10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
  - Gold
  - Penicillamine
  - Antimalarials
  - Drugs affecting the immune response
  - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

### 10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
  - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

### 10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

### 10.4 Miscellaneous preparations

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Rheumatoid arthritis in adults: management (NG100)  
 Osteoarthritis in over 16s: diagnosis and management (NG226)  
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)  
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)  
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)  
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)  
 Hyperuricaemia - febuxostat (TA164)  
 Psoriasis - ustekinumab (TA180)  
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)  
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)  
 Psoriatic arthritis - golimumab (TA220)  
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)  
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)  
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)  
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)  
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)  
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)  
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)  
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)  
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)  
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)  
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)  
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)  
 Tocilizumab for treating giant cell arteritis (TA518)  
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)  
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Nusinersen for treating spinal muscular atrophy (TA588)  
 Upadacitinib for treating severe rheumatoid arthritis (TA665)  
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)  
 Anakinra for treating Still's disease (TA685)  
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)  
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)  
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)  
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)  
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)  
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)  
 Risdiplam for treating spinal muscular atrophy (TA755)  
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)  
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)  
 Upadacitinib for treating active ankylosing spondylitis (TA829)  
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)  
 Bimekizumab for treating axial spondyloarthritis (TA918)  
 Tofacitinib for treating active ankylosing spondylitis (TA920)

## GMMM Formulary

Formulary Homepage  
 Chapter 10: Musculoskeletal & Joint Diseases (Complete)  
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

| 10.1 Drugs used in rheumatic diseases & gout                                                                                                                                                                                                   |  | GMMMG                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------|
| 10.1 Drugs used in rheumatic diseases & gout                                                                                                                                                                                                   |  | NICE CG177                                                    |
| 10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)                                                                                                                                                                                          |  | NICE NG100                                                    |
| MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks                                                                                                                                         |  |                                                               |
| MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment                                                                                                                     |  |                                                               |
| MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks                                                                                                                                    |  |                                                               |
| <b>Ibuprofen</b><br><br>200mg; 400mg; 600mg tablets; 5% gel<br>           |  | 1 <sup>st</sup> line use                                      |
| MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy                                                                                          |  |                                                               |
| MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk                                                                                                                                     |  |                                                               |
| <b>Naproxen</b><br><br>250mg; 500mg tablets<br>                           |  |                                                               |
| MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy                                                                                          |  |                                                               |
| <b>Celecoxib</b><br><br>100mg; 200mg capsules<br>                         |  | <b>RESTRICTED</b> - osteoarthritis in line with NICE NG226    |
| MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks                                                                                                                                    |  |                                                               |
| <b>Diclofenac Sodium</b><br><br>50mg tablets<br>                          |  | <b>RESTRICTED</b> - acute post-operative pain                 |
| MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy                                                                                          |  |                                                               |
| MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription                                                                                                                                                     |  |                                                               |
| MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings                                                                                                                                                               |  |                                                               |
| <b>Flurbiprofen</b><br><br>50mg tablets<br>                               |  |                                                               |
| <b>Mefenamic Acid</b><br><br>250mg; 500mg tablets<br>                     |  |                                                               |
| <b>Meloxicam</b><br><br>7.5mg; 15mg tablets<br>                       |  |                                                               |
| <b>Sulindac</b><br><br>100mg; 200mg tablets<br>                       |  |                                                               |
| <b>Etodolac</b><br><br>600mg tablets<br>                              |  | <b>RESTRICTED</b> Consultant Anaesthetist use only            |
| <b>Phenylbutazone</b><br><br>100mg; 200mg tablets<br>                 |  | <b>RESTRICTED</b> Specialist use only, ankylosing spondylitis |
| 10.1.2 Corticosteroids                                                                                                                                                                                                                         |  |                                                               |
| MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration                                                                                                 |  |                                                               |
| 10.1.2.1 Systemic corticosteroids                                                                                                                                                                                                              |  | NICE NG100                                                    |
| <b>Prednisolone</b><br><br>                                           |  |                                                               |
| 10.1.2.2 Local corticosteroid injections                                                                                                                                                                                                       |  | NICE NG100                                                    |
| <b>Hydrocortisone Acetate</b><br><br>25mg/mL injection<br>            |  |                                                               |
| <b>Methylprednisolone Acetate</b><br><br>40mg/mL injection<br>        |  |                                                               |
| <b>Triamcinolone Acetonide</b><br><br>10mg/mL; 40mg/mL injection<br>  |  |                                                               |
| <b>Triamcinolone Hexacetonide</b><br><br>20mg/mL injection<br>        |  | <b>RESTRICTED</b> Paediatric Rheumatology Consultants only    |

| 10.1.3 Drugs that suppress the rheumatic disease process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Gold                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NICE NG100                                                                   |
| <b>Auranofin</b><br><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| <b>Sodium Aurothiomalate</b><br><br>injection<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| <b>Penicillamine</b><br><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| <b>Antimalarials</b><br><b>Hydroxychloroquine</b><br><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions<br>MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                              |
| <b>Mepacrine hydrochloride</b><br> <br>100mg tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| Drugs affecting the immune response                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NICE NG100                                                                   |
| <b>Azathioprine</b><br><br>tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3)<br>                                                                                                                                                                                                                                                                                                                                                                                        | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| <b>Ciclosporin</b><br><br>capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)<br>                                                                                                                                                                                                                                                                                                                                                                                               | <b>RESTRICTED</b> Consultants only                                           |
| <b>Leflunomide</b><br><br>tablets<br>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>RESTRICTED</b> Rheumatology Consultants only                              |
| <b>Methotrexate</b><br> oral  parenteral<br>tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)<br>                                                                                                                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b> Consultants only                                           |
| MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions<br>MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                              |
| Cytokine modulators                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                              |
| <b>Abatacept</b><br> <br>injection; infusion<br>       | <b>RESTRICTED</b> Rheum. Consultants only in line with NICE / NHSE           |
| <b>Adalimumab</b><br> <br>injection (see also sections 1.5.3, 11.4.2 & 13.5.3)<br>                                                          | <b>RESTRICTED</b> Consultants only in line with NICE                         |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                              |
| <b>Anakinra</b><br> <br>injection<br>                  | <b>RESTRICTED</b> Consultants only in line with NICE / NHSE                  |
| <b>Apremilast</b><br> <br>10mg; 20mg; 30mg tablets<br>                                                                                                                                                                           | <b>RESTRICTED</b><br>3 <sup>rd</sup> / 4 <sup>th</sup> line as per NICE/GMMG |
| <b>Baricitinib</b><br> <br>2mg; 4mg tablets<br>        | <b>RESTRICTED</b> Rheumatology Consultants only in line with NICE            |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality<br>MHRA Drug Safety Update (Aug-20): Baricitinib (Olmiant▼): increased risk of diverticulitis, particularly in patients with risk factors<br>MHRA Drug Safety Update (Mar-20): Baricitinib (Olmiant▼): risk of venous thromboembolism                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                              |
| <b>Belimumab</b><br> <br>infusion<br>                                                                                                       | <b>RESTRICTED</b> Consultants only                                           |
| MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                              |
| <b>Bimekizumab</b><br> <br>injection (see also section 13.5.3)<br>                                                                          | <b>RESTRICTED</b> in line with NICE                                          |
| <b>Certolizumab</b><br> <br>injection (see also section 13.5.3)<br>                                                                                                                                                              | <b>RESTRICTED</b> Rheumatology Consultants in line with NICE                 |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                              |

|                                                                                                                                                               |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|-----------------------------------------------------------------------------------------------------------------------------------------|--|--|--------------------------------------------------------------------|--|--|
| <div>Etanercept</div> <div><div>Red</div><div>££</div></div>                                                                                                  |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only; in line with NICE                     |  |  |
| injection                                                                                                                                                     |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely                   |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Filgotinib</div> <div><div>Red</div><div>££</div></div>                                                                                                  |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| tablets                                                                                                                                                       |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Golimumab</div> <div><div>Red</div><div>££</div></div>                                                                                                   |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| injection                                                                                                                                                     |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely                   |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Guselkumab</div> <div><div>Red</div><div>££</div></div>                                                                                                  |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div></div>                                         |  |  | RESTRICTED<br>in line with NICE                                    |  |  |
| 100mg/mL injection                                                                                                                                            |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Infliximab</div> <div><div>Red</div><div>££</div></div>                                                                                                  |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only                                        |  |  |
| Remicade® infusion; Remsima® infusion                                                                                                                         |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely                   |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Ixekizumab</div> <div><div>Red</div><div>££</div></div>                                                                                                  |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| 80mg/1mL injection (see also section 13.5.3)                                                                                                                  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Rituximab</div> <div><div>Red</div><div>££</div></div>                                                                                                   |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE / NHSE               |  |  |
| injection; infusion (see also section 8.2.3)                                                                                                                  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Sarilumab</div> <div><div>Red</div><div>££</div></div>                                                                                                   |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Rheumatology Consultants only in line with NICE         |  |  |
| Kevzara® 150mg/1.14mL injection                                                                                                                               |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Secukinumab</div> <div><div>Red</div><div>££</div></div>                                                                                                 |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Rheumatology Consultants only in line with NICE         |  |  |
| Cosentyx® 150mg/1mL injection (see also section 13.5.3)                                                                                                       |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Tocilizumab</div> <div><div>Red</div><div>££</div></div>                                                                                                 |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| infusion                                                                                                                                                      |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation                        |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Tofacitinib</div> <div><div>Red</div><div>££</div></div>                                                                                                 |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| Xeljanz® 5mg; 10mg tablets (see also section 1.5.3)                                                                                                           |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies               |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections         |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Upadacitinib</div> <div><div>Red</div><div>££</div></div>                                                                                                |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Consultants only in line with NICE                      |  |  |
| MR tablet (see also sections 1.5.3 & 13.5.3)                                                                                                                  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality  |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| <div>Ustekinumab</div> <div><div>Red</div><div>££</div></div>                                                                                                 |  |  | <div><div><div>PbR X</div><div>NICE</div><div>MMC</div><div>BNF</div><div>emc</div></div><div><div>blue</div><div>teq</div></div></div> |  |  | RESTRICTED Dermatology TA340 / Gastro 3 <sup>rd</sup> line Crohn's |  |  |
| injection; infusion (see also section 13.5.3)                                                                                                                 |  |  |                                                                                                                                         |  |  |                                                                    |  |  |
| MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis                                                                       |  |  |                                                                                                                                         |  |  |                                                                    |  |  |

© Manchester University NHS Foundation Trust 2023

| 10.2 Drugs used in neuromuscular disorders                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | GMMMG                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| 10.2.1 Drugs that enhance neuromuscular transmission                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| Anticholinesterases                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Pyridostigmine Bromide</b>                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>1<sup>st</sup> line use</b>                                                              |
| tablets                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Neostigmine</b>                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| tablets; injection                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Edrophonium Chloride</b>                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b><br>diagnosis of myasthenia gravis<br><b>Licensed product discontinued</b> |
| injection                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| 10.2.2 Skeletal muscle relaxants                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Baclofen</b>                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>1<sup>st</sup> line use</b>                                                              |
| 10mg tablets; 5mg/mL oral solution                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Dantrolene Sodium</b>                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| 25mg; 100mg capsules; Ryanodex 250mg/20mL vial                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Diazepam</b>                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8 & 15.1.4.1)                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| <b>Tizanidine</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b><br>Consultant Neurologist only                                            |
| Amber                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| 2mg; 4mg tablets                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| Nocturnal leg cramps                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Quinine Sulfate</b>                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| tablets (see also section 5.4.1)                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                         |                                                                                             |
| MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions<br>MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| 10.2.3 Drugs used in neuromuscular disorders                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Ataluren</b>                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>Specialist use only</b><br>in line with NICE HST22                                       |
| Red                                                                                                                            |       |                                                                                             |
| oral suspension sachets                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Atidarsagene autotemcel</b>                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>Specialist use only</b><br>in line with NICE HST18                                       |
| Red                                                                                                                            |       |                                                                                             |
| Libmeldy® infusion                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Nusinersen</b>                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>Specialist use only</b><br>in line with NICE TA588 / NHSE<br><b>Named patient access</b> |
| Red                                                                                                                            |       |                                                                                             |
| injection                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| MHRA Drug Safety Update (Sep-18): Nusinersen (Spinraza ▼): reports of communicating hydrocephalus; discuss symptoms with patients & carers - investigate urgently                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Onasemnogene abeparvovec</b>                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>RESTRICTED</b> Paediatric Neurology<br>Consultants only NICE / NHSE                      |
| Red                                                                                                                            |       |                                                                                             |
| Zolgensma® infusion                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |
| <b>Risdiplam</b>                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>Specialist use only</b><br>in line with NICE TA755                                       |
| Red                                                                                                                            |       |                                                                                             |
| oral solution                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                             |

| 10.3 Drugs for the relief of soft-tissue inflammation |                                                                                                                                                                                                                                                          | GMMMG                                                                 |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| 10.3.1 Enzymes                                        |                                                                                                                                                                                                                                                          |                                                                       |
| Hyaluronidase                                         |                                                                                                                                                                                                                                                          | RESTRICTED<br>extravasation                                           |
| Red                                                   |                                                                                      |                                                                       |
| injection                                             |                                                                                                                                                                                                                                                          |                                                                       |
| 10.3.2 Rubefacients & other topical antirheumatics    |                                                                                                                                                                                                                                                          |                                                                       |
| Piroxicam                                             |                                                                                                                                                                                                                                                          |                                                                       |
| 0.5% gel                                              |                                                                                      |                                                                       |
| Capsaicin                                             |                                                                                                                                                                                                                                                          | Patch restricted to peripheral<br>neuropathic pain specialists at TGH |
| DNP                                                   |    |                                                                       |
| cream, patch                                          |                                                                                                                                                                                                                                                          |                                                                       |

10.4 Miscellaneous preparations

Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 13.14)

PbR X

MMC

emc



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy

## Section 11: Eye

Supported by the  
formulary ([click here](#))



### 11.3 Anti-infective eye preparations

11.3.1 Antibacterials

11.3.3 Antivirals

### 11.4 Corticosteroid & other anti-inflammatory preparations

11.4.1 Corticosteroids

11.4.2 Other anti-inflammatory preparations

### 11.5 Mydriatics & cycloplegics

### 11.6 Treatment of glaucoma

### 11.7 Local anaesthetics

### 11.8 Miscellaneous ophthalmic preparations

11.8.1 Tear deficiency, ocular lubricants & astringents

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment

11.8.3 Other preparations

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Glaucoma: diagnosis and management (NG81)  
 Macular degeneration (age related) ranibizumab & pegaptanib (TA155)  
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)  
 Macular oedema (diabetic) - ranibizumab (TA274)  
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)  
 Macular degeneration (wet age-related) - aflibercept (1<sup>st</sup> line) (TA294)  
 Vitreomacular traction - ocriplasmin (TA297)  
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)  
 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301)  
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)  
 Aflibercept for treating diabetic macular oedema (TA346)  
 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)  
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Holoclar for treating limbal stem cell deficiency after eye burns (TA467)  
 Aflibercept for treating choroidal neovascularisation (TA486)  
 Cenegermin for treating neurotrophic keratitis (TA532)  
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)  
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)  
 Brolocizumab for treating wet age-related macular degeneration (TA672)  
 Faricimab for treating diabetic macular oedema (TA799)  
 Faricimab for treating wet age-related macular degeneration (TA800)  
 Brolocizumab for treating diabetic macular oedema (TA820)  
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

## GMMM Formulary

Formulary Homepage  
 Chapter 11: Eye (Complete)  
 GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 11.3 Anti-infective eye preparations



### 11.3.1 Antibacterials

#### Chloramphenicol

0.5% eye drops, 1% eye ointment



MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years

#### Fusidic Acid (ophthalmic)

1% eye drops



#### Amikacin (ophthalmic)



2.5% eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only  
**NOT STOCKED**

#### Amphotericin

0.15% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Azithromycin (ophthalmic)



Azzyter® 1.5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Ceftazidime (ophthalmic)



5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only  
**NOT STOCKED**

#### Cefuroxime (ophthalmic)



5% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

#### Cefuroxime (intracameral injection)



Ximaract® 50mg in 5mL intracameral injection



**RESTRICTED** Consultant  
Ophthalmologist only

#### Chlorhexidine (ophthalmic)



0.02% eye drops



**RESTRICTED** acanthamoeba  
keratitis. Consultant only

#### Ciprofloxacin (ophthalmic)

0.3% eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions &amp; precautions for use due to rare reports of disabling &amp; long-lasting / irreversible side effects...

#### Erythromycin (ophthalmic)



0.5% eye ointment



**RESTRICTED** superficial eye  
infections

#### Gentamicin (ophthalmic)



1.5% eye drops (Use with cefuroxime eye drops)



**RESTRICTED** Consultant  
Ophthalmologist only

#### Levofloxacin (ophthalmic)



0.5% eye drops



**RESTRICTED** Consultant only corneal  
ulcers/ keratitis

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions &amp; precautions for use due to rare reports of disabling &amp; long-lasting / irreversible side effects...

#### Natamycin



5% eye drops



**RESTRICTED** fungal keratitis,  
conjunctivitis, fungal blepharitis

#### Ofloxacin



0.3% eye drops



**RESTRICTED** Consultant  
Ophthalmologist only

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions &amp; precautions for use due to rare reports of disabling &amp; long-lasting / irreversible side effects...

#### Penicillin (ophthalmic)



2,500 units/mL eye drops



**RESTRICTED** microbial keratitis.  
Consultant Ophthalmologist only

#### Polyhexamethylene Biguanide (PHMB)



0.02% eye drops



**NOT STOCKED**

|                                                                                                                                                                                                              |                                                                                                                                                                        |                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| <b>Polymyxin B Sulfate</b><br>eye ointment                                                                                                                                                                   |   | <b>RESTRICTED</b> gram negative bacteria, including pseudomonas                    |
| <b>Propamidine Isetionate</b><br> 0.1% eye drops                                                                             |   | <b>RESTRICTED</b> Consultant Ophthalmologist only                                  |
| <b>Vancomycin (ophthalmic)</b><br> 5% eye drops                                                                              |   | <b>RESTRICTED</b> gram positives, including MRSA but not VRE<br><b>NOT STOCKED</b> |
| <b>11.3.3 Antivirals</b>                                                                                                                                                                                     |                                                                                                                                                                        |                                                                                    |
| <b>Ganciclovir</b><br> 0.15% eye gel                                                                                         |   |                                                                                    |
| <b>Trifluorothymidine</b><br>  1% eye drops |   |                                                                                    |

## 11.4 Corticosteroid & other anti-inflammatory preparations



### 11.4.1 Corticosteroids

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

#### Betamethasone

0.1% eye drops & ointment



#### Dexamethasone

0.1% eye drops & minims



#### Dexamethasone (intravitreal implant)

Red

Ozurdex® 700micrograms intravitreal implant



**RESTRICTED** as per NICE TA229; TA460 & TA824

#### Fluocinolone Acetonide

Red

Iluvien® 190micrograms intravitreal implant



**RESTRICTED** as per NICE TA301 & TA590

#### Prednisolone

0.5% & 1% eye drops; 0.5% minims



#### Fluorometholone

Red

0.1% eye drops



#### Hydrocortisone sodium phosphate

Softacort® 3.35 mg/mL PF single use eye drops



#### Triamcinolone Acetonide

Red

Kenalog® 40mg/mL injectable suspension



**RESTRICTED** intralesional injection in skin grafts

#### Triamcinolone Acetonide

Red

Triesence® 40mg/mL injectable suspension



**RESTRICTED** uveitis; sympathetic ophthalmia

#### Triamcinolone Acetonide

Red

Intracinol® 40mg/mL ophthalmic suspension



**RESTRICTED** opacification of the vitreous humour

### Corticosteroids preparations with antibiotics

#### Betamethasone / Neomycin Sulphate

0.1% / 0.5% eye drops (Betnesol-N®)



#### Dexamethasone / Neomycin Sulphate / Polymyxin B Sulphate

1 mg/mL : 3500 IU/mL : 6000 IU/mL (Maxitrol® eye drops & ointment)



### 11.4.2 Other anti-inflammatory preparations

#### Sodium Cromoglicate

2% eye drops



#### Adalimumab

Red

Amgevita® injection (see also sections 1.5.3, 10.1.3 & 13.5.3)



**RESTRICTED Consultant Ophthalmologist only**  
Non-infectious Uveitis

#### Antazoline with Xylometazoline

0.5% eye drops



#### Azelastine

0.05% eye drops



**RESTRICTED** allergic conjunctivitis, children only

#### Ketotifen hydrogen fumarate

Ketofall® 0.25mg/mL PF eye drops



#### Lodoxamide

0.1% eye drops



**RESTRICTED** allergic conjunctivitis

#### Olopatadine

1mg/mL eye drops



**RESTRICTED** Seasonal allergic conjunctivitis

#### Potassium Ascorbate

10% eye drops



**RESTRICTED** management of chemical burns to the cornea

## 11.5 Mydriatics & cycloplegics



### Antimuscarinics

#### Atropine Sulphate

1% minims



#### Cyclopentolate Hydrochloride

1% eye drops, 0.5% &amp; 1% minims



#### Tropicamide

0.5% &amp; 1% eye drops, 0.5% &amp; 1% minims



### Sympathomimetics

#### Phenylephrine Hydrochloride

2.5% &amp; 10% minims



**10% contraindicated in children & the elderly**

### Sympathomimetics with tropicamide

#### Phenylephrine Hydrochloride with Tropicamide

Mydriaser® 5.4mg / 280micrograms ophthalmic insert



**RESTRICTED** Pre-operative mydriasis in cataract patients

| 11.6 Treatment of glaucoma                                                                                         |                                                                                                                                                                                                                                                                | GMMMG                                                                                |
|--------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Beta-blockers                                                                                                      |                                                                                                                                                                                                                                                                | NICE NG81                                                                            |
| <b>Timolol</b>                                                                                                     |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.25% & 0.5% eye drops                                                                                             |                                                                                           |                                                                                      |
| <b>Timolol once-daily</b>                                                                                          |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel                                         |                                                                                           |                                                                                      |
| <b>Betaxolol</b>                                                                                                   |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.25% & 0.5% eye drops, 0.25% minims                                                                               |                                                                                           |                                                                                      |
| <b>Levobunolol Hydrochloride</b>                                                                                   |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.5% eye drops                                                                                                     |                                                                                           |                                                                                      |
| Prostaglandin analogues and prostamides                                                                            |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Bimatoprost</b>                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                      |
| 100 microgram/mL eye drops                                                                                         |          |                                                                                      |
| <b>Latanoprost</b>                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                      |
| 50 microgram/mL eye drops                                                                                          |                                                                                           |                                                                                      |
| MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Latanoprost (preservative free)</b>                                                                             |                                                                                                                                                                                                                                                                |                                                                                      |
| 50 microgram/mL preservative free eye drops                                                                        |          |                                                                                      |
| MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Travoprost</b>                                                                                                  |                                                                                                                                                                                                                                                                |                                                                                      |
| 40 microgram/mL eye drops                                                                                          |          |                                                                                      |
| Prostaglandin analogues (combination products)                                                                     |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Latanoprost / Timolol</b>                                                                                       |                                                                                                                                                                                                                                                                |                                                                                      |
| 50microgram/mL / 5mg/mL eye drops; preservative free eye drops                                                     |    |                                                                                      |
| Sympathomimetics                                                                                                   |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Brimonidine Tartrate</b>                                                                                        |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.2% eye drops                                                                                                     |    |                                                                                      |
| <b>Apraclonidine</b>                                                                                               |                                                                                                                                                                                                                                                                | RESTRICTED to delay laser treatment / surgery in uncontrolled glaucoma               |
| Green or Red                                                                                                       |                                                                                                                                                                                                                                                                |                                                                                      |
| 0.5%; 1% eye drops                                                                                                 |                                                                                       |                                                                                      |
| Carbonic anhydrase inhibitors & systemic drugs                                                                     |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Acetazolamide</b>                                                                                               |                                                                                                                                                                                                                                                                |                                                                                      |
| Green                                                                                                              |                                                                                                                                                                                                                                                                |                                                                                      |
| 250mg tablets; <i>Diamox</i> SR® 250mg capsules                                                                    |                                                                                       |                                                                                      |
| <b>Brinzolamide</b>                                                                                                |                                                                                                                                                                                                                                                                |                                                                                      |
| 10mg/mL eye drops                                                                                                  |                                                                                       |                                                                                      |
| <b>Brinzolamide / Brimonidine</b>                                                                                  |                                                                                                                                                                                                                                                                | RESTRICTED glaucoma patients in whom monotherapy provides insufficient IOP reduction |
| <i>Simbrinza</i> ® 2% eye drops                                                                                    |    |                                                                                      |
| <b>Dorzolamide</b>                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                      |
| 2% eye drops; also preservative free                                                                               |                                                                                       |                                                                                      |
| <b>Dorzolamide / Timolol</b>                                                                                       |                                                                                                                                                                                                                                                                |                                                                                      |
| <i>Cosopt</i> ® 2% eye drops; also preservative free                                                               |                                                                                       |                                                                                      |
| Miotics                                                                                                            |                                                                                                                                                                                                                                                                |                                                                                      |
| <b>Pilocarpine</b>                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                      |
| 1%, 2% & 4% eye drops, 2% minims                                                                                   |                                                                                       |                                                                                      |
| <b>Pilocarpine</b>                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                      |
| 4% ophthalmic gel                                                                                                  |                                                                                       |                                                                                      |

| 11.7 Local anaesthetics                         |                                                                                                                                                                        | GMMMG |  |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--|
| Ocular Local anaesthetics                       |                                                                                                                                                                        |       |  |
| Lidocaine (Lignocaine) and Fluorescein (minims) |                                                                                                                                                                        |       |  |
| 4% / 0.25% eye drops                            |   |       |  |
| Oxybuprocaine (minims)                          |                                                                                                                                                                        |       |  |
| 0.4% eye drops                                  |   |       |  |
| Proxymetacaine (minims)                         |                                                                                                                                                                        |       |  |
| 0.5% eye drops                                  |   |       |  |
| Tetracaine (Amethocaine) (minims)               |                                                                                                                                                                        |       |  |
| 1% & 2% eye drops                               |   |       |  |

## 11.8 Miscellaneous ophthalmic preparations



### Other preparations

#### Botulinum toxin type A

Xeomin® injection

MMC BNF emc

**RESTRICTED**  
Consultant Ophthalmologist only  
blepharospasm & strabismus

#### Ciclosporin (eye)



2% eye drops

BNF emc

**RESTRICTED**  
Consultant Ophthalmologist only

#### Ciclosporin (Ikervis®)

Green

1mg/mL eye drops

NICE MMC BNF emc

**RESTRICTED**  
Consultant Ophthalmologist only  
in line with NICE TA369

#### Ciclosporin (Verkazia®)

Green

1mg/mL eye drops

MMC BNF emc

**RESTRICTED** Paediatrics for vernal  
keratoconjunctivitis /  
severe allergic eye disease

#### Mercaptamine

Red

FF

Cystadrops® eye drops

PbR X

MMC BNF emc blue-teq

**RESTRICTED**  
Specialist use only **NHSE**

NHS  
England

#### Sodium Chloride



Red

5% eye drops

BNF emc

#### Allogeneic Serum eye drops



Red

eye drops (minims) (from NHS Blood & Transplant Service) (not a medicine)

MMC blue-teq

**RESTRICTED**  
Consultant Ophthalmologist only

NHS  
England

### 11.8.1 Tear deficiency, ocular lubricants & astringents

#### Acetylcysteine



Ilube® 5% eye drops

BNF emc

#### Alteplase

25microgram in 0.1mL intravitreal injection

MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only

#### Carbomers

Viscotears® 0.2% eye drops

MMC BNF emc

#### Carmellose Sodium

Celluvisc® 0.5% eye drops

BNF emc

#### Cationorm®

preservative free eye drops

MMC BNF emc

#### Hydroxyethylcellulose

Minims® Artificial Tears preservative free eye drops

BNF emc

#### Hypromellose

0.3% eye drops

MMC BNF emc

#### Liquid Paraffin

Lacri-Lube® ointment

BNF emc

#### Poly (carboxymethylglucose sulfate)

Cacicol® eye drops (0.33mL)

MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only  
**NOT STOCKED**

#### Polyvinyl Alcohol

Liquifilm Tears® 1.4% eye drops

MMC BNF emc

#### Sodium Chloride (minims)

0.9% eye drops

BNF emc

#### Sodium Hyaluronate

Hylo-Forte® 0.2% eye drops

MMC BNF emc

| 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ocular diagnostic preparations                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Fluorescein Sodium</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1% & 2% preservative free eye drops                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                         |
| <b>Fluorescein Sodium</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 100mg/mL injection                                                                                                                                             |                                                                                                                                                                                                                                                                        |
| <b>Indocyanine green (ICG)</b>                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Verdyne® 5mg/mL injection                                                                                                                                      |                                                                                                                                                                                                                                                                        |
| Ocular peri-operative drugs                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Acetylcholine Chloride</b>                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 1% intraocular irrigation                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                         |
| <b>Apraclonidine</b>                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <i>Iopidine</i> ® 0.5% eye drops; 1% preservative free eye drops                                                                                               |                                                                                                                                                                                                                                                                                                                                                         |
| <b>Bromfenac</b>                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Yellox® 0.9 mg/mL eye drops                                                                                                                                    |                                                                                                                                                                                                                                                                        |
| <b>Ketorolac Trometamol</b>                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Acular® 0.5% eye drops                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                         |
| <b>Nepafenac</b>                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Nevanac® 1 mg/mL eye drops                                                                                                                                     |                                                                                                                                                                                                                                                                        |
| <b>Povidone-Iodine</b>                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 5% eye drops                                                                                                                                                   |                                                                                                                                                                                                                                                                        |
| <b>Heavy Silicone oil</b>                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Densiron® 68 - 10mL syringe                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                       |
| Subfoveal choroidal neovascularisation                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Aflibercept</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Eylea® 40mg in 1mL injection                                                                                                                                   |                                                                                            |
| <b>Bevacizumab</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |
| Avastin® 100mg in 4mL vial                                                                                                                                     |                                                                                          |
| <b>Brolucizumab</b>                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Beovu® 120mg in 1mL injection                                                                                                                                  |                                                                                            |
| MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Faricimab</b>                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Vabysmo® 120mg/mL injection                                                                                                                                    |                                                                                            |
| <b>Ranibizumab</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lucentis® / Ongavia® 10mg/mL injection                                                                                                                         |       |
| <b>Verteporfin</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Visudyne® 15mg vial                                                                                                                                            |                                                                                                                                                                               |
| Vitreomacular traction                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Ocriplasmin</b>                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Jetrea® 0.5 mg/0.2mL injection                                                                                                                                 |                                                                                            |
| 11.8.3 Other preparations                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Voretigene                                                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Voretigene neparvovec</b>                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Luxturna® 2mL vial                                                                                                                                             |                                                                                          |
| Insulin eye drops                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Insulin (soluble) eye drops</b>                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Red                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Humulin S® in Systane® lubricant eye drops                                                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Section 12: Ear, nose & oropharynx

Supported by the  
formulary ([click here](#))



### 12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

### 12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

### 12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

## Trust Guidelines

Adult medicines and prescribing guidelines  
Paediatric medicines and prescribing guidelines  
Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)  
Sore throat (acute): antimicrobial prescribing (NG84)  
Otitis media (acute): antimicrobial prescribing (NG91)  
Tinnitus: assessment and management (NG155)  
Otitis media with effusion in under 12s (NG233)  
Allergic rhinitis (CKS)

## GMMM Formulary

Formulary Homepage  
Chapter 12: Ear, nose & oropharynx (Complete)  
GMMM Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMM Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 12.1 Drugs acting on the ear



### 12.1.1 Otitis externa

#### Astringent preparations

##### Aluminium Acetate

ear drops



#### Anti-inflammatory preparations

##### Betamethasone Sodium Phosphate

Betnesol® 0.1% ear drops



##### Prednisolone Sodium Phosphate

Predsol® 0.5% ear drops



#### Anti-inflammatory with antibacterial preparations

##### Dexamethasone / Neomycin Sulphate

Otomize® 0.1% / 3250u per mL ear spray



##### Dexamethasone / Framycetin Sulphate / Gramicidin

Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops



##### Flumetasone Pivalate / Clioquinol

Locorten-Vioform® 0.02% / 1% ear drops



##### Hydrocortisone / Gentamicin

1% / 0.3% ear drops



##### Hydrocortisone / Neomycin Sulfate / Polymyxin B Sulphate

Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops



#### Analgesic / Anti-inflammatory / local anaesthetic preparations

##### Phenazone with Lidocaine

Otigo® 40mg/g / 10mg/g ear drops



**RESTRICTED**  
paeds in line with NICE NG91

#### Anti-infective preparations

##### Ciprofloxacin

Green

Cetraxal® 0.2% ear drops



MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects

##### Clotrimazole

1% ear drops



### 12.1.3 Removal of ear wax

##### Chlorobutanol / Arachis oil

Cerumol® ear drops



##### Olive oil ear drops

DNP

ear drops



##### Sodium Bicarbonate

DNP

5% ear drops



| 12.2 Drugs acting on the nose                                                                                                                  |                  | GMMMG                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------|
| 12.2.1 Drugs used in nasal allergy                                                                                                             |                  |                                                              |
| Antihistamines                                                                                                                                 |                  |                                                              |
| <b>Azelastine Hydrochloride</b>                                                                                                                |                  |                                                              |
| 140micrograms nasal spray                                                                                                                      | NICE BNF emc     |                                                              |
| Corticosteroids                                                                                                                                |                  |                                                              |
| MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |                  |                                                              |
| <b>Beclometasone Dipropionate</b>                                                                                                              |                  | 1 <sup>st</sup> line use                                     |
| 50micrograms nasal spray                                                                                                                       | BNF emc          |                                                              |
| <b>Betamethasone Sodium Phosphate</b>                                                                                                          |                  |                                                              |
| 0.1% nose drops                                                                                                                                | BNF emc          |                                                              |
| <b>Mometasone Furoate</b>                                                                                                                      |                  | 1 <sup>st</sup> line use nasal polyps                        |
| 50micrograms nasal spray                                                                                                                       | MMC BNF emc      |                                                              |
| <b>Fluticasone Furoate</b>                                                                                                                     |                  |                                                              |
| Avamys® 27.5micrograms nasal spray                                                                                                             | MMC BNF emc      |                                                              |
| <b>Fluticasone Propionate / Azelastine Hydrochloride</b>                                                                                       |                  | RESTRICTED 3 <sup>rd</sup> line use                          |
| Green                                                                                                                                          | NICE MMC BNF emc |                                                              |
| Dymista® 50micrograms / 137micrograms nasal spray                                                                                              |                  |                                                              |
| Cromoglicate                                                                                                                                   |                  |                                                              |
| <b>Sodium Cromoglicate</b>                                                                                                                     |                  |                                                              |
| 4% nasal spray                                                                                                                                 | BNF emc          |                                                              |
| 12.2.2 Topical nasal decongestants                                                                                                             |                  |                                                              |
| Sympathomimetics                                                                                                                               |                  |                                                              |
| <b>Ephedrine Hydrochloride</b>                                                                                                                 |                  | 1 <sup>st</sup> line use                                     |
| 0.5%; 1% nasal drops                                                                                                                           | BNF emc          |                                                              |
| <b>Sodium Chloride</b>                                                                                                                         |                  |                                                              |
| 0.9% nasal drops                                                                                                                               | BNF emc          |                                                              |
| <b>Xylometazoline Hydrochloride</b>                                                                                                            |                  |                                                              |
| 0.1% nasal drops                                                                                                                               | BNF emc          |                                                              |
| Antimuscarinics                                                                                                                                |                  |                                                              |
| <b>Ipratropium Bromide</b>                                                                                                                     |                  | Rhinorrhoea associated with allergic & non-allergic rhinitis |
| 0.03% nasal spray                                                                                                                              | BNF emc          |                                                              |
| 12.2.3 Nasal preparations for infection                                                                                                        |                  |                                                              |
| <b>Chlorhexidine Dihydrochloride / Neomycin</b>                                                                                                |                  | 1 <sup>st</sup> line use staphylococcal infections           |
| Naseptin® 0.1% / 0.5% nasal cream                                                                                                              | MMC BNF emc      |                                                              |
| <b>Mupirocin</b>                                                                                                                               |                  | RESTRICTED MRSA / post nasal cautery                         |
| 2% nasal ointment                                                                                                                              | MMC BNF emc      |                                                              |

## 12.3 Drugs acting on the oropharynx



### 12.3.1 Drugs for oral ulceration & inflammation

#### Local Analgesics

##### Benzydamine Hydrochloride

Green

0.15% oral rinse; 0.15% spray



##### Carmellose Sodium

30g protective paste



#### Corticosteroids

##### Hydrocortisone

muco-adhesive buccal tablets



### 12.3.2 Oropharyngeal anti-infective drugs

#### Oropharyngeal fungal infections

##### Miconazole

DNP

2% oral gel



MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin

##### Nystatin

DNP

100,000 units/mL oral suspension



### 12.3.4 Mouthwashes, gargles & dentifrices

##### Chlorhexidine Gluconate

0.2% mouthwash; 1% dental gel



### 12.3.5 Treatment of dry mouth

#### Local treatment

##### AS Saliva Orthana®

spray; lozenges



##### BioXtra®

oral gel



#### Systemic treatment

##### Pilocarpine

5mg tablets



**RESTRICTED** Consultant use only  
following irradiation for head & neck  
cancer

#### Treatment of Dental Caries

##### Silver Diamine Fluoride (SDF) 38%

liquid



## Section 13: Skin

Supported by the  
formulary (click here)



### 13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

### 13.3 Topical local anaesthetics & antipruritics

### 13.4 Topical corticosteroids

### 13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

Cytokine Modulators

### 13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

### 13.7 Preparations for warts & calluses

### 13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

### 13.9 Shampoos & other preparations for scalp/hair conditions

### 13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasitocidal preparations

13.10.5 Preparations for minor cuts & abrasions

### 13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 Iodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

### 13.12 Antiperspirants

### 13.13 Topical circulatory preparations

### 13.14 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines

Adult medicines and prescribing guidelines  
 Paediatric medicines and prescribing guidelines  
 Neonatal guidelines (link to Staffnet site)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Atopic eczema in children (CG57)  
 Psoriasis: assessment and management (CG153)  
 Pressure Ulcers (CG179)  
 Pubic lice CKS (2011)  
 Scabies CKS (2011)  
 Acne vulgaris CKS (2014)  
 Head lice CKS (2015)  
 Surgical site infections: prevention and treatment (NG125)  
 Atopic dermatitis (eczema) - topical steroids (TA81)  
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)  
 Psoriasis - efalizumab and etanercept (TA103) **EMA (efalizumab)**  
 Psoriasis - infliximab (TA134)  
 Psoriasis - adalimumab (TA146)  
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)  
 Psoriasis - ustekinumab (TA180)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)  
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)  
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)  
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)  
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)  
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)  
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)  
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)  
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)  
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)  
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)  
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)  
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)  
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)  
 Bimekizumab for treating active psoriatic arthritis (TA916)

## GMMMG Formulary

Formulary Homepage  
 Chapter 13: Skin (Complete)  
 GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List  
 GMMMG Paediatric **Red/Amber/Green** Drug List

## 13.2 Emollient & barrier preparations



### 13.2.1 Emollients

#### Non-Proprietary emollient preparations

MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available

MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions

MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients

MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns

#### Aqueous cream BP

cream



#### Emulsifying ointment BP

ointment



#### Liquid & white soft paraffin

ointment



#### Paraffin, white soft BP

white petroleum jelly



#### Paraffin, yellow soft BP

yellow petroleum jelly



#### Proprietary emollient preparations

##### Diprobase®

cream; ointment



##### Doublebase®

gel



##### Hydromol®

cream; ointment



##### Oilatum®



#### Preparations containing urea

##### Balneum® Plus



#### With antimicrobials

##### Dermol® & Dermol® 500



**RESTRICTED** patients unable to tolerate 1<sup>st</sup> / 2<sup>nd</sup> line antimicrobial washes

#### 13.2.1.1 Emollient bath and shower preparations

DNP

##### Emollient bath and shower preparations without antimicrobials

When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute

DNP

##### With antimicrobials

##### Dermol® 600

Grey Green

bath emollient



##### Oilatum® Plus

bath emollient



**2<sup>nd</sup> line**  
MRSA decolonisation therapy

#### 13.2.2 Barrier preparations

##### Proprietary barrier preparations

##### Metanium®

ointment



**2<sup>nd</sup> line**  
only at parental request

##### Sudocrem®

cream



**2<sup>nd</sup> line**  
only at parental request

## 13.3 Topical local anaesthetics & antipruritics



### 13.3 Topical local anaesthetics & antipruritics

#### Crotamiton

cream; lotion



#### Mepyramine Maleate

2% w/w cream



## 13.4 Topical corticosteroids



### Corticosteroid only preparations

**NICE TA81**

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

#### HYDROCORTISONE

##### Canesten HC®

hydrocortisone 1% plus clotrimazole 1% cream


**Mild**

##### Daktacort®

hydrocortisone 1%, miconazole nitrate 2% cream; ointment


**Mild**

##### Eurax-Hydrocortisone®

hydrocortisone 0.25%, crotamiton 10% cream


**Mild**

##### Fucidin H®

hydrocortisone 1%, fusidic acid 1% cream


**Mild**

#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

##### Betamethasone valerate

0.025% ointment, cream


**Moderate**

##### Betnovate-RD®

Betamethasone valerate 0.025% cream; ointment


**Moderate**

#### CLOBETASONE BUTYRATE

**Potency**

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

##### Eumovate®

0.05% cream; ointment


**Moderate**

#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

##### Betamethasone valerate

0.1% ointment; cream; lotion; scalp lotion


**Potent**

##### Betnovate®

0.1% cream; ointment; scalp application; lotion


**Potent**

##### Betamethasone valerate / Clioquinol

0.1% / 3% ointment; cream


**Potent**

##### Betamethasone valerate / Neomycin sulfate

0.1% / 0.5% cream; ointment


**Potent**

##### Diprosalic®

Betamethasone dipropionate 0.05%, salicylic acid 3% ointment


**Potent**

##### Fucibet®

Betamethasone valerate 0.1% plus fusidic acid 2% cream


**Potent**

##### Betnovate®

ointment 25% in coal tar


**Potent**
**DERMATOLOGY ONLY**

#### CLOBETASOL PROPIONATE

**Potency**

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

##### Dermovate®

clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion


**Very potent**

##### Dermovate NN®

clobetasol propionate 0.05% / neomycin / nystatin cream


**Very potent**

##### Etrivex®

clobetasol propionate 500micrograms/g shampoo


**Very potent**
**RESTRICTED - 1<sup>st</sup> Care referral**

#### DIFLUCORTOLONE VALERATE

**Potency**

##### Diflucortolone valerate



0.3% oily cream


**Very potent**
**RESTRICTED Consultant Gynaecologist**

| 13.5 Preparations for eczema & psoriasis                                                                                                                                                                                                                                                                                              |  | GMMMG                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------------------------|
| <b>13.5.1 Preparations for eczema</b>                                                                                                                                                                                                                                                                                                 |  |                                                                                                  |
| <b>Alitretinoin</b><br><span>Red</span> <span>££</span><br>10mg; 30mg capsules<br>PbR X NICE MMC BNF emc                                                                                                                                                                                                                              |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic<br>MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women |  |                                                                                                  |
| <b>13.5.2 Preparations for psoriasis</b>                                                                                                                                                                                                                                                                                              |  |                                                                                                  |
| <b>Topical preparations for psoriasis</b>                                                                                                                                                                                                                                                                                             |  | <b>NICE CG153</b>                                                                                |
| <b>Calcipotriol</b><br>Dovonex® ointment; with Betamethasone (Dovobet® 0.05% ointment)<br>BNF emc                                                                                                                                                                                                                                     |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Dithranol</b><br><span>Green</span> <span>Red</span> (unlicensed preps)<br>Dithocream® 0.1% & 0.25% cream<br>BNF emc                                                                                                                                                                                                               |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Salicylic acid</b><br>Zinc & Salicylic acid paste BP (Lassar's Paste)<br>BNF emc                                                                                                                                                                                                                                                   |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Tacalcitol</b><br>Curatoderm® lotion; ointment<br>BNF emc                                                                                                                                                                                                                                                                          |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Tars</b>                                                                                                                                                                                                                                                                                                                           |  |                                                                                                  |
| <b>Coal tar paste BP</b><br>paste<br>BNF emc                                                                                                                                                                                                                                                                                          |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Coccolis®</b><br>scalp ointment<br>BNF emc                                                                                                                                                                                                                                                                                         |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Oral retinoids for psoriasis</b>                                                                                                                                                                                                                                                                                                   |  |                                                                                                  |
| <b>Acitretin</b><br><span>Red</span><br>10mg; 25mg capsules<br>BNF emc                                                                                                                                                                                                                                                                |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Dimethyl Fumarate</b>                                                                                                                                                                                                                                                                                                              |  |                                                                                                  |
| <b>Dimethyl Fumarate</b><br><span>Red</span> <span>££</span><br>30mg; 120mg tablets<br>PbR X NICE MMC BNF bluefeq emc                                                                                                                                                                                                                 |  | <b>RESTRICTED</b><br>3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG<br>Referral to SRFT |
| <b>13.5.3 Drugs affecting the immune response</b>                                                                                                                                                                                                                                                                                     |  |                                                                                                  |
| <b>Abrocitinib</b><br><span>Red</span> <span>££</span><br>Cibingo® 50mg; 100mg; 200mg tablets<br>PbR X NICE MMC BNF bluefeq emc                                                                                                                                                                                                       |  | <b>RESTRICTED</b><br>Dermatology Consultants only<br>in line with NICE                           |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality                                                                                                                                                                        |  |                                                                                                  |
| <b>Azathioprine</b><br><span>Amber</span><br>25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)<br>BNF emc                                                                                                                                                                                                                  |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Ciclosporin</b><br><span>Amber</span><br>25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)<br>PbR X MMC BNF emc                                                                                                                                                                                      |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Methotrexate</b><br><span>Amber</span><br>2.5mg tablets (see also sections 8.1.3 & 10.1.3)<br>MMC BNF emc                                                                                                                                                                                                                          |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Pimecrolimus</b><br><span>Green</span><br>1% cream<br>NICE MMC BNF emc                                                                                                                                                                                                                                                             |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Tacrolimus</b> (specially made by SRFT)<br><span>Green</span><br>0.03%; 0.1% ointment<br>PbR X NICE MMC BNF emc                                                                                                                                                                                                                    |  | <b>RESTRICTED</b><br>Dermatology Consultants only                                                |
| <b>Upadacitinib</b><br><span>Red</span> <span>££</span><br>Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)<br>PbR X NICE MMC BNF bluefeq emc                                                                                                                                                                         |  | <b>RESTRICTED</b><br>Dermatology Consultants only<br>in line with NICE                           |
| MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality                                                                                                                                                                        |  |                                                                                                  |

| <b>Cytokine Modulators</b>                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (see also section 10.1.3)                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| <b>Adalimumab</b><br> <br>injection (see also sections 1.5.3, 10.1.3 & 11.4.2) |                   | <b>RESTRICTED</b><br>Dermatology Consultants only                                                       |
| <b>Apremilast</b><br> <br>10mg; 20mg; 30mg tablets                             |                                                                                                      | <b>RESTRICTED</b><br>3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG<br><b>Referral to SRFT</b> |
| <b>Bimekizumab</b><br> <br>Bimzelx® injection (see also section 10.1.3)        |                   | <b>RESTRICTED</b><br>in line with NICE                                                                  |
| <b>Brodalumab</b><br> <br>Kyntheum® 140mg/mL injection                         |                                                                                                      | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Certolizumab</b><br> <br>Cimzia® 200mg injection (see also section 10.1.3)  |                                                                                                      | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Dupilumab</b><br> <br>Dupixent® 150mg/mL injection (see also section 3.4.2) |                   | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Etanercept</b><br> <br>injection (see also section 10.1.3)                  |                   | <b>RESTRICTED</b><br>Dermatology Consultants only                                                       |
| <b>Guselkumab</b><br> <br>100mg/mL injection                                   |                                                                                                      | <b>RESTRICTED</b><br>in line with NICE                                                                  |
| <b>Infliximab</b><br> <br>100mg injection (see section 10.1.3)                 |                   | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Ixekizumab</b><br> <br>80mg/1mL injection (see also section 10.1.3)       |                                                                                            | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Risankizumab</b><br> <br>75mg; 150mg injection                          |       | <b>RESTRICTED</b><br>Specialist use only in line with NICE                                              |
| <b>Secukinumab</b><br> <br>150mg/1mL injection                             |       | <b>RESTRICTED</b><br>Dermatology only in line with NICE                                                 |
| <b>Tildrakizumab</b><br> <br>100mg injection                               |                                                                                            | <b>RESTRICTED</b><br>Dermatology only in line with NICE<br><b>NOT STOCKED</b>                           |
| <b>Ustekinumab</b><br> <br>injection (see section 10.1.3)                  |       | <b>RESTRICTED</b> Dermatology NICE<br>TA180 & 455 / Gastro 3 <sup>rd</sup> line Crohn's                 |

## 13.6 Acne & Rosacea



### 13.6.1 Topical preparations for acne

#### NICE CKS: Acne

**For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1<sup>st</sup> line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.**

#### Benzyl peroxide & azelaic acid

##### Benzoyl Peroxide

DNP

4% cream; 5% gel



1<sup>st</sup> line

##### Azelaic acid

Skinoren® 20% cream



2<sup>nd</sup> line

#### Topical antibacterials for acne

##### Clindamycin

Dalacin T® 1% topical lotion



2<sup>nd</sup> / 3<sup>rd</sup> line

##### Erythromycin

Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion



2<sup>nd</sup> / 3<sup>rd</sup> line

#### Topical retinoids & related preparations for acne

##### Adapalene

Differin® 0.1% cream; 0.1% gel



1<sup>st</sup> line

#### Topical retinoids with antibacterial

##### Isotretinoin with Erythromycin

Isotrexin® 500micrograms/1g : 20mg/1g gel



**RESTRICTED**  
Dermatology Consultants only

### 13.6.2 Oral preparations for acne

#### NICE CKS: Acne

**Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.**

##### Lymecycline

408mg capsules (see also section 5.1.3)



**RESTRICTED**  
GP referral only

#### Hormone treatment for acne

##### Co-cyprindiol

Cyproterone acetate 2mg / ethinylestradiol 35micrograms tablets



**RESTRICTED**  
GP referral only

#### Oral retinoid for acne

##### Isotretinoin

Red

5mg; 10mg; 20mg; 40mg capsules



**RESTRICTED**  
Dermatology Consultants only

MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s  
 MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s  
 MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic  
 MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review  
 MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions  
 MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women  
 MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido  
 MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders

## 13.7 Preparations for warts & calluses



### 13.7 Preparations for warts & calluses

#### Salicylic acid

DNP

ointment; liquid



#### Silver Nitrate

pencil



#### Silver Nitrate

75% applicator



#### Anogenital warts

#### Podophyllotoxin

0.15% cream



#### Imiquimod

Green

5% cream



**RESTRICTED**  
Dermatology Consultants only

**RESTRICTED**  
ENT - nasal cautery

**1<sup>st</sup> line**

**RESTRICTED**  
GUM Consultant only

| 13.8 Sunscreens & camouflagers                                                                                                                                                                                                                                                                      |  |       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|
| 13.8.1 Sunscreen preparations                                                                                                                                                                                                                                                                       |  |                                                                                         |
| Photodamage                                                                                                                                                                                                                                                                                         |  |                                                                                         |
| <b>Methyl-5-Aminolevulinate</b><br>                                                                                                                                                                                 |  | <b>RESTRICTED</b> Dermatology Consultants & Vulval Intraepithelial Neoplasia (VIN) only |
| 160mg/g cream<br>                               |  |                                                                                         |
| <b>Diclofenac Sodium</b>                                                                                                                                                                                                                                                                            |  | <b>RESTRICTED</b> Dermatology Consultants                                               |
| Solaraze® 3% gel<br>                                                                                                             |  |                                                                                         |
| <b>Fluorouracil / Salicylic acid</b>                                                                                                                                                                                                                                                                |  | <b>RESTRICTED</b> Dermatology Consultants as per MMC                                    |
| Actikerall® 0.5% / 10% cutaneous solution<br>   |  |                                                                                         |

| 13.9 Shampoos & other preparations for scalp / hair conditions       |                                                                                                                                                                                                                                                               |  |
|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| <b>Shampoos</b>                                                      |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Ketoconazole</b>                                                  | <br>                                                                                      | <b>RESTRICTED</b> persistent / severe seborrhoeic dermatitis / dandruff             |
| <i>Nizoral</i> ® 2% shampoo                                          |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Capasal®</b>                                                      | <br>                                                                                      | <b>RESTRICTED</b><br>Dermatology Consultants only                                   |
| coal tar 1%, coconut oil 1% &, salicylic acid 0.5% shampoo           |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Ceanel Concentrate®</b>                                           | <br>                                                                                      | <b>RESTRICTED</b><br>Dermatology Consultants only                                   |
| cetrimide 10%, undecenoic acid 1% & phenylethyl alcohol 7.5% shampoo |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Other scalp preparations</b>                                      |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Polytar®</b>                                                      | <br>                                                                                      |                                                                                     |
| 40mg/mL coal tar scalp shampoo                                       |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Hirsutism</b>                                                     |                                                                                                                                                                                                                                                               |                                                                                     |
| <b>Eflornithine</b>                                                  | <br><br> | <b>RESTRICTED</b><br>Dermatology Consultants only                                   |
| <i>Vaniqa</i> ® 11.5% cream                                          |                                                                                                                                                                                                                                                               |                                                                                     |

## 13.10 Anti-infective skin preparations



### 13.10.1 Antibacterial preparations

**Topical antibacterials should generally be avoided for the treatment of infections**

#### 13.10.1.1 Antibacterial preparations only used topically

##### Mupirocin

2% cream; ointment

MMC BNF emc+

##### Fusidic acid

2% cream; ointment

BNF emc+

**RESTRICTED**  
superficial impetigo

##### Metronidazole

0.75% topical gel; cream

BNF emc+

**RESTRICTED**  
topical treatment of rosacea

##### Silver Sulfadiazine

1% w/w cream

BNF emc+

**RESTRICTED**  
Treatment/prophylaxis of burns

### 13.10.2 Antifungal preparations

##### Amorolfine

5% nail lacquer

MMC BNF emc+

**1<sup>st</sup> line**  
antifungal for nail infections

##### Benzoic acid ointment, compound, BP

benzoic acid 6% / salicylic acid 3% / in emulsifying ointment

BNF emc+

**1<sup>st</sup> line**  
treatment of ringworm

##### Clotrimazole

1% cream

BNF emc+

**1<sup>st</sup> line**  
fungal skin infections

##### Miconazole

2% cream

BNF emc+

**2<sup>nd</sup> line**  
fungal skin infections

##### Terbinafine

1% cream

BNF emc+

**2<sup>nd</sup> line**  
fungal skin infections

### 13.10.3 Antiviral preparations

##### Aciclovir

5% cream

BNF emc+

**1<sup>st</sup> line**

### 13.10.4 Parasitocidal preparations

**NICE CKS: Head lice**

**NICE CKS: Pubic lice**

**NICE CKS: Scabies**

##### Ivermectin



tablets

MMC BNF emc+

##### Malathion

0.5% aqueous solution

BNF emc+

##### Permethrin

1% crème rinse; 5% dermal cream

BNF emc+

**MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...**

### 13.10.5 Preparations for minor cuts & abrasions

##### Proflavine cream, BPC

0.1% cream

BNF emc+

##### Brulidine

0.15% w/w cream

emc+

**RESTRICTED**  
Theatres only

### Preparations for boils

##### Magnesium Sulfate

paste, BP

emc+

### Skin tissue adhesive

##### Histoacryl®

0.5mL skin adhesive

BNF emc+

**RESTRICTED**  
Theatres only

| 13.11 Skin cleansers, antiseptics & desloughing agents                                            |                                                                                                                                                                        | GMMMG                                    |
|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| <b>13.11.1 Alcohols &amp; saline</b>                                                              |                                                                                                                                                                        |                                          |
| Isopropyl Alcohol 70%                                                                             |    |                                          |
| Sodium Chloride                                                                                   |    |                                          |
| 0.9% irrigation solution                                                                          |    |                                          |
| <b>13.11.2 Chlorhexidine salts</b>                                                                |                                                                                                                                                                        |                                          |
| Chlorhexidine Gluconate                                                                           |    |                                          |
| <b>13.11.4 Iodine</b>                                                                             |                                                                                                                                                                        |                                          |
| Alcoholic Iodine solution BP                                                                      |    |                                          |
| Iodine weak solution                                                                              |    |                                          |
| Povidone-Iodine                                                                                   |    |                                          |
| <b>13.11.6 Oxidisers &amp; dyes</b>                                                               |                                                                                                                                                                        |                                          |
| Hydrogen Peroxide solution, BP                                                                    |    | <b>RESTRICTED</b><br>Specialist use only |
| 3% solution; 6% solution                                                                          |    |                                          |
| Potassium Permanganate                                                                            |    | <b>RESTRICTED</b><br>Specialist use only |
| 400mg tablets for cutaneous solution                                                              |   |                                          |
| National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate |                                                                                                                                                                        |                                          |
| <b>13.11.7 Desloughing agents</b>                                                                 |                                                                                                                                                                        |                                          |
| <b>CONTACT THE TISSUE VIABILITY TEAM on x64042</b>                                                |                                                                                                                                                                        |                                          |

| 13.12 Antiperspirants                                                            |                                                                                                                                                                                                                                                         | GMMMG                                                                  |
|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| <b>Aluminium salts</b>                                                           |                                                                                                                                                                                                                                                         |                                                                        |
| <b>Aluminium Chloride Hexahydrate</b>                                            |                                                                                                                                                                                                                                                         |                                                                        |
| 20% solution                                                                     |                                                                                     |                                                                        |
| <b>Glycopyrronium Bromide</b>                                                    |                                                                                                                                                                                                                                                         |                                                                        |
| <b>Glycopyrronium Bromide</b>                                                    |                                                                                                                                                                                                                                                         |                                                                        |
| Robinul®                                                                         |    |                                                                        |
| <b>Glycopyrrolate</b>                                                            |                                                                                                                                                                                                                                                         | <b>RESTRICTED</b><br>Diabetes Consultants only<br>(gustatory sweating) |
|  |    |                                                                        |
| 0.5% cream                                                                       |                                                                                                                                                                                                                                                         |                                                                        |

13.13 Topical circulatory preparations



Topical circulatory preparations

Hirudoid®

0.3% cream; 0.3% gel



## 13.14 Miscellaneous preparations



### 8-Methoxypsoralen



10mg tablets

MMC

emc

**RESTRICTED**  
Dermatology Consultants only

### Fumaric Acid Esters



Fumaderm® tablets

MMC

emc

**RESTRICTED**  
Dermatology Consultants only

### Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 &amp; 10.4)

PbR X

MMC

emc

**RESTRICTED**  
2<sup>nd</sup> line rescue therapy

### Hyaluronic acid / Lidocaine



Juvederm® / Belotero® injection

MMC

emc

**RESTRICTED**  
vocal cord paralysis

## Non-Formulary Items

### Ingenol Mebutate

Picato® 150 micrograms/g gel (face &amp; scalp); 500 micrograms/g gel (trunk &amp; extremities)

MMC

BNF

emc

**WITHDRAWN**

MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy

MHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies

## Section 14: Immunological products & vaccines

Supported by the  
formulary ([click here](#))



### 14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

### 14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

## Trust Guidelines

Adult medicines and prescribing guidelines  
Paediatric medicines and prescribing guidelines  
Neonatal guidelines (link to Staffnet site)  
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin  
Immunoglobulin follow up form  
Immunoglobulin Prescribing and Administration Guidelines  
Immunoglobulin Prescribing Flow Chart  
Immunoglobulin request form  
National Demand Programme for Immunoglobulin - Clinical Info  
[Non-formulary Conversion Table](#)

## NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

## GMMM Formulary

Formulary Homepage  
Chapter 14: Immunological products & vaccines (**ON HOLD**)  
GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMM Paediatric **Red/Amber/Green** Drug List

## Other Links

National Immunoglobulin Database  
DH: Clinical guidelines for immunoglobulin use (2<sup>nd</sup> edition update)  
Immunoglobulin handbook (HPA)

## 14.4 Vaccines & antisera

MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed

### **Bacillus Calmette-Guérin (BCG) vaccines**

Bacillus Calmette-Guérin (BCG) vaccine

injection



**BCG vaccine diagnostic agent** (Tuberculin purified protein derivative (PPD))

injection



### **Botulism antitoxin**

Botulism antitoxin

injection



**RESTRICTED**  
Emergencies only

### **COVID-19 vaccine**

**Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)**

Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)



**12 years of age and older**  
**pending availability of XBB1.5**

**Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)**

Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)



**12 years of age and older**

**Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)**

Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)



**5 to 11 year olds**

**AstraZeneca COVID-19 vaccine**

Vaxzevria® injection



**DISCONTINUED**

**Moderna Biotech COVID-19 vaccine**

Spikevax® injection



**DISCONTINUED**

**Novavax COVID-19 vaccine**

Nuvaxovid® injection



**PAUSED by JCVI**

MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023

MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023

MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023

MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022

MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022

MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022

MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022

MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022

MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022

MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022

MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022

MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022

MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022

MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022

MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022

MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021

MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021

MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021

MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021

MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021

MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021

MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021

MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021

MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021

MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice

MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19

### **Diphtheria vaccines (children under 10yrs old)**

**Pediacel®**

injection



**Infanrix-IPV+Hib®**

injection



**Infanrix-IPV®**

injection



**Repevax®**

injection



| <b>Diphtheria vaccines (children over 10yrs old &amp; adults)</b>      |                                                                                                                                                                                                                                                          |
|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Revaxis®</b>                                                        |                                                                                                                                                                                                                                                          |
| injection                                                              |                                                                                     |
| <b>Haemophilus type B conjugate vaccine</b>                            |                                                                                                                                                                                                                                                          |
| <b>Haemophilus Influenzae B vaccine</b>                                |                                                                                                                                                                                                                                                          |
| Hiberix® injection                                                     |                                                                                     |
| <b>Haemophilus Influenzae B &amp; Meningitis C vaccine</b>             |                                                                                                                                                                                                                                                          |
| Menitorix® injection                                                   |                                                                                     |
| <b>Hepatitis A vaccine</b>                                             |                                                                                                                                                                                                                                                          |
| <b>Hepatitis A vaccine</b> single component                            |                                                                                                                                                                                                                                                          |
| Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection |                                                                                     |
| <b>Hepatitis B vaccine</b>                                             |                                                                                                                                                                                                                                                          |
| <b>Hepatitis B</b> single component                                    |                                                                                                                                                                                                                                                          |
| Engerix B®; Engerix B® Paediatric injection                            |                                                                                     |
| <b>Hepatitis B</b> single component                                    |                                                                                                                                                                                                                                                          |
| HBvaxPRO®; HBvaxPRO® Paediatric injection                              |                                                                                     |
| <b>Human papilloma virus (HPV) vaccine</b>                             |                                                                                                                                                                                                                                                          |
| <b>Human Papilloma Virus (HPV)</b> quadrivalent vaccine                | <b>RESTRICTED</b><br><b>Paediatric Immunology Consultant</b>                                                                                                                                                                                             |
| Gardasil® injection                                                    |    |

|                                                                |                                                                                                                                                                                                                                                          |                                                                              |
|----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| <b>Influenza vaccine</b>                                       |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Influenza vaccine</b>                                       |                                                                                                                                                                                                                                                          |                                                                              |
| injection, intranasal                                          |                                                                                     |                                                                              |
| <b>Measles, Mumps &amp; Rubella (MMR) vaccine</b>              |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Measles, Mumps &amp; Rubella vaccine</b>                    |                                                                                                                                                                                                                                                          |                                                                              |
| injection                                                      |                                                                                     |                                                                              |
| <b>Meningococcal vaccines</b>                                  |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Meningococcal Polysaccharide A, C, W135 &amp; Y vaccine</b> |                                                                                                                                                                                                                                                          |                                                                              |
| injection                                                      |                                                                                     |                                                                              |
| <b>Meningococcal group B vaccine</b>                           |                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>childhood immunisation schedule<br>& high risk patients |
| <i>Bexsero</i> ® injection                                     |    |                                                                              |
| <b>Meningococcal group C vaccine</b>                           |                                                                                                                                                                                                                                                          |                                                                              |
| injection                                                      |                                                                                     |                                                                              |
| <b>Pneumococcal vaccines</b>                                   |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Pneumococcal Polysaccharide vaccine</b>                     |                                                                                                                                                                                                                                                          |                                                                              |
| injection                                                      |                                                                                     |                                                                              |
| <b>Poliomyelitis vaccines</b>                                  |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Poliomyelitis vaccine inactivated</b>                       |                                                                                                                                                                                                                                                          |                                                                              |
|                                                                |                                                                                     |                                                                              |
| <b>Rabies vaccines</b>                                         |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Rabies vaccine inactivated</b>                              |                                                                                                                                                                                                                                                          | <b>RESTRICTED</b><br>Not Stocked                                             |
| <i>Rabipur</i> ® injection                                     |                                                                                   |                                                                              |
| <b>Tetanus vaccines</b>                                        |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Tetanus vaccine adsorbed</b>                                |                                                                                                                                                                                                                                                          |                                                                              |
| injection                                                      |                                                                                 |                                                                              |
| <b>Typhoid vaccines</b>                                        |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Typhoid polysaccharide vaccine</b>                          |                                                                                                                                                                                                                                                          |                                                                              |
| <i>Typhim Vi</i> ® injection                                   |                                                                                 |                                                                              |
| <b>Varicella-zoster vaccines</b>                               |                                                                                                                                                                                                                                                          |                                                                              |
| <b>Varicella-Zoster live attenuated vaccine</b>                |                                                                                                                                                                                                                                                          |                                                                              |
| <i>Varivax</i> ® injection                                     |                                                                                 |                                                                              |

## 14.5 Immunoglobulins

IVIG Request Form

### 14.5.1 Normal immunoglobulin Red (for ITP & home treatment programmes)

#### For intramuscular use

#### Normal immunoglobulin injection

Red ££

injection

PbR X

BNF BNF emc

**RESTRICTED**

Specialist use only

IVIG Request Form

#### For subcutaneous use

#### Normal immunoglobulin injection

Red ££

injection

PbR X

MMC BNF BNF emc

**RESTRICTED**

Specialist use only

IVIG Request Form

#### For intravenous use

#### Human normal immunoglobulin

Red ££

injection

PbR X

MMC BNF BNF emc

**RESTRICTED**

Specialist use only

IVIG Request Form

### 14.5.2 Disease-specific immunoglobulins

#### Hepatitis B immunoglobulin

#### Hepatitis B immunoglobulin

injection

BNF emc

**RESTRICTED**

Not Stocked

#### Tetanus immunoglobulin

#### Tetanus immunoglobulin

injection

BNF emc

#### Varicella-Zoster immunoglobulin

#### Varicella-Zoster immunoglobulin

Green

injection

BNF emc

**RESTRICTED**

Not Stocked

#### Cytomegalovirus (CMV) immunoglobulin

#### Human normal immunoglobulin (CMV)

injection

MMC BNF BNF emc

**RESTRICTED**

Specialist use only

### 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

#### Anti-D (Rh<sub>0</sub>) immunoglobulin

Red

injection

NICE MMC BNF BNF emc

## Section 15: Anaesthesia

Supported by the  
formulary ([click here](#))



### 15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
  - 15.1.4.1 Benzodiazepines
  - 15.1.4.2 Non-opioid analgesics
  - 15.1.4.3 Opioid analgesics
  - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
  - Non-depolarising neuromuscular blocking drugs
  - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
  - Anticholinesterases
  - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

### 15.2 Local anaesthesia

- Local Anaesthetic Toxicity
- Other agents

## Trust Guidelines

Adult medicines and prescribing guidelines  
Paediatric medicines and prescribing guidelines  
Neonatal guidelines (link to Staffnet site)  
Paediatric Anaesthesia Website  
Children's Pain Management Website  
PICU Emergency Drugs Calculator  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

## GMMMG Formulary

Formulary Homepage  
Chapter 15: Anaesthesia (**ON HOLD**)  
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMMG Paediatric **Red/Amber/Green** Drug List

## 15.1 General anaesthesia

### 15.1.1 Intravenous anaesthetics

#### Etomidate

injection



#### Ketamine



injection



#### Propofol

injection; infusion



#### Thiopental Sodium

injection



### 15.1.2 Inhalational anaesthetics

#### Volatile liquid anaesthetics

##### Desflurane

anaesthetic agent



**RESTRICTED**  
Theatres only

##### Isoflurane

anaesthetic agent



##### Methoxyflurane

Pentrox® inhalation vapour



**RESTRICTED**  
ED only

##### Sevoflurane

anaesthetic agent



#### Nitrous oxide

##### Nitrous Oxide



##### Nitrous Oxide 50% & Oxygen 50%

Entonox®



### 15.1.3 Antimuscarinic drugs

#### Atropine Sulfate

600microgram/1mL injection



Adults 600microgram/1mL  
I.M. or I.V.

#### Glycopyrronium Bromide

200micrograms/1mL; 600micrograms/3mL injection



Adults 200-400microgram I.V.

#### Hyoscine Hydrobromide

400microgram/mL injection



### 15.1.4 Sedative & analgesic post-operative drugs

#### 15.1.4.1 Benzodiazepines

##### Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2 &amp; 4.8.2)



##### Lorazepam

tablets; injection (see also sections 4.1.2 &amp; 4.8.2)



##### Midazolam



oromucosal solution; injection; infusion (see also section 4.8.2)



##### Temazepam



tablets; oral solution (see also section 4.1.1)



### 15.1.4.2 Non-opioid analgesics

#### Ketorolac Trometamol

injection



#### Parecoxib

injection



**RESTRICTED**  
Theatres only - acute postop. pain

| 15.1.4.3 Opioid analgesics                                                                                          |                                                                                                                                                                                                                                                                |                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| <b>Alfentanil</b>                                                                                                   |                                                                                                                                                                                                                                                                |                                                                                                             |
|  injection                          |                                                                                           |                                                                                                             |
| <b>Fentanyl</b>                                                                                                     |                                                                                                                                                                                                                                                                |                                                                                                             |
|  injection (see also section 4.7.2) |                                                                                           |                                                                                                             |
| <b>Remifentanyl</b>                                                                                                 |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b><br>Specialist use only                                                                    |
|  injection                          |          |                                                                                                             |
| 15.1.4.4 Other drugs for sedation                                                                                   |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Dexmedetomidine</b>                                                                                              |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b><br>Specialist use only                                                                    |
| infusion                                                                                                            |          |                                                                                                             |
| 15.1.5 Neuromuscular blocking drugs                                                                                 |                                                                                                                                                                                                                                                                |                                                                                                             |
| Non-depolarising neuromuscular blocking drugs                                                                       |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Atracurium Besilate</b>                                                                                          |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                           |                                                                                                             |
| <b>Cisatracurium</b>                                                                                                |                                                                                                                                                                                                                                                                | <b>RESTRICTED</b><br>Consultant only                                                                        |
| injection                                                                                                           |          |                                                                                                             |
| <b>Mivacurium</b>                                                                                                   |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                           |                                                                                                             |
| <b>Rocuronium Bromide</b>                                                                                           |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                           |                                                                                                             |
| <b>Vecuronium Bromide</b>                                                                                           |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                         |                                                                                                             |
| Depolarising neuromuscular blocking drugs                                                                           |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Suxamethonium Chloride</b>                                                                                       |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| 15.1.6 Drugs for reversal of neuromuscular blockade                                                                 |                                                                                                                                                                                                                                                                |                                                                                                             |
| Anticholinesterases                                                                                                 |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Neostigmine Metilsulfate</b>                                                                                     |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| <b>Neostigmine Metilsulfate with Glycopyrronium Bromide</b>                                                         |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| Other drugs for reversal of neuromuscular blockade                                                                  |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Sugammadex</b>                                                                                                   |                                                                                                                                                                                                                                                                | <b>RESTRICTED - Consultant</b><br>(Emergency) use in Theatres only<br>Complete Trust incident & audit forms |
| Bridion® injection                                                                                                  |    |                                                                                                             |
| 15.1.7 Antagonists for central & respiratory depression                                                             |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Doxapram Hydrochloride</b>                                                                                       |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection (see also section 3.5.1)                                                                                  |                                                                                       |                                                                                                             |
| <b>Flumazenil</b>                                                                                                   |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| <b>Naloxone Hydrochloride</b>                                                                                       |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| 15.1.8 Drugs for malignant hyperthermia                                                                             |                                                                                                                                                                                                                                                                |                                                                                                             |
| <b>Dantrolene Sodium</b>                                                                                            |                                                                                                                                                                                                                                                                |                                                                                                             |
| injection                                                                                                           |                                                                                       |                                                                                                             |
| MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals                              |                                                                                                                                                                                                                                                                |                                                                                                             |

| 15.2 Local anaesthesia                                                                                                                                                 | AAGBI SAFETY GUIDELINE                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>15.2 Local anaesthesia</b>                                                                                                                                          |                                                                                                                                                                                                                                                                |
| <b>Lidocaine Hydrochloride</b>                                                                                                                                         |                                                                                                                                                                                                                                                                |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
| 0.5%, 1% & 2% injection                                                                                                                                                |                                                                                           |
| <b>with adrenaline</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                |
| <b>Lidocaine with Adrenaline</b>                                                                                                                                       |                                                                                                                                                                                                                                                                |
| 1%, 2% injection                                                                                                                                                       |                                                                                           |
| <b>for surface anaesthesia</b>                                                                                                                                         |                                                                                                                                                                                                                                                                |
| <b>Lidocaine with Chlorhexidine</b>                                                                                                                                    |                                                                                                                                                                                                                                                                |
| Instillagel® 2% gel                                                                                                                                                    |                                                                                           |
| <b>Lidocaine with Phenylephrine</b>                                                                                                                                    |                                                                                                                                                                                                                                                                |
| Co-phenylcaine® 5% / 0.5% spray                                                                                                                                        |          |
| <b>Lidocaine with Prilocaine</b>                                                                                                                                       |                                                                                                                                                                                                                                                                |
| EMLA® 5% cream                                                                                                                                                         |                                                                                           |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
| 4% topical solution                                                                                                                                                    |                                                                                           |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
| Laryngojet® 4% (160mg/4mL) jet spray                                                                                                                                   |                                                                                           |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
| 5% ointment                                                                                                                                                            |                                                                                           |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
| Xylocaine® 10% spray                                                                                                                                                   |                                                                                       |
| <b>Lidocaine</b>                                                                                                                                                       |                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                |
| Versatis® 700mg medicated plaster                                                                                                                                      |    |
| <b>Bupivacaine Hydrochloride</b>                                                                                                                                       |                                                                                                                                                                                                                                                                |
| <b>Bupivacaine Hydrochloride</b>                                                                                                                                       |                                                                                                                                                                                                                                                                |
| 0.25% Infusion (500mL)                                                                                                                                                 |                                                                                       |
| <b>Bupivacaine Hydrochloride with Glucose</b>                                                                                                                          |                                                                                                                                                                                                                                                                |
| Marcaïn Heavy® 0.5% Injection                                                                                                                                          |                                                                                       |
| <b>with adrenaline</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                |
| <b>Bupivacaine and Adrenaline</b>                                                                                                                                      |                                                                                                                                                                                                                                                                |
| 0.25% with 1:200,000 injection                                                                                                                                         |                                                                                       |
| <b>Bupivacaine and Adrenaline</b>                                                                                                                                      |                                                                                                                                                                                                                                                                |
| 0.5% with 1:200,000 injection                                                                                                                                          |                                                                                       |
| <b>with other ingredients</b>                                                                                                                                          |                                                                                                                                                                                                                                                                |
| <b>Bupivacaine and Fentanyl</b>                                                                                                                                        |                                                                                                                                                                                                                                                                |
|                                                                                      |                                                                                       |
| 0.125% with 1mg/500mL infusion                                                                                                                                         |                                                                                       |
| <b>Bupivacaine and Sodium Chloride</b>                                                                                                                                 |                                                                                                                                                                                                                                                                |
| 0.08% in 0.9%                                                                                                                                                          |                                                                                       |
| <b>Bupivacaine Hydrochloride with Glucose</b>                                                                                                                          |                                                                                                                                                                                                                                                                |
| 20mg with 320mg/4mL spinal injection                                                                                                                                   |                                                                                       |
| <b>Levobupivacaine</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                |
| <b>Levobupivacaine</b>                                                                                                                                                 |                                                                                                                                                                                                                                                                |
| Chirocaine® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL                                                                                            |    |
| <b>Levobupivacaine with Fentanyl</b>                                                                                                                                   |                                                                                                                                                                                                                                                                |
|                                                                                      |                                                                                       |
| 0.1% with 2microgram/mL epidural                                                                                                                                       |                                                                                       |

**RESTRICTED**  
Consultant / specialist pain team only

|                                                                                              |                                                                                                                                                                                                                                                               |                                                                                                       |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| <b>Prilocaine Hydrochloride</b>                                                              |                                                                                                                                                                                                                                                               |                                                                                                       |
| <b>Prilocaine Hydrochloride</b>                                                              |                                                                                                                                                                                                                                                               |                                                                                                       |
| <i>Citanest</i> ® 1% injection                                                               |                                                                                          |                                                                                                       |
| <b>Prilocaine Hydrochloride</b>                                                              |                                                                                                                                                                                                                                                               |                                                                                                       |
| <i>Prilotekal</i> ® 2% injection                                                             |         |                                                                                                       |
| <b>Prilocaine with Felypressin</b>                                                           |                                                                                                                                                                                                                                                               |                                                                                                       |
| <i>Octapressin</i> ® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)                 |                                                                                          |                                                                                                       |
| <b>Ropivacaine Hydrochloride</b>                                                             |                                                                                                                                                                                                                                                               |                                                                                                       |
| <b>Ropivacaine</b>                                                                           |                                                                                                                                                                                                                                                               | For Consultant use on CDU (elective CS), Theatre 1 (ortho) & wards 1 & 2 (following surgery in Th. 1) |
| injection; infusion                                                                          |         |                                                                                                       |
| <b>Tetracaine (Amethocaine)</b>                                                              |                                                                                                                                                                                                                                                               |                                                                                                       |
| <b>Tetracaine</b>                                                                            |                                                                                                                                                                                                                                                               | RESTRICTED children under 1yr by specific doctor request or /V team                                   |
| 4% gel                                                                                       |         |                                                                                                       |
| <b>Local Anaesthetic Toxicity</b>                                                            |                                                                                                                                                                                                                                                               | <b>AAGBI SAFETY GUIDELINE</b>                                                                         |
| <b>Intralipid 20%</b>                                                                        |                                                                                                                                                                                                                                                               |                                                                                                       |
| 20% injection                                                                                |                                                                                          |                                                                                                       |
| <b>Other agents</b>                                                                          |                                                                                                                                                                                                                                                               |                                                                                                       |
| <b>Cocaine</b>                                                                               |                                                                                                                                                                                                                                                               |                                                                                                       |
|  5% solution |                                                                                          |                                                                                                       |
| <b>Ethyl Chloride</b>                                                                        |                                                                                                                                                                                                                                                               |                                                                                                       |
| <i>Cryogesic</i> ® spray                                                                     |    |                                                                                                       |
| <b>Mepivacaine Hydrochloride</b>                                                             |                                                                                                                                                                                                                                                               |                                                                                                       |
| 3% injection                                                                                 |                                                                                      |                                                                                                       |
| <b>Neomycin Sulfate / Fluocinolone Acetonide / Lidocaine Hydrochloride</b>                   |                                                                                                                                                                                                                                                               | RESTRICTED Paediatrics.<br>Intra-urethral steroid ointment                                            |
| <i>Nefluan</i> ® 10g gel                                                                     |                                                                                       |                                                                                                       |

## Section 16: Miscellaneous

Supported by the  
formulary ([click here](#))



### 16.1 Organ Perfusion Fluids

16.1.1 Cardiac Perfusion Fluids

16.1.2 Kidney / Pancreas / Liver perfusion fluids

16.1.3 Contrast Agents

## Trust Guidelines

Adult medicines and prescribing guidelines

Paediatric medicines and prescribing guidelines

Neonatal guidelines (link to Staffnet site)

[Non-formulary Conversion Table](#)

## NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

## GMMMG Formulary

Formulary Homepage

GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and Grey Drug List

GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

## 16.1 Organ Perfusion fluids

### 16.1.1 Cardiac perfusion fluids

Aspartate / Glutamate Solution



100mL

MMC

Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK)



Custodiol Cardioplegia® solution (1000mL)

MMC

emc

Cardioplegia in Ringer's Solution



1000mL

MMC

Cardioplegic ULTH Formula A



500mL

MMC

Cardioplegic ULTH Formula B



500mL

MMC

Sterile Concentrate for Cardioplegia Infusion

20mL

MMC

emc

### 16.1.2 Kidney / Pancreas / Liver perfusion fluids

Cold Storage Solution (UW Solution)

Belzer UW® (1000mL)

MMC

emc

Kidney Perfusion Fluid

Soltran® (1000mL)

MMC

emc

Lung Perfusion Solution

Perfadex® (1000mL)

MMC

emc

Machine Perfusion Solution

Belzer MPS® UW machine perfusion solution (1000mL)

MMC

emc

### 16.1.3 Contrast Agents

Gadobutrol

Gadovist® (1.0mmol/mL) injection

MMC

emc

Gadoteric acid

Dotarem® (0.5mmol/mL) injection

MMC

emc

Gadoxetic acid

Primovist® (0.25mmol/mL) injection

MMC

emc

Perflutren

Luminity® (150microlitres/mL) lipid microspheres for injection

MMC

emc

Sulphur Hexafluoride

SonoVue® (8microlitre/mL) injection

MMC

emc